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SUMMARY 
Understanding regional diversity in the human biliary tree through transcriptomic 
profiling of primary tissues and in vitro derived organoids 
Casey Allison Rimland 
The biliary tree is a series of ductular tissues responsible for the drainage of bile produced by the 
liver and pancreatic secretions from the pancreas. The biliary tree is affected by a diversity of life-
threatening diseases collectively called cholangiopathies. Cholangiopathies show regionalization, 
with some diseases such as biliary atresia predominantly targeting extrahepatic bile ducts 
(EHBDs) outside of the liver. Despite this, little is known on whether anatomical location within 
the biliary tree contributes to differences in functionality of biliary epithelium, especially in the 
EHBD compartment. Additionally, reports have demonstrated the possibility for in vitro culture 
of bile duct stem/progenitor cell organoids from both intrahepatic (IHBD) and EHBD sources. 
The relation of these organoid systems to each other, and to their tissue of origin, is largely 
unknown.  
In this dissertation, I address these major questions by combining transcriptional analyses and in 
vitro culture of human bile duct organoids derived from primary IHBD and EHBD epithelium. 
First, I show that in vitro organoids can be derived from four regions of the human biliary tree: 
gallbladder, common bile duct, pancreatic duct, and intrahepatic bile ducts. Characterization of 
these organoids demonstrated expression of adult stem cell (LGR5/PROM1) and ductal 
(KRT19/KRT7) markers suggesting these cultures contained cells with a biliary stem/progenitor 
phenotype. Further, I show that IHBD organoids are distinct from EHBD organoids requiring 
different conditions for sustained growth. Using RNA-Sequencing, I demonstrate that primary 
tissues from different regions of the extrahepatic biliary tree display unique expression profiles 
and identify novel tissue-specific markers. I also show that only a limited number of these tissue 
specific differences are maintained in the in vitro organoids and that the organoids are very 
different from their tissue of origin. Finally, I demonstrate that IHBD, but not EHBD organoids, 
express a low-level of hepatocyte-specific markers under differentiation conditions. 
Taken together, the work in this dissertation has uncovered regional specific markers for different 
anatomical regions of the human biliary tree. Further, I demonstrate that major differences exist 
between IHBD organoids and EHBD organoids in vitro and discover that only IHBD organoids 
have the capacity to express hepatocyte markers under differentiation conditions. Ultimately, 
these results may help to identify new targets for therapeutic development for cholangiopathies 
and regenerative medicine. They have also provided important insight to the understanding of 
both basic biliary physiology and also the field of biliary stem/progenitor cell organoids.  
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1 INTRODUCTION 
1.1 Characteristics of Mammalian Stem Cells 
 
Stem cells are unique cells found in multicellular organisms which possess two key 
characteristics (Figure 1.1).1,2 The first is the capacity for self-renewal, the ability to 
divide and give rise to additional stem cells. The second is the capacity for differentiation, 
in which stem cells must also be able to divide under certain conditions to yield 
differentiated cells with specialized functions. Stem cells are broadly classified by their 
source and/or potency (Table 1.1). Potency, or plasticity, refers to the range of cells a 
stem cell is capable of producing.2 Totipotent stem cells are capable of giving rise to all 
three germ layer cell types (endoderm, mesoderm, and ectoderm) of an organism as well 
as extra-embryonic tissues. Pluripotent stem cells are more restricted and cannot give rise 
to extra-embryonic tissues. Multipotent stem cells are even more restricted and are only 
able to give rise to a select few types of specialized cells found within a tissue. Lastly, 
unipotent stem cells only give rise to a single specialized type of cell while also having 
the capacity for self-renewal.  
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Table 1.1 Classification of stem cells.  
Table detailing the classification systems for different types of stem cells. Modified with permission from 
Hui et al. 2011.2 
 
Classification Definition Examples 
Source/Type 
 Embryonic 
Stem Cells 
(ES Cells) 
Pluripotent stem cells derived from the inner cell 
mass of the blastocyst embryo 
Human ES cell lines  
Induced 
Pluripotent 
Stem Cells  
(iPS Cells) 
Pluripotent stem cells derived by direct epigenetic 
reprogramming of somatic cells through ectopic 
expression of specific pluripotency factor genes 
Human iPS cell lines 
Adult Stem 
Cells  
(adSCs) 
Stem cells which are found in adult tissues. These 
cells tend to be restricted in their differentiation 
potential and only differentiate into tissue-specific 
specialized cells. These cells are important in tissue 
repair and regeneration. 
Intestinal Lgr5+ stem 
cells, hematopoietic 
stem cells (HSCs), 
mesenchymal stem 
cells (MSCs) 
Potency 
 Totipotent Cells which have the potential to give rise to all cell 
types in an organism including embryonic tissues 
from all three germ layers (endoderm, mesoderm, 
ectoderm) as well as extra-embryonic 
trophectoderm placental tissue. 
Zygote to Morula 
 Pluripotent Cells which have the potential to give rise to all cell 
types of the embryo but cannot give rise to extra-
embryonic placental tissues. 
Human ES Cells from 
the blastocyst inner 
cell mass 
 Multipotent Cells which have a limited differentiation potential 
confined to producing only differentiated cells 
found in a single tissue type 
Intestinal LGR5+ 
stem cells, 
HSCs/MSCs 
 Unipotent Cells which retain the ability of self-renewal and 
proliferation, however they are capable of 
producing only one differentiated cell type. 
Muscle Satellite cells 
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Figure 1.1 Stem Cell Biology.  
Diagram depicting the two key characteristics, self-renewal and differentiation capacity, which are unique 
to stem cells. Figure created using artwork from Servier Medical Art under a creative commons license. 
 
1.1.1 Embryonic and induced pluripotent stem cells 
 
Embryonic stem cells are pluripotent cells derived from the inner cell mass of 
blastocysts.2–4 Work on embryonic stem cells (ESCs) initially began in the mouse, with 
mouse ESCs (mESCs) being discovered in 1981.5 Mouse ESCs were found to provide a 
source of pluripotent cells with essentially limitless proliferation capacity and were 
capable of in vitro differentiation to all three germ cell layers. The historical work on 
mESCs paved the way for the isolation and establishment of human ESCs (hESCs) in 
1998 by James Thomson.1,6 hESCs are derived from donated embryos which were 
originally produced for clinical in vitro fertilization therapy.3,6 These embryos, at the 5-
day blastocyst stage, are used to isolate inner cell mass (ICM) cells which are then used 
to establish in vitro hESC lines (Figure 1.2).3 Several signalling pathways have been 
shown to be required for maintaining pluripotency of hESCs including the 
Activin/Nodal/TGF-ß and FGF pathways.7 hESCs express several characteristic genes 
which are integral in maintaining pluripotency such as OCT4, NANOG, and SOX2.8,9  
 
Stem Cell
Specialized 
Differentiated
Cells
Stem
Cell
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Figure 1.2 Origin and derivation of ESCs. 
Diagram depicting the developmental origin and derivation of ESCs. Figure created using artwork from 
Servier Medical Art under a creative commons license. 
 
Induced pluripotent stem cells (iPSCs) were first described by Shinya Yamanaka’s group 
in 2006 in mice and in 2007 with human cells.10,11 iPSCs are pluripotent cells initially 
derived from mature, somatic cells which express a similar transcriptional profile and 
show similar differentiation capacity as ESCs. iPSCs are produced by taking a somatic 
cell, for instance a fibroblast, and exposing the cell to four transcription factors such as 
OCT4, SOX2, KLF4, MYC. These factors were initially introduced into cells through 
integrational retrovirus/lentivirus gene delivery techniques.12 However, recent advents in 
the field allow for non-integrative methods such as episomal DNA, direct mRNA 
delivery, or recombinant protein delivery, which eliminates the risk of mutations 
occurring at the site of integration.12 The development of iPSC technology has 
revolutionized the field of stem cell biology. iPSCs allow for stem cell derivation from 
patients with rare diseases to develop, in most cases for the first time, an in vitro model 
of human disease. Additionally, the advent of iPSC technology provides hope for one day 
being able to derive allogenic stem cell lines from patients that can be then be used for 
cell based therapies and personalized medicine.12  
Due to their extensive in vitro expansion and differentiation capacities, both ESCs and 
iPSCs have been proposed as cell sources for regenerative medicine and cell therapy. 
However, several challenges still exist with these cells that must be overcome before they 
become useful for clinical applications. This includes the lack of in vitro differentiation 
Fertilized egg
Cultured undifferentiated
Embryonic stem cells
Embryo
Isolated
ICM cells Blastocyst
Inner	Cell	Mass
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protocols to produce mature, adult cell types. For example, current protocols for 
differentiating hepatocyte-like-cells from hESCs/iPSCs produce cells more closely 
resembling fetal hepatocytes than adult hepatocytes.13–15 Additionally, the ethical 
implications of using hESCs are still of concern due to their embryo-derived nature. 
However, the availability of iPSCs may help to bypass this ethical problem and may serve 
as an alternative pluripotent cell source. Finally, the potential for teratoma formation by 
contaminating pluripotent cells in a sample of iPSC/ESC derived differentiated cells is 
another concern when considering these cells for therapy. 
1.1.2 Adult tissue stem/progenitor cells 
 
Adult stem cells (adSCs) are multipotent stem cells which reside in adult tissues and are 
capable of self-renewal and differentiation into a limited number of organ/tissue-specific 
cell types.2,16,17 Historically, the gold-standard adSC was hematopoietic stem cells 
(HSCs).18 HSCs are rare cells, found in the bone marrow, which are capable of self-
renewal. They are also able to differentiate into all blood cell lineages. HSCs divide to 
give rise to progressively more differentiated progenitor cell populations. These 
progenitor cells then further differentiate to give rise to mature blood cell lineages 
including red cells, megakaryocytes, myeloid cells, and lymphocytes. The presence of 
HSCs is what allows for bone marrow transplantation to be an effective therapy and is 
the first example of stem cell therapy in humans.18  
Recently, an additional source of adSCs has been described. These adSCs have been 
discovered in a remarkably large number of epithelial lined tissues including the skin, 
stomach, intestine, mammary glands, kidney, prostate, and others.17,19–24 These epithelial 
adSCs, despite residing in specialized tissues with unique functional requirements, have 
been found to rely on similar niche signals across tissues.17,25 One pathway that is 
important for maintaining these stem/progenitor cells is the WNT signalling pathway. 
This pathway is well-conserved in multicellular organisms.25–27 WNT proteins are 
important regulators of development and morphogenesis in multiple tissues and there are 
over 20 WNT proteins in mammals. The WNT signalling pathway is complex with 
several different divergent pathways within it. The most well-known is the canonical 
WNT pathway (Figure 1.3).  
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Figure 1.3 Canonical WNT signalling pathway and the LGR5/RSPO axis. 
Diagram depicting the canonical WNT signalling pathway and its amplification through LGR5/RSPO. 
Modified with permission from Koo et al (2014).28  
 
This pathway consists of WNT ligands that bind to a family of Frizzled (FZD) receptors. 
This initiates a signalling cascade resulting in the activation of ß-catenin which translates 
into the nucleus to activate the TCF/LEF transcription factor. This ultimately leads to the 
transcription and translation of WNT target genes which exert the biological effects of 
the WNT pathway.28 When WNT ligands are not present, ß-Catenin is inactivated through 
phosphorylation by the destruction complex (members include APC, Axin, GSK3ß). 
Phosphorylated ß-catenin is targeted to the proteasome for degradation. The canonical 
WNT pathway has been shown to be critical in maintaining self-renewal and proliferation 
of epithelial stem cells. Further, the orphan G-protein coupled receptor LGR5 has recently 
been identified as a marker of adult epithelial stem cells in multiple tissues. LGR5, along 
with its ligands R-Spondin 1, 2, and 3 (RSPO), acts to modulate and enhance WNT 
signalling by inhibiting RNF43.28 RNF43 usually targets the FZD and LRP5/6 receptors 
for degradation and acts as a negative regulator of WNT signalling. LGR5/RSPO prevent 
this, thereby increasing the longevity of FZD and LRP5/6 receptors on the cell surface 
potentiating WNT signalling (Figure 1.3). The discovery of the LGR5/RSPO axis has 
been critical for the isolation of LGR5+ adSCs from a number of epithelial tissues and 
the discovery of RSPO has made it possible to culture these cells in vitro using 
recombinant RSPO proteins.  
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1.2 Hepatobiliary compartment – Liver  
 
The liver is the largest internal organ in the human body, weighing over one kilogram and 
making up 2.5% of adult body weight.29,30 The liver is responsible for hundreds of critical 
biological functions such as the detoxification of xenobiotics and metabolic breakdown 
products, lipid and cholesterol synthesis, red blood cell recycling, protein synthesis 
including blood clotting factors and complement, and glycogen storage.31 The liver is 
macroscopically divided into two lobes and receives blood supply from both the hepatic 
artery and portal vein, with vascular drainage accomplished via the central vein.29–31  
Human diseases of the liver are responsible for high morbidity and mortality and are the 
12th leading cause of death in the United States.32 Cirrhosis is a common endpoint for 
patients with end-stage liver disease (ESLD). Common complications of cirrhosis include 
portal hypertension, ascites, hepatic encephalopathy, variceal haemorrhaging, and 
death.32 Cirrhosis develops after years of chronic injury to the liver that results in 
progressive fibrosis and loss of functional liver tissue.33 Aetiologies of liver fibrosis are 
varied and include those such as alcoholic liver disease, Schistosoma infection, viral 
hepatitis, non-alcoholic fatty liver disease, autoimmune hepatitis, a variety of genetic 
disorders including inborn errors of metabolism, and drug or toxin induced liver failure.33 
Currently, ESLD can only be cured by orthotopic liver transplantation.32,34 
1.2.1 Anatomy and embryology of the liver  
 
At the microscopic level, the adult liver is highly organized. There are five specific cell 
types of the liver well characterized so far (Table 1.2).31 These cell types are classified 
into either parenchymal or non-parenchymal types. Parenchymal cells consist of 
hepatocytes which are the main functional cell type of the liver. Non-parenchymal cells 
consist of hepatic stellate cells, kupffer cells (resident macrophages), sinusoidal 
endothelial cells, and cholangiocytes. The basic organizational unit of the liver is the 
hepatic lobule, composed of a central vein surrounded by portal triads (Figure 1.4).  
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Table 1.2 Predominant cell types of the liver and their functions. 
Modified with permission from Si-Tayeb et al (2010).31 
Cell Type Function 
Hepatocytes ~70% of the liver cells 
Protein synthesis and secretion 
Bile acid synthesis and secretion 
Cholesterol metabolism 
Detoxification 
Urea metabolism 
Glucose/Glycogen metabolism 
Acute phase response 
Blood clotting 
Cholangiocytes ~3% of the liver cells 
Form ductular system to transport bile 
Control bile flow 
Modify and concentrate bile 
Secrete H20 and Bicarbonate 
Control pH of bile 
Stellate Cells ~1-2% of liver cells 
Extracellular matrix maintanence 
Activated to become myofibroblasts 
Participate in regenerative response to 
injury 
Vitamin A storage 
Secrete cytokines 
Endothelial Cells ~2.5% of liver cells 
Vasculature cells 
Form veins, arteries, venuoles, and 
arterioles 
Control blood flow 
Paticipate in parenchymal zonation 
Kupfer Cells ~2% of liver cells 
Resident macrophages  
Scavengers of foreign material 
Chapter 1: Introduction 
    
 
9 
 
Figure 1.4 Functional anatomy and microscopic architecture of the liver.  
Diagram depicting the microscopic anatomy of the liver lobule and the components of the portal triad. 
Image modified with permission from Si-Tayeb et al (2010).31 
 
Portal triads consist of a portal vein, hepatic artery, and bile duct. Blood flows from the 
portal vein to the central vein via sinusoids. Hepatocytes lining sinusoids uptake, modify, 
and transport substances actively into the circulation. Hepatocytes also produce bile, 
which is secreted into bile canaliculi that are lined with cholangiocyte cells. Bile 
ultimately drains into larger ducts and out of the liver through the biliary system. This 
fully mature liver structure is not obtained until the post-natal period.31 During 
embryogenesis, the liver is derived from the definitive endoderm and ventral foregut.31,35 
Hepatogenesis relies heavily on reciprocal signalling interactions between the endoderm 
and mesoderm. The hepatic diverticulum forms from the ventral foregut and is the first 
evidence of liver development. The hepatic diverticulum is in close proximity to the 
embryonic heart and gives rise to the liver bud. The liver bud is composed of bipotential 
progenitors, called hepatoblasts, which differentiate to form hepatocytes and intrahepatic 
bile duct cholangiocytes. The septum transversum mesenchyme gives rise to stellate cells 
in the liver. As the embryonic liver continues to develop, it is vascularized and ultimately 
acts as the primary site of embryonic haematopoiesis.31,35 
1.2.2 Liver regeneration and homeostatic turnover 
 
The liver has long been known to possess a remarkable, yet complex capacity for 
regeneration.36 After partial hepatectomy, rodents are capable of regenerating their entire 
pre-surgical liver mass in as little as 5-7 days.36,37 Liver regeneration and the predominant 
mechanism by which new cells are derived, is dependent on the type of liver injury pattern 
present. In the partial hepatectomy model, it has been shown that regeneration is driven 
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largely by the proliferation of mature cell types in the liver, which re-enter the cell cycle 
and divide to supply new hepatocytes and restore tissue mass.36,37  
However, in injury models where mature hepatocyte growth is impaired, such as in 
chronic fibrotic disease, it has been suggested that liver stem/progenitor cells (LPCs) may 
become the primary source of cells for regeneration, although the origin and identity of 
these cells is still controversial in the field.36–40 It has been suggested that both the 
hepatocyte and biliary compartments of the liver can act as sources of regenerating cells. 
Which compartment becomes activated may depend on the degree and/or aetiology of 
liver injury. In the hepatocyte compartment, two sub-populations of hepatocytes are 
thought to contribute to liver regeneration under different circumstances: (1) Pericentral 
diploid, Axin-2 positive hepatocytes contribute to homeostatic liver turnover and (2) 
Periportal Hybrid Hepatocytes (HybHeps) participate in regeneration under states of 
chronic liver injury.39,41 Within the biliary compartment, it has been proposed that a 
subpopulation of intrahepatic biliary epithelial cells, called oval cells or liver progenitor 
cells, have the ability to differentiate into both cholangiocytes and hepatocytes.42–44 Oval 
cells are thought to act as the regenerative cell type when hepatocyte division is 
impaired.38,45 These biliary progenitor cells will be discussed in more detail below in 
relation to the stem cells of the biliary compartment. Here we will focus on the hepatocyte 
compartment.  
1.2.2.1 Pericentral diploid axin2-positive hepatocytes  
 
Wang et al (2015) first described a population of hepatocytes which lie adjacent to the 
central veins in murine livers.41 In the course of their work, they noticed that a portion of 
hepatocytes lining central veins expressed the WNT pathway target gene AXIN2 along 
with the early hepatoblast/pluripotency gene TBX3. Using lineage-tracing techniques, 
they were able to demonstrate that Axin2 positive hepatocytes were capable of self-
renewal while also giving rise to 40% of all hepatocytes in the liver over the course of 
one year. These pericentral hepatocytes were also found to be unique in that they were 
diploid, whereas most mature hepatocytes are polyploid. Polyploid cells are thought to 
have a lower replicative potential and are usually associated with senescent cells in 
comparison to diploid cells. The authors suggest that the diploid status of the Axin2 
positive pericentral hepatocytes may explain their ability to continue to divide and restore 
hepatocytes under homeostatic conditions. The authors also demonstrated that the central 
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vein endothelium secretes WNT ligands (WNT2 and WNT9b) thought to be the source 
of WNT signals responsible for maintaining the niche of these pericentral hepatocytes. 
This work represents a major discovery into the regenerative mechanisms at play in the 
liver. Further, for the first time, they demonstrated that a population of cells, with stem 
cell like characteristics, exists in the hepatocyte compartment of the liver and are 
responsible for hepatocyte turnover in homeostasis. The role these pericentral hepatocytes 
play in liver injury was not assessed and remains to be studied. In 2015, it was discovered 
that an additional population of hepatocytes, located at the opposite end of the liver lobule 
at the portal vein, are capable of regenerating the damaged liver. These cells, called 
periportal hybrid hepatocytes (HybHPs), are discussed below.  
1.2.2.2 Periportal hybrid hepatocytes 
 
HybHPs were first described by Font-Burgada, et al (2015).39 Their work identified a 
population of hepatocytes adjacent to the portal vein and in close contact to the bile ducts. 
These periportal hepatocytes were named hybrid hepatocytes due to their expression of 
both biliary and hepatocyte lineage markers (Figure 1.5). Using lineage-tracing 
techniques these HybHPs were shown to proliferate in mice following treatment with 
liver toxins such as carbon tetrachloride. Further, HybHPs showed high engraftment 
ability in a FAH-/- mouse model. These HybHPs were transcriptionally unique from 
conventional hepatocytes and bile ducts. However, the HybHPs expressed several key 
markers of biliary cells including SOX9 and SPP1, while also expressing markers of 
mature hepatocytes such as HNF4A and HNF1A. Interestingly, expression of oxidative 
metabolism genes was lower in HybHPs than conventional hepatocytes. The authors 
suggest that this may mean HybHPs do not play a large role in the detoxification function 
of the liver. HybHPs may then be protected from many of the insults related to liver 
toxicities, making them a likely cell type to participate in regeneration.39 
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Figure 1.5 Diagram depicting the two sources of regenerative hepatocytes in the 
liver.  
Reproduced with permission from Bird et al (2015).46 
 
1.3 Hepatobiliary Compartment – Biliary Tree 
1.3.1 Anatomy of the biliary and pancreatic duct systems 
 
The biliary tree is a series of ductular tissues whose primary responsibilities include the 
drainage and modification of bile produced by the liver and pancreatic digestive 
secretions from the pancreas.47,48 The biliary system can be anatomically divided into 
three broad compartments: intrahepatic, extrahepatic, and pancreatic (Figure 1.6). The 
intrahepatic compartment, which consists of the bile ducts inside the liver parenchyma, 
is further divided based on duct diameter.49 The smallest intrahepatic ducts begin at the 
canals of Hering and proceed in increasing size from terminal cholangioles (<15 um 
diameter), interlobular ducts (15-100 μm), septal ducts (100-300 μm), area ducts (300-
400 μm), segmental ducts (400-800 μm) to ultimately terminate at the hepatic ducts (>800 
μm).49 The right and left hepatic ducts merge to form the common hepatic duct, which 
marks the beginning of the extrahepatic compartment. The extrahepatic compartment is 
defined not by duct size but instead by anatomical region. The extrahepatic compartment 
includes the common hepatic duct, gallbladder (GBD), cystic duct, and common bile duct 
(CBD). Additionally, inside the pancreatic parenchyma, a pancreatic ductal system also 
exists, which, similarly to intrahepatic bile ducts inside the liver, are categorized based 
on duct size.50 Pancreatic duct diameter increases successively from the smallest 
intercalated ducts, to intralobular ducts, interlobular ducts, and ultimately merge to form 
the main pancreatic duct (PancD).50 Common to each of these regions of the biliary tree 
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is a lining by specialized epithelial cells called cholangiocytes.49 Cholangiocytes are 
highly polarized cells with an apical and basolateral domain. They contain apical 
microvilli and have primary cilia. Cholangiocytes ubiquitously express the cytokeratins 
KRT19 and KRT7 as well as epithelial cell markers such as EPCAM.49 In the smallest 
intrahepatic and intrapancreatic ducts, cholangiocytes are cuboidal in shape. As duct 
diameter increases, cholangiocytes become columnar in shape. The large intrahepatic and 
intrapancreatic ducts, extrahepatic ducts, main pancreatic duct, and gallbladder are all 
lined by a simple columnar epithelium (Figure 1.6). Unique to the gallbladder is a folded 
mucosa with a structure resembling the intestine with an underlying smooth muscle layer 
allowing for gallbladder contraction.51  
 
 
Figure 1.6 Anatomy and histology of the human biliary tree.  
Diagram depicting the anatomy of the biliary tree (modified with permission from Cardinale et al. (2012)) 
and histological images of different regions of the biliary tree stained for EPCAM (green) an epithelial cell 
specific marker, with DAPI (blue) counterstaining of the nuclei.52  
 
Additionally, the larger intrahepatic bile ducts, extrahepatic bile ducts and pancreatic 
ducts have glandular structures underlying the main epithelium. These glandular 
structures are called peribiliary glands (PBGs) or pancreatic duct glands (PDGs) in bile 
and pancreatic ducts respectively, and largely serve an unknown biological function. 
Intrahepatic Ducts
Gallbladder
Common Bile Duct
Pancreatic Duct
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Recently, the PBGs/PDGs have been shown to be connected to the main epithelium 
through small channels and are thought to harbour mucin producing cells.53 Reports 
suggest that the PBGs/PDGs possess cells with a regenerative capacity and contain biliary 
stem/progenitor cells, however this still remains to be definitely shown.54  
1.3.2 Heterogeneity in the intrahepatic biliary epithelium 
 
Within the intrahepatic biliary tree, cholangiocyte heterogeneity exists.55–58 Two types of 
cholangiocytes have been described: small and large. Small cholangiocytes, which are 
around 8-9 μm in diameter, line the smallest intrahepatic ductules and canals of Hering.55 
Large cholangiocytes, around 14-15 μm in diameter, line larger intrahepatic ducts.55 
Almost all of this work has been performed in rodents, led by Gianfranco Alpini and 
others. Using laser microdissection techniques, Alpini and colleagues were able to isolate 
intrahepatic bile duct units from rat livers and select for duct size, in order to specifically 
study small or large ducts independently.59 Additionally, in vitro small and large 
cholangiocyte cell lines have been established using counterflow elutriation and 
immunoaffinity separation.60 Subsequent investigation of these cell lines and also on the 
intrahepatic bile duct units, uncovered differential expression of markers and differences 
in biologic function between the two types of cholangiocytes (Figure 1.7).55–60 Large 
cholangiocytes are responsible for biliary secretory functions and respond to secretin and 
somatostatin. The biological function of small cholangiocytes is less well-understood but 
they may act as a reservoir for regenerating large cholangiocytes in states of injury.55–60 
Ultimately this work indicates that cholangiocytes are not a uniform cell population 
within the liver. It is important to note that most of this work has been performed on 
rodent intrahepatic bile ducts and only limited work has been performed in human 
intrahepatic bile ducts.56 Furthermore, although it is largely assumed that the large 
extrahepatic bile ducts are lined by cholangiocytes similar to the large intrahepatic 
cholangiocytes, the direct comparison of extrahepatic cholangiocytes to either type of 
intrahepatic cholangiocyte has not been performed.61 
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Figure 1.7 Characteristics of small and large intrahepatic cholangiocytes 
Table detailing the differential expression of markers between small and large intrahepatic bile ducts as 
well as images showing a large and small intrahepatic bile duct unit and isolated small/large cholangiocyte 
cells. Figure modified with permission from Han et al (2013).58 ALP: alkaline phosphatase; CFTR: cystic 
fibrosis transmembrane conductance regulator; Cl−/HCO3− AE2: chloride bicarbonate anion exchanger 2; 
γ-GT: γ-glutamyl transpeptidase.  
 
1.3.3 Function of the biliary and pancreatic duct systems 
 
1.3.3.1 Transport and modification of bile 
 
The main functional responsibility of the intrahepatic bile ducts, extrahepatic bile ducts, 
and gallbladder is to transport bile from the liver into the intestine. Bile is an aqueous 
solution made up predominantly of water (95%).62,63 Bile production is initiated in the 
liver where hepatocytes actively secrete components across the canalicular membrane, 
which drain into the beginnings of the biliary tree, the canals of Hering. The liver can 
produce up to 500-1000 mL of bile a day. Bile is made up of the following major 
components:  
Small
Cholangiocytes
Large
Cholangiocytes
Chapter 1: Introduction 
    
 
16 
(1) Bile Acids/Salts, (2) Phospholipids, (3) Cholesterol, (4) Bile pigments/Conjugated 
Bilirubin, (5) Inorganic Salts (K+, Na+, HCO3-), (6) Proteins, (7) Fatty Acids, (8) 
Xenobiotics such as drug metabolism by-products.62,63  
Bile acids are 24-carbon molecules formed from the breakdown of cholesterol. Cholic 
Acid and Chenodeoxycholic acid, primary bile acids, are the two most commonly found 
in human bile.62,63 Prior to secretion into bile, bile acids are conjugated to the amino acids, 
glycine or taurine, which increases their solubility and ability to form sodium salts. Once 
secreted, bile acids form micelles with phospholipids, of which phosphatidylcholine is 
the most common. These micelles help to solubilize free cholesterol in bile and allow bile 
secretion to be the predominant source of cholesterol excretion from the body. 
Additionally, bile acids are amphipathic molecules that promote fatty acid digestion once 
in the intestine. Bacteria in the intestine can also further modify primary bile acids to 
create secondary bile acids. Bile acids are almost entirely reabsorbed in the intestinal 
ileum by what is known as the enterohepatic circulation which returns bile acids directly 
into the portal venous circulation.62,63 It has recently been shown that bile acids, beside 
playing a key role in cholesterol and lipid metabolism, are also capable of acting as 
signalling molecules through nuclear receptors FXR, PXR, and VDR as well as two G-
protein coupled receptors TGR5 and S1P2.64  
Bile pigments consist of conjugated bilirubin, the result of heme degradation pathways.65 
Bilirubin is formed through the oxidation of Heme, a by-product of red blood cell 
turnover. Heme is oxidized by the enzyme heme oxygenase to form biliverdin which is 
then converted to unconjugated bilirubin by the enzyme biliverdin reductase. 
Unconjugated bilirubin is transported to the liver in the blood stream while bound to 
albumin. Bilirubin is finally conjugated to glucuronic acid by members of the family of 
enzymes called uridine-diphosphoglucuronic glucuronosyltransferases. Bacterial flora in 
the colon can further modify conjugated bilirubin to urobilinogen and stercobilinogen 
which is excreted in the stool.65 
Cholangiocytes of the intrahepatic and extrahepatic compartments actively participate in 
the modification of bile through both absorption and secretion, especially in the 
gallbladder.51 These cholangiocytes have been shown to be capable of modifying the 
content of bile by the secretion or absorption of fluid, ions, lipids, cholesterol, bile acids, 
mucins, and even xenobiotic compounds.51 These capabilities are possible due to the 
expression of various transporters on cholangiocytes that are summarized in Figures 1.8 
and 1.9. Additionally, certain hormones and signalling molecules act on cholangiocytes 
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to promote fluid and bicarbonate secretion including secretin, vasoactive intestinal 
polypeptide (VIP), acetylcholine (ACh), and bombesin.49 Other molecules act on 
cholangiocytes to inhibit secretion such as somatostatin (SST) and endothelin-1 (ET-1).49 
Many of these signalling factors are produced by intestinal neuroendocrine cells, coupling 
intestinal digestion states directly to bile modification. Interestingly, the expression of 
some transporters and receptors for signalling factors may differ along the biliary tree.51  
 
 
Figure 1.8 Diagram depicting the molecular mechanisms thought to regulate 
lipophilic molecule transport in bile duct cholangiocytes 
Biliary cholangiocytes secrete and absorb various lipophilic molecules such as cholesterol, bile acids, and 
xenobiotics. BAs can be transported across the apical membrane of cholangiocytes through the Apical 
Sodium Bile Acid Transporter (ASBT/SLC10A2) or the OATP-A transporter. While bile acids efflux from 
the basolateral membrane through either the OST or ABCC3 transporters. Cholesterol transporters on the 
apical membrane include ones such as ABCG5/8. While cholesterol efflux is accomplished through the 
ABCA1 transporter on the basolateral membrane. Xenobiotics are secreted across the apical membrane 
through ABCG2, ABCC2, and ABCB1 transporters. Diagram modified with permission from Housset et 
al (2016).51 
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Figure 1.9 Diagram depicting the molecular mechanisms thought to regulate fluid 
and ion transport in cholangiocytes 
On the left, isosmotic fluid absorption from the apical to basolateral side of cholangiocytes is depicted. 
NaCl is transported across the apical membrane through the Na+/H+ exchanger (NHE3) and the HCO3-/Cl- 
exchanger (anion exchanger of type 2 or AE2). This allows sodium to enter cholangiocytes down its 
concentration gradient which is maintained by basolateral Na+/K+ ATPase active transport pumps. Water 
absorption then occurs passively down an osmotic gradient through paracellular transport or alternatively 
through aquaporin water transport channels (i.e. AQP1, AQP4, AQP8). On the right, molecular mechanisms 
involved in net fluid and bicarbonate secretion are depicted. Cyclic AMP (cAMP) is produced by Adenylate 
Cyclase (AC) which itself is modified by several pathways. Ultimately, cAMP acts to activate Protein 
Kinase A (PKA). PKA then inhibits the NHE3 transporter stopping fluid absorption. PKA also activates 
the Cystic Fibrosis Transmembrane Receptor (CFTR) which secretes chloride out of cholangiocytes, across 
the apical membrane, to create a chloride gradient which then shifts the AE2 exchanger in favour of net 
bicarbonate secretion. Additionally, bile acids (BA) and Vasoactive Intestinal Polypeptide (VIP) act to 
enhance these pathways. Water is then secreted passively down its osmotic gradient through AQPs or 
paracellular transport. Diagram modified with permission from Housset et al (2016).51 
 
For example, secretin receptor (SCTR) was found to be expressed in intrahepatic bile 
ducts but not gallbladder epithelial cells, while the VIP receptor was highly expressed in 
gallbladder epithelial cells.51,66 Gallbladder epithelial cells in vitro are responsive to 
secretin hormone treatment, but these experiments have usually been performed with 
supra-physiologic levels of secretin. Secretin has also been found to bind to VIP receptors 
Apical
Basolateral
Apical
Basolateral
Fluid Absorption
Fluid and Bicarbonate Secretion
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which may explain this in vitro observation.51 Similarly, the apical sodium bile acid 
transporter (ASBT/SLC10A2) is thought to be highly expressed in gallbladder 
cholangiocytes but not intrahepatic cholangiocytes.51 These observations have not been 
extensively studied and the relationship between different regions of the biliary tree are 
still not fully understood. 
1.3.3.1 Transport and modification of pancreatic exocrine secretions 
 
The pancreas, similarly to the liver, is a highly organized tissue that has two main 
functional compartments: endocrine and exocrine.67 The exocrine compartment of the 
pancreas consists of exocrine acinar cells and ductal cholangiocytes and makes up over 
95% of the total pancreatic mass.68 The endocrine compartment, as well as stromal cells, 
nerves, and blood vessels, make up the remainder (Figure 1.10).67,68 The endocrine, or 
hormone producing cells of the pancreas, reside in the Islets of Langerhans and are 
interspersed throughout the exocrine pancreas. Within the islets, specialized cells produce 
specific hormone types, many of which act to regulate blood glucose levels. Alpha-cells 
produce glucagon, Beta-cells produce insulin, Delta-cells produce Somatostatin, and PP-
cells produce pancreatic polypeptide.67,68 
The pancreatic ductal system within the pancreas makes up only 10% of the total tissue 
mass.50 Pancreatic ducts, unlike bile ducts, which transport bile, function to transport 
pancreatic secretions to the intestine. Pancreatic secretions are first produced by exocrine 
acinar cells, which are highly specialized cells that produce digestive enzymes including 
the zymogen proteases trypsinogen and chymotrypsinogen, pancreatic lipase, nucleases, 
and amylase.69 These enzymes are secreted into the intra-pancreatic ductal system that 
drains into the main pancreatic duct. The main pancreatic duct then merges with the 
common bile duct and drains into the duodenum at the hepatopancreatic ampulla. The 
pancreatic ductal system is lined by cholangiocytes that participate in the modification of 
acinar cell secretions, similarly to bile duct cells that modify bile.50 Pancreatic ductal 
cells, in particular, are responsible for secreting a bicarbonate rich solution that is essential 
for neutralizing the acidic chyme that enters the intestine from the stomach.69 Pancreatic 
ducts also secrete mucins.50 It is thought that many of the same molecular mechanisms 
involved in bile duct fluid and bicarbonate secretion are conserved in pancreatic ducts. 
Indeed, many of the same transporters in bile ducts have been shown to be expressed in 
pancreatic ducts, such as CFTR.50,69 Further, pancreatic duct cells have been shown to 
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respond similarly to SCT, VIP, ACh, and bombesin as bile duct cells.50,69 Interestingly, 
several groups have observed that rare endocrine hormone producing cells may reside in 
the pancreatic ductal compartment and could act to directly secrete hormones such as 
insulin, glucagon, and SST into the pancreatic exocrine secretions.70–72 
 
 
Figure 1.10 Diagram depicting the anatomy and microstructure of the pancreatic 
endocrine and exocrine system. 
Image reproduced with permission from Anatomy and Physiology by OpenStax, Chapter 23.6 Accessory 
Organs in Digestion: The Liver, Pancreas, and Gallbladder 
 
1.3.4 Embryology of the biliary and pancreatic duct systems 
 
Developmentally, the liver and biliary tree derives from the ventral foregut endoderm 
which gives rise to the hepatic diverticulum.73–76 However, the intrahepatic, extrahepatic, 
and pancreatic ductal compartments arise from separate progenitor populations which 
derive from the foregut endoderm. Biliary precursor cells, that will ultimately become 
intrahepatic cholangiocytes, form around the 8th week of digestion in humans.73 They are 
derived from bipotential hepatoblasts in the liver bud that forms from the cranial portion 
of the hepatic diverticulum of the foregut endoderm (Figure 1.11).73–77  
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These bipotential hepatoblasts give rise to both hepatocytes and cholangiocytes (Figure 
1.12).74 Intrahepatic bile duct precursors form from the ductal plate.73–75 The ductal plate 
is a ring-like structure formed from hepatoblasts adjacent to the developing portal vein 
mesenchyme that are induced to become cholangiocyte precursors. Ultimately, the ductal 
plate gives rise to tubular primitive intrahepatic bile duct structures that will become fully 
mature after birth.75  
 
 
Figure 1.11 Diagram depicting the embryological development of the intrahepatic 
and extrahepatic biliary tree and the pancreas. 
Reproduced with permission from Vakili and Pomfret (2008).77 
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Figure 1.12 Developmental origin of intrahepatic and extrahepatic bile ducts, 
hepatocytes, and pancreas. 
Diagram depicting the developmental cellular origin and key markers expressed by these progenitors for 
the intra- and extrahepatic bile ducts, hepatocytes, and ventral pancreas. Reproduced with permission from 
Zong and Stranger (2011).74 
 
Several signalling pathways have been found to be important for the differentiation and 
development of intrahepatic cholangiocytes. Many of these signals are derived from the 
portal mesenchyme, which lies adjacent to the ductal plate (Figure 1.13).73 One of the 
most important of these pathways is the Notch signalling pathway. It has been shown that 
Notch signalling is a master regulator of biliary specification factors HES1, SOX9, 
HNF1B, and HNF6, whose expression is important in committing hepatoblasts to a biliary 
fate. Periportal mesenchymal cells and developing cholangiocytes themselves express 
Jagged 1, the ligand for Notch receptors. In humans, mutations in either Jagged 1 or Notch 
2 have been shown to cause congenital abnormalities in intrahepatic bile ducts, leading 
to bile duct paucity, a syndrome known as Alagille Syndrome.73–76,78 Recent reports have 
also demonstrated the importance of both the Hippo and WNT signalling pathways in bile 
duct development. Not pictured in Figure 1.13, the Hippo downstream regulators, 
YAP/TAZ act to directly increase TGF-ß expression to commit hepatoblasts to a 
cholangiocyte fate.79 Additionally, the tight regulation of WNT signalling and ß-Catenin 
levels are crucial for normal bile duct development and morphogenesis.80 
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Figure 1.13 Molecular mechanisms controlling hepatoblast commitment to a biliary 
precursor fate.  
Diagram depicting important molecular mechanisms controlling biliary commitment in developing liver. 
Image reproduced with permission from Lemaigre (2010).73 Note that this figure is an overview and other 
important pathways such as Hippo and WNT are not shown here. 
 
The development of the extrahepatic bile duct compartment has not been as well-studied 
as the intrahepatic compartment.73–77 Little is known on the molecular mechanisms 
regulating extrahepatic development. However, several factors are common to both intra- 
and extrahepatic cholangiocyte development. The extrahepatic bile ducts and gallbladder 
arise before the intrahepatic biliary system. In the mouse, the extrahepatic and 
intrahepatic compartments are physically separate and anastomose later in development. 
However, in humans, the extrahepatic bile duct compartment is always in contact with 
the liver. The extrahepatic biliary tree and ventral pancreatic buds are derived from 
progenitor cells in the caudal portion of the hepatic diverticulum. These progenitor cells 
express both SOX17 and PDX1, whereas intrahepatic precursors do not express these 
markers.73–76,78 These cells will eventually become specified towards either a biliary or 
pancreatic fate and SOX17 seems to control this.78 It has been shown that SOX17 is 
necessary for the biliary specification of these cells. In the absence of SOX17, gallbladder 
agenesis occurs and common bile duct tissue is replaced with ectopic pancreatic tissue.78 
Likewise, overexpression of SOX17 leads to the ectopic development of biliary tissue in 
the pancreas, stomach, and duodenum.  
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Similar to intrahepatic bile ducts, there is evidence for the importance of HES1, HNF1B, 
and HNF6 in extrahepatic biliary specification.73–76,78 In the absence of HES1, 
intrahepatic bile ducts do not develop normally and pancreas tissue replaces extrahepatic 
ductal tissues.73–76,78   
The pancreas and pancreatic ductal systems are formed from a combination of the ventral 
pancreatic bud (derived from the hepatic diverticulum) and the dorsal pancreatic bud 
(derived directly from the foregut endoderm).81,82 The main pancreatic duct is formed 
through fusion of the ventral pancreatic duct with the distal portion of the dorsal 
pancreatic duct and arises from PDX1+/SOX17- progenitor cells.74,82 The proximal 
portion of the dorsal pancreatic duct often regresses and forms an accessory pancreatic 
duct which drains into the duodenum through the minor papilla. It does not anastomose 
with the common bile duct as the main pancreatic duct does.81 Interestingly, this suggests 
that portions of the pancreatic ductal system may have a closer embryologic origin to the 
duodenum than to the cells arising from the hepatic diverticulum which give rise to the 
ventral pancreas, gallbladder, cystic duct, common bile duct and common hepatic duct.82  
 
1.3.5 Diseases of the biliary and pancreatic duct systems 
 
The human biliary tree is impacted by a range of disease states and many of these diseases 
show regionalization. These biliary disorders are collectively termed cholangiopathies 
and are responsible for 16% of all liver transplants and 50% of paediatric liver 
transplants.83 When bile flow out of the liver is disturbed in these disease states, it leads 
to hepatotoxicity and ultimately can cause liver fibrosis and ESLD necessitating 
transplant. Therapeutic treatment options for most of these diseases are limited, as is the 
understanding of the underlying disease pathogenesis.83 Several cholangiopathies 
preferentially target small intrahepatic bile ducts such as Primary Biliary Cirrhosis, an 
autoimmune inflammatory disorder. While others, such as Primary Sclerosing 
Cholangitis, Biliary Atresia, and non-anastomotic biliary strictures, target large 
intrahepatic ducts and/or extrahepatic bile ducts early in disease.84,85 Cholangiocarcinoma 
of the intrahepatic bile ducts, extrahepatic bile ducts, and gallbladder represent unique 
entities and show phenotypical heterogeneity. It is unclear why these diseases target 
particular regions of the biliary tree.  
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However, it does suggest key differences may exist within these tissues. The 
regionalization of certain cholangiopathies is summarized in Figure 1.14. 
 
 
Figure 1.14 Regionalization of human cholangiopathies. 
Overview of the regionalization and target areas of human cholangiopathies. This is a simplified view and 
represents the usual clinical presentation of the disease. However, several of these diseases can impact more 
than a single region of the biliary tree or have rarer subtypes of disease that may impact more regions than 
presented here. Image modified with permission from Cardinale et al (2012).52 
1.4 Organoids 
 
Organoid is a broad term, but generally is defined as any in vitro culture system which 
utilizes a three dimensional extracellular matrix in order to support the growth of self-
organizing cellular structures.86,87 Organoids can be derived from a broad range of cell 
types but are often derived from stem cells including cells differentiated from iPS/ES 
cells or adSCs. However, organoids do not have to be derived from stem cells and can be 
derived from mature cell types and even tumour cells.88 Generally, organoid cultures 
share many features of the tissue types from which they were derived including tissue 
specific marker expression and functionality. Most organoid culture systems contain only 
one cell lineage, most often epithelial cells.86,87 However, co-cultured organoids 
containing both epithelial and mesenchymal lineages have also been described.86,87,89  
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1.4.1 Adult stem cell derived organoids  
 
Adult stem cell derived organoids are thought to be established from tissue resident 
adSCs.16,87 The culture conditions used to grow adSC organoids attempt to recreate the in 
vivo stem cell niche. Alternatively, conditions may act to mimic states of tissue injury or 
inflammation which activate adSCs.87 Remarkably, most adSC organoid systems rely on 
a well-conserved set of factors, with only minor differences between tissue types and even 
between species. As previously mentioned, one of the crucial factors in the ability to 
propagate adSCs in vitro as organoids was the discovery of the RSPO/LGR5/WNT 
axis.25,87 adSC organoid systems rely heavily on a source of WNT and almost always 
include RSPO and often also a canonical WNT pathway agonist such as WNT3A or CHIR 
99021 (a small molecule inhibitor of one of the destruction complex members, GSK3b) 
in the media. Additionally, it has been shown that modifying other signalling pathways is 
often integral to the establishment of organoid cultures. These include: 
(1) Activation of the Epidermal Growth Factor (EGF) pathway 
(2) TGF-ß inhibition (often accomplished using small molecule inhibitors such as A 
83-01) 
(3) Bone Morphogenic Protein (BMP) pathway inhibition (often accomplished by 
using the inhibitor, Noggin).   
(4) An extracellular matrix (ECM) source, most commonly Matrigel. Matrigel is a 
semi-solid gel that is derived from murine Engelbreth-Holm-Swarm sarcoma 
tumour cell lines. At 4°C it is liquid but at 37°C it solidifies. This makes it an ideal 
ECM matrix source for embedding cells in three-dimensional (3D) in vitro culture 
systems.90 
One of the first organoid systems to be described was for culturing small intestinal, 
LGR5+ adSCs.21 This culture system was developed by Hans Clevers and colleagues and 
revolutionized the field of organoid research. Key to this discovery was decades of work 
invested in understanding the stem cell niche within the intestine. The intestine is a highly 
regenerative tissue with the human intestinal epithelium turning over completely in 2-3 
weeks.67 The intestinal epithelium consists of a highly organized structure, with villus 
and crypt domains that are organized to provide the maximal surface area for digestion 
(Figure 1.15).67  
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Figure 1.15 Anatomy and microstructure of the intestine. 
Diagram reproduced with permission from Anatomy and Physiology by OpenStax, Chapter 23.5 The 
Digestive System: The Small and Large Intestines.67 
 
The intestinal epithelium contains a heterogenous population of cell types including 
absorptive enterocytes, mucin producing goblet cells, paneth cells which secrete 
lysozyme and can act as phagocytes, and enteroendocrine hormone producing cells (i.e. 
S-cells which secrete Secretin or I-cells which secrete Cholecystokinin (CCK)).  
It was discovered through lineage tracing studies that a LGR5+ stem cell population 
resides within the crypts of the intestine.21,91 These stem cells are called crypt based 
columnar cells (CBCs) and are capable of giving rise to all of the differentiated cell types 
of the intestine (Figure 1.16). As LGR5+ cells divide to produce daughter cells, they 
migrate up the crypt towards the villi tip. Signalling gradients are produced by 
mesenchymal and other niche cells that lead to progressive differentiation of these cells 
as they migrate up the villi. These intermediately differentiated, proliferative cells are 
called transit-amplifying (TA) cells. This understanding of intestinal regeneration, as well 
as the discovery of RSPO/LGR5, led to the discovery that intestinal organoids could be 
cultured in vitro. 
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Figure 1.16 Adult stem cell niche of the intestine 
Diagram depicting the adult stem cell niche of the intestine and the process by which LGR5+ stem cells 
divide to give rise to proliferative transit-amplifying (TA) cells which ultimately differentiate to give rise 
to the mature cell types of the intestine. Diagram reproduced with permission from Barker (2014).92 
 
These organoids, which could be grown from single LGR5+ cells embedded in matrigel, 
remarkably self-organize into “mini-guts”, with budding structures reminiscent of the 
crypt/villus domain of the adult intestine. Furthermore, in vitro intestinal organoids not 
only contain LGR5+ stem cells but also give rise to all the differentiated cell lineages of 
the intestine in vitro. The composition and percentage of these differentiated cells can be 
altered and NOTCH and WNT signalling pathways appear crucial for this.93 Following 
the discovery of intestinal organoids, it was found that many other adult tissues from 
endoderm, mesoderm, and ectodermal tissues are capable of forming in vitro organoids 
and that many of these tissues also express the intestinal CBC cell marker LGR5. adSC 
organoids have been derived from tissues including the mammary glands, prostate, lung, 
salivary gland, stomach, large intestine, and oesophagus.20,24,28,87,88 Recently it has also 
been shown in both mice and humans that organoids, potentially containing adSCs, can 
be derived from intrahepatic bile ducts (often termed Liver Organoids), intrapancreatic 
ducts (often termed Pancreas Organoids), and even the gallbladder.94–98 These biliary 
organoids will be discussed below.  
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1.4.2 Biliary stem/progenitor cells and organoids 
1.4.2.1 Liver progenitor cells/oval cells 
 
Within the biliary tree, several groups have reported the existence of candidate 
stem/progenitor cells. Most of this work has historically focused on the intrahepatic bile 
duct compartment, in particular liver progenitor/oval cells. As mentioned above, in mild, 
acute injuries to the liver, such as partial hepatectomy, mature hepatocytes and 
cholangiocytes re-enter the cell cycle and divide to replace the lost cell mass. Whereas in 
chronic or severe acute liver injuries, it has been demonstrated that a population of 
bipotent progenitor cells of biliary origin may be responsible for regenerating lost 
hepatocyte and cholangiocyte mass.36 These cells, called liver progenitor cells (LPCs), 
have been identified in both mice and humans and are thought to be capable of 
differentiating towards either cholangiocyte or hepatocyte fates.43,44,99–102 However, the 
role that these cells play in regeneration and repair of the liver has become controversial 
in the field, with several recent studies indicating that biliary cells do not differentiate 
into hepatocytes in liver injury models to any appreciable degree.103 A recent report by 
Forbes and colleagues may have definitively answered this debate by showing when 
murine hepatocytes are induced to become senescent and prevented from dividing, as is 
found in many human disease states, cells from the biliary compartment are capable of 
replacing these lost hepatocytes.38  
The first liver progenitor cell population to be identified, termed oval cells, was 
discovered in rats in 1956 by Farber.42 These cells were shown to appear after acute liver 
injury in periportal regions and had oval shaped nuclei.42 Further research by multiple 
groups including Evarts et al. 1989 and Lazaro et al. 1998, suggested that these cells are 
bipotent, with the ability to give rise to hepatocytes and cholangiocytes in vivo and in 
vitro. They are thought to arise from a population of cells within intrahepatic bile 
ducts.43,99 Similar cells have since been identified in human liver samples from a 
multitude of disease states as well as healthy livers.44,97,100–102 Despite the discovery of 
oval cells in rodents and hepatic progenitor cells in humans, research on these cells was 
historically hindered due to the lack of specific molecular markers necessary for 
identifying these cells and allowing for their isolation.43 However, recent research has 
begun to identify several possible markers of LPCs including: SOX9, FOXL1, SPP1, 
PROM1, CD24 and most recently LGR5.45,97,98,104–106 Furthermore, recent research has 
also begun to identify important elements of the niche occupied by hepatic progenitor 
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cells and a more extensive understanding of these cells has been emerging. These cells 
are thought to reside in the canals of Hering, which is a boundary zone between 
intrahepatic bile ducts and hepatic cords surrounded by a laminin sheath.37,107,108 
1.4.2.2 Intrahepatic biliary organoids 
 
Within the biliary compartment, several organoid culture systems have been described. 
Huch et al. (2013) used lineage tracing to discover a population of cells in the intrahepatic 
biliary compartment of damaged livers of mice which may represent an oval cell/liver 
progenitor population.98 In the mouse liver, these cells appeared in periportal regions 
following CCl4 induced liver damage but were absent in normal livers.  This population 
of cells was shown to express LGR5 and could be cultured in vitro in 3D organoid 
conditions for over 12 months. The organoids were cultured in media promoting WNT 
signalling, which contained RSPO and EGF, among other factors. These cells were 
subjected to differentiation protocols in an attempt to generate functional hepatocytes in 
vitro and were found to be capable of expressing low-levels of hepatocyte markers.86 
These differentiated cells were then transplanted into a mouse FAH-/- model to further 
test their differentiation ability. Engraftment rates however were low (0.1% to 1%) and 
phenotypic rescue was not demonstrated, although, survival in animals where 
engraftment took place was prolonged and transplanted cells appeared to take on 
hepatocyte-like fates in vivo. 
Following this study, Huch and colleagues extended their work to human liver tissue in 
2015.97 From human livers, they were able to isolate intrahepatic biliary ducts and culture 
them as organoids in conditions promoting WNT signalling. Like their mouse 
counterparts, these cells expressed LGR5 and demonstrated long-term proliferative 
ability. These intrahepatic organoids also showed the capability of expressing hepatocyte 
specific markers under differentiation conditions. However, the expression of these 
markers was lower than adult liver tissue. The human cells were capable of engrafting in 
a mouse liver injury model in vivo and produced detectable levels of human albumin for 
120 days post-transplantation. 
Taken together, these reports strongly suggest that a stem/progenitor population exists in 
the intrahepatic bile duct compartment of both mouse and human livers. These cells can 
be cultured as 3D organoids and express markers of adSCs. However, it is important to 
note that it is still difficult to definitively conclude whether this population of cells derives 
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solely from intrahepatic bile ducts. In the mouse, bipotent periportal cells deriving from 
hepatocytes, and not cholangiocytes, have been reported to also participate in liver 
regeneration after injury.109 
1.4.2.3 Extrahepatic biliary organoids 
 
Despite the decades of work seeking to identify an intrahepatic biliary stem/progenitor 
cell, only a handful of studies have examined the extrahepatic compartment.53,54,110 
Several groups have suggested the existence of a stem/progenitor cell population more 
distally in the extrahepatic biliary tree.53,54,110–117 These cells, similarly to intrahepatic 
cells detailed above, are thought to express markers of adSCs, such as LGR5, and may 
even be capable of differentiating towards other endodermal lineages, such as hepatocytes 
and pancreatic endocrine cells, in vitro.53,54,110–117 Additionally, several reports have 
shown that extrahepatic and pancreatic biliary cells can be cultured as organoids. 
Within the pancreas, it has been reported that intrapancreatic ducts can give rise to 
organoids. Huch et al (2013) described the derivation of intrapancreatic organoids from 
mice.96 Similarly to their work in the liver, Huch and colleagues demonstrated that, 
following injury to the pancreatic ductal system using pancreatic duct ligation, a 
population of LGR5+ cells emerge from the intrapancreatic ducts. These LGR5+ cells 
could be subsequently isolated and cultured as organoids and relied on a RSPO based 
culture media. The organoids expressed markers of ductal cell lineages and markers 
commonly expressed in intestinal stem cells. These organoids could be expanded long-
term, in vitro, and when aggregated with embryonic pancreatic cells and transplanted 
under the kidney capsule in mice, were shown to generate predominately ductal structures 
but also appeared capable of generating a low-level of endocrine hormone producing cell 
types. This work was subsequently extended to include the derivation of human 
intrapancreatic organoids and also pancreatic adenocarcinoma organoids.95,118 Together, 
these reports suggest that a progenitor population may exist in the intrapancreatic ducts. 
However, the differentiation capacity of these cells is still unclear. Common to all of these 
reports, is that these cells, if they do differentiate beyond a ductal fate, do so at an 
extremely low efficiency. It also remains unclear how functional these cells truly are.95,119 
Interestingly, a report by Dorrell et al (2014) compared the organoid initiating cells from 
murine intrahepatic and intrapancreatic ducts. They found that the two cell types were 
very similar in surface marker expression and that intrapancreatic organoids were also 
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capable of engrafting in the livers of FAH-/- mice, suggesting similarities between these 
organoid systems may exist.120 
Several groups have reported the possibility of culturing extrahepatic ductal organoids 
from the common bile duct and gallbladder. Lugli et al (2016) reported on the derivation 
of gallbladder derived organoids from both mouse and human tissues. These gallbladder 
organoids, similarly to intrahepatic and intrapancreatic organoids, relied on culture 
conditions containing RSPO. The murine gallbladder organoids were subjected to a 
differentiation protocol and were shown to upregulate expression of the hepatocyte 
marker Albumin in a small subset of cells. However, when the organoids were 
transplanted in vivo, under the liver capsule, they exclusively generated ductal lineages. 
Further, no differentiation potential was assessed for the human gallbladder organoids.  
Additional reports by Manohar et al (2011 and 2015) identified a clonogenic population 
of potential progenitor cells in the adult mouse gallbladder and fetal human 
gallbladder.115,117 These cells were cultured in two-dimensional (2D) cultures on 
fibroblast feeders. When transferred into a matrigel 3D-growth assay containing RSPO, 
they formed cystic and tubular organoid structures. Furthermore, these clonogenic 
gallbladder cells were shown to be distinct from intrahepatic biliary cells and expressed 
different surface markers as well as showed transcriptional differences. Additionally, 
work by Lola Reid and colleagues has suggested that a population of multipotent, 
endodermal progenitor cells may exist in the human extrahepatic bile duct and 
gallbladder.111,113 These cells have been derived from EPCAM positive cells in adult 
gallbladder and common bile duct and may have the capacity to differentiate towards 
hepatic or pancreatic endocrine lineages, albeit at a low level. It is important to note that 
these cells display a limited proliferation capacity in vitro and until recently could not be 
serially passaged.121 Further, the cells are reported to express markers of pluripotency 
such as OCT4, however, this finding has never been confirmed by other studies and is 
surprising given the absence of these pluripotent markers in adult tissues. 
 Lastly, our own group recently reported on an in vitro organoid system capable of 
expanding human common bile duct and gallbladder epithelial cells.122 These organoids 
were grown in a 3D matrigel system with RSPO1, EGF, and DKK-1 (a canonical WNT 
pathway inhibitor). These organoids, called Extrahepatic Cholangiocyte Organoids 
(ECOs), displayed long-term proliferative ability without expressing markers associated 
with adSCs and instead appeared phenotypically to represent a functional, differentiated 
cholangiocyte population. Further supporting this was that ECOs were capable of 
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colonizing synthetic bio-scaffolds that were subsequently used to reconstruct the murine 
gallbladder and common bile duct. These organoid cells remained integrated in the 
scaffolds in vivo and maintained a mature cholangiocyte phenotype.122   
Ultimately, as can be seen from the summary above, the literature relating to biliary 
organoids/progenitor cells is mixed. Some reports suggest the existence of progenitor 
cells capable of differentiation beyond a biliary fate throughout the biliary tree, while 
others suggest a more limited differentiation capacity for these cells, especially in the 
extrahepatic biliary tree. Additionally, the relationship between these numerous systems 
and the organoids derived from these different tissues is still largely unknown. Therefore, 
the goal of this dissertation was to address some of these key questions and is further 
detailed below.  
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1.5 Dissertation Objectives 
 
The overarching goal of this dissertation was to explore what regionalization may exist 
in the human biliary tree. We sought to not only understand whether differences exist 
between primary tissue regions in vivo but also what differences may exist in cells 
cultured as in vitro organoids from these tissues.  
To accomplish this, I first developed an in vitro organoid culture system capable of 
expanding cells from both intrahepatic and extrahepatic/pancreatic biliary tissues. 
Chapters 3 and 4 aim to address the following questions using these organoid systems 
and primary tissues: 
(1) Can a population of cells with an adult stem/progenitor cell phenotype be isolated 
from the human common bile duct, gallbladder, and pancreatic duct (referred to 
collectively as extrahepatic tissues/cells)? Can these extrahepatic cells be 
expanded long-term in vitro in an organoid culture system promoting WNT 
signalling? 
(2) How do the cells isolated from different regions of the extrahepatic biliary tree 
compare to their tissue of origin, to each other, and to intrahepatic bile duct 
organoids? 
(3) Do different anatomical regions of the biliary tree demonstrate unique 
transcriptional profiles? 
Finally, Chapter 5 aims to describe the differentiation capacity of these organoid systems 
and in particular aims at addressing the following question: 
(4) Do these extrahepatic cells represent a stem/progenitor population with bi- or 
multipotentiality? If so, what is the differentiation capacity of these cells? 
Overall, the work of this dissertation seeks to advance the understanding of biliary 
physiology and the understanding of how different regions of the human biliary tree may 
differ in vivo and in in vitro organoid systems. Secondly, it aims to assess whether human 
extrahepatic biliary tissues are capable of giving rise to organoid cultures with a 
progenitor cell phenotype and whether they are capable of differentiation towards a 
hepatocyte fate, as has been suggested with intrahepatic tissues.
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2 MATERIALS AND METHODS 
2.1 Statement of Source 
 
The methods presented here are largely based on experiments presented in the following 
first author manuscript written by the author of this dissertation. Therefore, some parts of 
these methods have been taken verbatim or with only minor changes from this source.  
Rimland CA, Tilson S, Morell C, Tomaz R, Lu WY, Adams S, Georgakopoulos N, 
Otaizo-Carrasquero F, Myers T, Sun HW, Gieseck RL, Sampaziotis F, Tysoe O, 
Wesley B, Oniscu GC, Hannan NRF, Forbes S, Saeb-Parsy K, Wynn TA, Vallier 
L. (2018) Regional differences in human biliary tissues and corresponding in 
vitro derived organoids. Manuscript in preparation. 
2.2 Human Tissue Material 
 
Human GBD, CBD, PancD, and liver samples were obtained from organ donors at either 
Cambridge University Hospitals or the Royal Infirmary of Edinburgh in the United 
Kingdom. CBD, PancD, and liver samples were obtained when a liver or pancreas was 
deemed unsuitable for transplant, whereas GBD samples were obtained even when a liver 
was suitable for transplant, as the GBD is not routinely transplanted. Informed consent 
for the use of human tissues for research purposes was obtained from each donor’s next 
of kin and protocols were reviewed and approved by the ethics committees at both 
hospitals and consent recorded according to the NHSBT consent regulations.  
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Tissue samples were stored on ice in University of Wisconsin Solution until processed 
for cell isolation as described below. Donor demographics and corresponding cell lines 
derived from each tissue sample are listed in Table 2.1.  
 
Table 2.1 Donor Demographics  
Details of donor tissue samples used for organoid cell line generation or for collection of primary tissue 
RNA.  
 
 
Tissue Donor 
Demographics 
Tissue Sample / Cell Line RNA-Seq 
T=tissue 
O=organoids 
Internal 
ID 
Gallbladder 21, Male Tissue and Cell Line (-A8301/FSK) Not sequenced GBD1 
Gallbladder 33, Female Tissue and Cell Line (-A8301/FSK) Not sequenced GBD2 
Gallbladder 39, Male Tissue and Cell Line Not sequenced GBD3 
Gallbladder 21, Female Tissue and Cell Line T GBD4 
Gallbladder 55, Female Tissue and Cell Line Not sequenced GBD5 
Gallbladder 44, Male Tissue and Cell Line T GBD6 
Gallbladder 63, Male Tissue and Cell Line T/O GBD8 
Gallbladder 61, Female Tissue and Cell Line T/O GBD10 
Gallbladder 67, Male Tissue and Cell Line T/O GBD11 
Gallbladder 67, Male Tissue and Cell Line Not sequenced GBD12 
Gallbladder 68, Female Cell Line only Not sequenced GBD13 
Common Bile Duct 50, Female Cell Line only (-A8301/FSK) Not Sequenced CBD2 
Common Bile Duct 63, Male Tissue and Cell Line T/O CBD4 
Common Bile Duct 20, Male Tissue and Cell Line T/O CBD5 (PD4) 
Common Bile Duct 67, Male Cell Line only O CBD6 
Common Bile Duct 58, Female Tissue only T CBD8 
Common Bile Duct 43, Female Tissue Only T PD1 
Common Bile Duct 48, Female Tissue and Cell Line T/O PD2 
Common Bile Duct 36, Male Tissue and Cell Line T/O PD3 
Common Bile Duct 48, Female Tissue and Cell Line T/O PD5 
Common Bile Duct 61, Female Cell Line only Not sequenced PD6 
Pancreatic Duct 42, Male Tissue and Cell Line T/O PancD1 
Pancreatic Duct 27, Female Tissue and Cell Line T/O PancD2 
Pancreatic Duct 37, Male Cell Line only O PancD4 
Pancreatic Duct 53 , Male Tissue only T PancD5 
Liver 50, Male Tissue and Cell Line 
IHBD_ex, IHBD_Huch 
O-IHBD_Huch
O- IHBD_ex 
IHBD1 
Liver 30, Female Tissue and Cell Line 
IHBD_ex 
O-IHBD_ex IHBD2 
Liver 50, Female Tissue and Cell Line 
IHBD_ex 
O-IHBD_ex IHBD3 
Liver 67, Female Cell Line only 
IHBD_ex, IHBD_Huch 
O-IHBD_Huch IHBD4 
Liver 76, Male Cell Line only 
IHBD_ex, IHBD_Huch 
O-IHBD_Huch
O-IHBD_ex 
IHBD5 
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2.3 Extrahepatic epithelial cell isolation and organoid culture 
 
GBD samples were received as either whole intact GBDs or small 2 cm2 tissue segments. 
Whole GBDs were first punctured with a scalpel and drained of bile. The neck of the 
GBD was then dissected away and discarded. A longitudinal incision was used to open 
the GBD and expose the mucosal surface. No further processing was required for the 
GBD segment samples. CBD and PancD samples were received intact. To expose the bile 
duct lumen the wall of the duct was incised with a scalpel. All samples were washed 3 
times with ice cold Hanks Balanced Salt Solution (HBSS) without Ca2+, Mg2+, or Phenol 
Red. Tissues were then transferred to cold ADV/DMEM F12 media supplemented with 
100 U/mL penicillin and 100 μg/mL streptomycin. The mucosa was then abraded with a 
scalpel to mechanically dissociate the cells (Figure 2.1).  
 
 
Figure 2.1 Extrahepatic biliary epithelial cell isolation procedure. 
Diagram depicting the mechanical isolation method employed to obtain biliary epithelial cells and image 
showing the sheets of epithelial cells recovered. 
 
Cell suspensions were centrifuged at 300 x g for 5 min, washed twice, and re-suspended 
in growth factor reduced matrigel. 50 μL droplets were plated per well into a 24-well 
plate. Matrigel was allowed to solidify for 5-10 min at 37°C before adding 500 μL of 
ADV/DMEM F12 media containing 1x N2-serum free supplement, 1x B27-serum free 
supplement, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. The 
following growth factors were added: 20% R-Spondin conditioned media or 500 ng/mL 
recombinant human R-Spondin 1, 3 μM CHIR 99021, 100 ng/mL recombinant human 
noggin, 2.5 μM PGE2, 100 ng/mL recombinant human EGF, 5 μM A 83-01, and 10 μM 
forskolin. For the first 48 h, 10 μM Y-27632 was added to the media. Media was changed 
Pancreatic
Duct
Common
Bile Duct
Gallbladder
Mechanical
Dissociation
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every 2-3 days. Within 24-48 hr, small cystic organoid structures could be observed. 
Organoids reached confluence after 5-10 days and were split using the procedure below. 
Cells could be readily freeze/thawed using Cell Banker 2 freezing media. 
2.4 Intrahepatic bile duct isolation and organoid culture 
 
Small pieces of human liver tissue (2x2 cm2) were frozen in Cell Banker 2 and stored at 
-80°C until duct isolation was required. For duct isolation (Figure 2.2), frozen liver tissue 
was removed from -80°C and thawed in a 37°C water bath. The thawed tissue was then 
minced into small pieces using a scalpel blade in a 10cm2 tissue culture plate. The tissue 
fragments were washed off the plate and placed into a 50mL conical tube with 20mL of 
digestion media. Digestion media consisted of DMEM High Glucose + Glutamax with 
1% Fetal Calf Serum (FCS), 100 U/mL penicillin, 100 μg/mL streptomycin, 128.4 μg/mL 
of dispase II and 128.4 μg/mL of collagenase from Clostridium histolyticum. Liver tissue 
in digestion media was placed in a 37°C water bath. Every 20 min, for 4-5 hr, the tissue 
was disrupted with a serological pipette of decreasing volume (25mL, 10mL, 5mL, 2mL) 
and ultimately a p1000 pipette to release ducts from surrounding liver tissue. Every 1-2 
hr the tissue pieces were allowed to settle to the bottom of the tube and the digestion 
medium was replaced with new media.  
 
 
Figure 2.2 Intrahepatic bile duct isolation procedure 
Diagram depicting the isolation procedure for intrahepatic bile ducts and image showing an isolated duct. 
 
After 4-5 hr the suspension became clear and could easily pass through a p1000 pipette. 
Ducts were manually picked under a microscope using a p200 pipette and placed into a 
tube containing DMEM High Glucose + Glutamax media with 5% FCS. Ducts were 
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centrifuged for 5 min at 200 x g. Supernatant was aspirated and ducts were re-suspended 
in growth factor reduced matrigel. 50μL droplets of matrigel were plated in a 24-well 
culture plate and allowed to solidify at 37°C. Ducts were overlaid with 500uL of one of 
two medias (1) extrahepatic culture media as described above with 10 μM Y-27632 or 
(2) intrahepatic isolation media for 3 days after which the media was changed to 
intrahepatic expansion media as described in Huch et al (2015) and Broutier et al 
(2016).97,123 See Table 2.2 for all reagents and manufacturers used in cell culture. 
2.5 Organoid passaging 
 
Extrahepatic organoid cultures were split every 5-10 days at a ratio of 1:2-1:4. Culture 
media was removed and cells were incubated in cell recovery solution for 30 min at 4°C. 
Extrahepatic organoids were washed 2 times with ADV/DMEM F12 media and pelleted 
at 300 x g for 4 min. Extrahepatic organoids were mechanically dissociated into small 
clumps and re-suspended in fresh matrigel and re-plated as above. For the first 2 days 
after splitting, media was supplemented with 10 μM Y-27632. 
Intrahepatic organoids were subjected to a similar passaging procedure, with one 
exception. Intrahepatic organoids were not passaged using cell recovery solution and 
were instead mechanically dissociated in cold ADV/DMEM F12 media, disrupted with a 
p200 pipette, washed once and pelleted at 300 x g for 3 min. All other steps remained the 
same as detailed above for extrahepatic organoids. 
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Table 2.2 Reagents used for cell culture 
Basal Organoid Medium = ADF+ Final Concentration Supplier (catalog number) 
Advanced DMEM/F12 (ADF) N/A Thermo Fisher (12634010) 
N2 Supplement 100X 1 X Thermo Fisher (17502048) 
B27TM Supplement 50X, serum-free 1 X Thermo Fisher (17504044) 
L-Glutamine 2 mM Thermo Fisher (25030081) 
Penicillin/Streptomycin 100 U/mL  / 100 
µg/mL 
Thermo Fisher (15140122) 
Extrahepatic Organoid Expansion Media 
(EHBD organoids or IHBD_ex organoids) 
Final Concentration Supplier (catalog number) 
ADF+ See above See above 
RSPO-conditioned media 
or 
Recombinant Human R-Spondin 1 
20% (vol/vol) 
500 ng/mL 
Cambridge Stem Cell 
Institute (homemade) 
R&D (4645-RS) 
CHIR 99021 3 µM Tocris (4423) 
Recombinant Human Noggin Fc Chimera 100 ng/mL R&D (3344-NG) 
Prostaglandin E2 2.5 µM R&D (2296) 
Recombinant Human EGF, carrier free 100 ng/mL R&D (236-EG) 
A 83-01 5 µM Tocris (2939) 
Forskolin (FSK) 10 µM Sigma (F6886) 
Rock Inhibitor Y-27632 
(added for first two days after isolation or splitting) 
10 µM Selleck Chem (S1049) 
Intrahepatic Organoid Isolation Media 
(IHBD_Huch organoids for first 3 days after 
isolation) 
Final Concentration Supplier (catalog number) 
ADF+ See above See above 
RSPO-conditioned media 10% vol/vol Cambridge Stem Cell 
Institute (homemade) 
Wnt-conditioned media 30% vol/vol Cambridge Stem Cell 
Institute (homemade) 
Recombinant Human Noggin Fc Chimera 25 ng/mL R&D (3344-NG) 
N-acetylcysteine 1.25 mM Sigma (A9165) 
Nicotinamide 10 mM Sigma (N0636) 
Human Gastrin I 10 nM Sigma (G9145) or 
R&D (3006/1) 
Recombinant Human EGF, carrier free 50 ng/mL R&D (236-EG) 
Recombinant Human HGF 25 ng/mL Peprotech (100-39) 
Recombinant Human FGF-10 100 ng/mL Peprotech (100-26) or 
Autogen BioClear (ABC144) 
A 83-01 5 µM Tocris (2939) 
Forskolin (FSK) 10 µM Sigma (F6886) 
Rock Inhibitor Y-27632 10 µM Selleck Chem (S1049) 
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Table 2.2 (continued) Reagents used for cell culture 
Intrahepatic Organoid Expansion Media 
(IHBD_Huch organoids) 
Final Concentration Supplier (catalog number) 
ADF+ See above See above 
RSPO-conditioned media 10% vol/vol Cambridge Stem Cell 
Institute (homemade) 
N-acetylcysteine 1.25 mM Sigma (A9165) 
Nicotinamide 10 mM Sigma (N0636) 
Human Gastrin I 10 nM Sigma (G9145) or 
R&D (3006/1) 
Recombinant Human EGF, carrier free 50 ng/mL R&D (236-EG) 
Recombinant Human HGF 25 ng/mL Peprotech (100-39) 
Recombinant Human FGF-10 100 ng/mL Peprotech (100-26) or  
Autogen BioClear (ABC144) 
A 83-01 5 µM Tocris (2939) 
Forskolin (FSK) 10 µM Sigma (F6886) 
Rock Inhibitor Y-27632 
(added only for first two days after splitting) 
10 µM Selleck Chem (S1049) 
Huch et al (2015) Differentiation Media Phase I Final Concentration Supplier (catalog number) 
Intrahepatic Organoid Expansion Media See above See above 
Recombinant Human BMP-7 25ng/mL Peprotech (120-03) 
Huch et al (2015) Differentiation Media Phase II Final Concentration Supplier (catalog number) 
ADF+ See above See above 
N-acetylcysteine 1.25 mM Sigma (A9165) 
Human Gastrin I 10 nM Sigma (G9145) or 
R&D (3006/1) 
Recombinant Human EGF, carrier free 50 ng/mL R&D (236-EG) 
Recombinant Human HGF 25 ng/mL Peprotech (100-39) 
A 83-01 0.5 µM Tocris (2939) 
Recombinant Human BMP-7 25ng/mL Peprotech (120-03) 
Dexamethasone 3 µM Sigma (D4902) 
DAPT 10 µM Sigma (D5942) 
Recombinant Human FGF19, carrier free 100 ng/mL R&D (969-FG/CF) 
Additional Reagents used for cell culture and 
liver tissue digestion 
Final Concentration Supplier (catalog number) 
Cell Banker 2 N/A Amsbio (11891) 
Growth Factor Reduced Matrigel (with or without 
phenol red) 
100% Corning (354230) or 
(356231) 
Cell Recovery Solution N/A Corning (354253) 
TrpLE Express N/A Thermo Fisher (12604013) 
Dispase II 128.4 µg/mL Gibco (17105-041) 
Collagenase from Clostridium histolyticum 128.4 µg/mL Sigma (C9407) 
DMEM High Glucose + Glutamax N/A Thermo Fisher (10566016) 
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2.6 Flow cytometry 
 
Primary epithelial cell scrapings and/or organoid cultures were dissociated to single cells 
using TrypLE Express for 5-10 min at 37°C. Cells were washed once with 1% BSA to 
remove any remaining TrypLE and centrifuged at 400 x g for 3 min. Cells were then fixed 
with 4% Paraformaldehyde (PFA) for 20 min on ice. Cells were washed twice with 1% 
Bovine Serum Albumin (BSA) and pelleted at 400 x g for 3 min and re-suspended in 1% 
BSA and stored at 4°C until needed. Cells were blocked with 10% donkey serum/0.1% 
Triton-X for 30 min at room temperature. Primary antibodies, diluted in 1% donkey 
serum/0.1% Triton-X (antibody diluent), were applied at room temperature for 1 hr. Cells 
were washed 3 times with antibody diluent. Secondary antibodies, diluted in antibody 
diluent, were applied at room temperature for 1 hr. Cells were washed 3 times with 
antibody diluent and filtered through a 40 μm mesh filter prior to sorting. Gates were set 
using single stained, fluorescence minus one (FMO) controls and with cells stained with 
secondary antibodies alone. 10,000 or greater events were captured for each sample.  
2.7 Immunocytochemistry 
2.7.1 Whole mount organoids 
 
Organoids in matrigel were grown in 48-well tissue culture plates (Corning) on 9 mm 
sterilized round glass coverslips (VWR). Culture media was carefully removed and 
organoids were washed for 5 min in Phosphate Buffered Saline (PBS). Organoids were 
then fixed in 4% PFA for 20 min at room temperature to maintain integrity of the matrigel. 
Organoids were washed 2 times with PBS to remove any remaining PFA. Organoid 
coverslips were blocked and permeabilized in 10% donkey serum/0.1% Triton-X for 3 
hr. Primary antibodies, diluted in 1% donkey serum/0.1% Triton-X (antibody diluent), 
were applied overnight at 4°C. Organoid coverslips were washed 3 times at room 
temperature in the antibody diluent for 1 hr per wash. Secondary antibodies were applied 
overnight at 4°C and then washed 2 times for 1 hr each at room temperature. Nuclei were 
stained with Hoechst 33258 (1:10,000, Sigma) in PBS for 30 min at room temperature.  
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Organoid coverslips were washed once more with PBS for 1 hr. Coverslips were carefully 
removed using forceps and mounted on glass slides using Fluoromount G. A list of 
antibodies used can be found in Table 2.3. 
 
 
Table 2.3 List of antibodies used 
Immunocytochemistry (IC), immunocytochemistry on frozen sections (IC-Fr) or flow cytometry (FC) 
Antibody Species Company/Product # Dilution Application
EPCAM Mouse Monoclonal R&D / MAB9601 1:100 IC
IC-Fr
FC
KRT7 Rabbit Monoclonal AbCam / ab68459 1:100 IC
IC-Fr
FC
KRT7 Mouse Monoclonal AbCam / ab9021 1:100 IC
IC-Fr
KRT19 Mouse Monoclonal AbCam / ab7754 1:100 IC
IC-Fr
FC
HNF4α Rabbit Monoclonal AbCam / ab92378 1:100 IC
IC-Fr
Sox9 Rabbit Monoclonal AbCam / ab185230 1:100 IC
IC-Fr
β-Catenin Goat Polyclonal R&D / AF1329 1:100 IC
IC-Fr
Ki67 Rabbit Monoclonal AbCam / ab15580 1:100 IC
IC-Fr
CDX2 Rabbit Monoclonal AbCam / ab76541 1:100 IC
IC-Fr
SOX17 Goat Polyclonal R&D / AF1924 1:100 IC
IC-Fr
Alexa Fluor 488 Donkey anti-goat IgG Invitrogen / A11055 1:1000 IC
IC-Fr
Alexa Fluor 488 Donkey anti-mouse IgG Invitrogen / A10037 1:1000 IC
IC-Fr
FC
Alexa Fluor 488 Chicken anti-mouse IgG Thermo / A21200 1:1000 IC
IC-Fr
Alexa Fluor 488 Chicken anti-goat IgG Thermo / A21467 1:1000 IC
IC-Fr
Alexa Fluor 568 Donkey anti-goat IgG Invitrogen / A11057 1:1000 IC
IC-Fr
Alexa Fluor 568 Donkey anti-mouse IgG Invitrogen / A10037 1:1000 IC
IC-Fr
Alexa Fluor 568 Donkey anti-rabbit IgG Invitrogen / A10042 1:1000 IC
IC-Fr
Alexa Fluor 647 Donkey anti-rabbit IgG Invitrogen / A31573 1:1000 FC
TRITC Donkey anti-Goat IgG Thermo / A16010 1:1000 IC
IC-Fr
TRITC Donkey anti-rabbit IgG Thermo / A16040 1:1000 IC
IC-Fr
Hoechst 33258 Nuclear Stain Sigma / 94403 1:10,000 IC
IC-Fr
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2.7.2 Tissue and OCT-embedded organoids 
 
Tissue samples were washed twice in HBSS and fixed on ice for 30-45 min in 4% PFA. 
Tissues were then cryoprotected in 30% sucrose overnight on ice. Organoids were 
removed from matrigel using cell recovery solution and fixed for 20 min in 4% PFA and 
washed twice with PBS. Tissue and organoids were then embedded in Optimal Cutting 
Temperature (OCT), snap frozen, and sectioned at 8 µm. Slides were blocked with 10% 
donkey serum/0.1% Triton-X for 1 hr. Primary antibodies, diluted in 1% donkey 
serum/0.1% Triton-X (antibody diluent), were applied overnight at 4°C. Slides were 
washed 3 times for 5 min with antibody diluent. Secondary antibodies in antibody diluent 
were applied for 1 hr at RT. Slides were washed three times with antibody diluent for 5 
min, nuclei counter-stained with Hoechst 33258 for 5 min, and mounted with 
Fluoromount G. All images were acquired using either a Zeiss LSM700 laser scanning 
confocal or a Leica DMLB fluorescent microscope and analysed using ImageJ. 
 
2.8 Quantitative RT-PCR (qPCR) 
 
Total RNA was extracted using either the RNeasy Mini Kit or RNeasy Micro Kit from 
Qiagen depending on the expected RNA yield of each sample. Total RNA was reverse-
transcribed using Superscript II Reverse Transcriptase (Invitrogen). 10μL qPCR reaction 
mixtures were prepared using the SensiMix SYBR Low-ROX Kit (Bioline) and run on 
either a Life Technologies QuantStudio 12K Flex or QuantStudio 6 machine in technical 
duplicate. All genes were normalized to the housekeeping gene Ubiquitin (UBC). Primer 
sequences used are listed in Table 2.4. 
2.8.1 Primary human controls for qPCR  
 
Primary human hepatocytes were purchased from Biopredic International, France. RNA 
was isolated from primary hepatocytes using the GenElute mammalian total RNA 
isolation kit (Sigma-Aldrich) and qPCR carried out as above in technical duplicate.  
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Primary human sigmoid colon organoids were derived from biopsy samples and cultured 
as described previously124 and RNA isolated using the RNeasy Micro Kit (Qiagen) and 
qPCR reactions were carried out as above in technical duplicate. 
Human embryonic stem cells were cultured as previously described7 and the line H9 used 
for all experiments. RNA was isolated using the RNeasy Micro Kit (Qiagen) and qPCR 
reactions were carried out as above in technical duplicate. 
 
 
Table 2.4 List of primers used for qPCR 
 
2.9 RNA-Sequencing 
 
RNA was isolated from 3 to 7 biological replicates from either organoid cell lines at 
Passage 5 or from primary extrahepatic tissues as described above. RNA samples were 
sent for next-generation sequencing at the NIAID Genomics Technologies Branch. 
Stranded, poly-A purified mRNA truSeq libraries were prepared using the Illumina 
NeoPrep system. Single-end 75 bp reads were obtained using a NextSeq500. At least 20 
million reads/sample evenly distributed across the lanes were obtained. If this number of 
reads was not reached, the samples were re-sequenced to reach at least 20 million reads. 
Reads were trimmed to 70 bp and reads less than 40 bp were discarded. Transcript 
abundance was estimated using Salmon with default settings.125 The Tximport package 
was used to summarize transcript abundances to the gene level and the DeSeq2 package 
was used to combine sequencing replicates and for principal component and differential 
*ene ForZard Primer ReYerse Primer
/*R5 CTCCCAGGTCTGGTGTGTTG GAGGTCTAGGTAGGAGGTGAAG
PROM1 AGTCGGAAACTGGCAGATAGC GGTAGTGTTGTACTGGGCCAAT
SOX9 CTCTGGAGACTTCTGAACGAGAG CCTTGAAGATGGCGTTGGGG
HNF4A CATGGCCAAGATTGACAACCT TTCCCATATGTTCCTGCATCAG
A/%8MIN CCTTTGGCACAATGAAGTGGGTAACC CAGCAGTCAGCCATTTCACCATAG
T%X3 TGGAGCCCGAAGAAGAGGTG TTCGCCTTCCCGACTTGGTA
C<P3A4 TGTGCCTGAGAACACCAGAG GTGGTGGAAATAGTCCCGTG
TTR ATGGCTTCTCATCGTCTGCT TGTCATCAGCAGCCTTTCTG
KRT19 ACGACCATCCAGGACCTGC TCCCACTTGGCCCCTCAGC
KRT7 GATTGCTGGCCTTCGGGGT TCATCACAGAGATATTCACGGCTC
HNF1% GCACCCCTATGAAGACCCAG GGACTGTCTGGTTGAATTGTCG
CDX2 GGCAGCCAAGTGAAAACCAG TTCCTCTCCTTTGCTCTGCG
SOX17 CGCACGGAATTTGAACAGTA GGATCAGGGACCTGTCACAC
HOX%2 CCTAGCCTACAGGGTTCTCTC CACAGAGCGTACTGGTGAAAAA
8%C ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
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gene expression analyses in R.126,127 Only genes classified as protein coding in the 
Ensembl BioMart GRCh38 database were included in the analyses. A significance cut-
off for differentially expressed genes was set as False Discovery Rate (FDR) less than 
0.05 and a log2FoldChange with an absolute value greater than 1 for all analyses. Code 
used for DeSeq2 analyses in R can be found in Appendix II. 
Heatmaps of the variance stabilized transformed counts were generated using Morpheus 
(https://software.broadinstitute.org/morpheus). Hierarchical clustering was performed 
using one minus pearson correlation with average linkage for all heatmaps. Gene 
ontology enrichment analyses were performed using GOrilla.128 
2.10 Statistical Analyses 
 
Statistical analyses were carried out in Prism 7. One-way ANOVAs were performed 
followed by post-hoc analyses using either Dunnett’s, Sidak’s, or Tukey’s multiple 
comparisons tests. 
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3 ESTABLISHMENT AND 
CHARACTERIZATION OF 
HUMAN BILIARY ORGANOIDS 
3.1 Statement of source 
 
The data and text presented in this chapter are largely based on the following first author 
manuscript written by the author of this dissertation. Some parts of this chapter have been 
taken verbatim or with only minor changes from this source.  
Rimland CA, Tilson S, Morell C, Tomaz R, Lu WY, Adams S, Georgakopoulos N, 
Otaizo-Carrasquero F, Myers T, Sun HW, Gieseck RL, Sampaziotis F, Tysoe O, 
Wesley B, Oniscu GC, Hannan NRF, Forbes S, Saeb-Parsy K, Wynn TA, Vallier 
L. (2018) Regional differences in human biliary tissues and corresponding in 
vitro derived organoids. Manuscript in preparation. 
Figures 3.1 and 3.3 contain data from the following publication first published in Nature 
Medicine, on which the author of this dissertation was a co-author and collaborator. 
However, the data in Figures 3.1 and a portion of the data in Figure 3.3 was generated by 
Dr. Fotios Sampaziotis and do not represent experiments performed by the dissertation 
author. These experiments provided proof-of-principle for several of the experiments 
performed by the author of this dissertation and are presented here to provide important 
context. 
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Sampaziotis F, Justin AW, Tysoe OC, Sawiak S, Godfrey EM, Upponi SS, Gieseck RL 
3rd, de Brito MC, Berntsen NL, Gómez-Vázquez MJ, Ortmann D, Yiangou L, 
Ross A, Bargehr J, Bertero A, Zonneveld MCF, Pedersen MT, Pawlowski M, 
Valestrand L, Madrigal P, Georgakopoulos N, Pirmadjid N, Skeldon GM, Casey 
J, Shu W, Materek PM, Snijders KE, Brown SE, Rimland CA, Simonic I, Davies 
SE, Jensen KB, Zilbauer M, Gelson WTH, Alexander GJ, Sinha S, Hannan NRF, 
Wynn TA, Karlsen TH, Melum E, Markaki AE, Saeb-Parsy K, Vallier L. 
(2017). Reconstruction of the mouse extrahepatic biliary tree using primary 
human extrahepatic cholangiocyte organoids. Nature Medicine. 23(8): 954-963. 
Three of the liver tissue samples used for derivation of intrahepatic bile duct organoids 
were obtained in collaboration with Dr. Wei-Yu Lu and Dr. Stuart Forbes at the 
University of Edinburgh. Additionally, three of the intrahepatic organoid cell lines grown 
in extrahepatic organoid conditions were isolated and maintained in culture by Dr. Wei-
Yu Lu. However, all characterization (qPCR, IF analyses, etc.) on intrahepatic organoids 
was performed by the author of this dissertation. 
3.2 Introduction 
 
The biliary tree is a series of interconnected ductular tissues responsible for the drainage, 
storage, and concentration of bile produced by the liver and pancreatic juices from the 
pancreas, which are released into the intestine to aid in digestion.47 The biliary tree can 
be broadly divided into two main compartments, that which is within the liver, 
intrahepatic, and that which is outside of the liver, extrahepatic.47,48 The intrahepatic 
compartment is further divided based on duct size, while the extrahepatic compartment is 
divided by anatomical region, including the common hepatic duct, gallbladder (GBD), 
cystic duct, common bile duct (CBD).48 Additionally, the main pancreatic duct (PancD) 
is often considered as part of the extrahepatic biliary tree.48 Embryologically, the 
extrahepatic and intrahepatic biliary compartments arise from different precursor cells.74 
Intrahepatic cholangiocytes arise from bipotent hepatoblasts, which also give rise to 
hepatocytes. Extrahepatic cholangiocytes share an embryologic origin with the ventral 
pancreas.74  
Research on cholangiocyte diversity has historically focused exclusively on the 
intrahepatic compartment.56 Analysis of intrahepatic bile ducts in rodents has 
demonstrated the existence of two populations of cholangiocytes: small and large 
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cholangiocytes.55,57 Small cholangiocytes line the smallest intrahepatic ductules and are 
cuboidal in shape. Large cholangiocytes line larger intrahepatic ducts and are columnar 
in shape. Further, it has been shown that large and small cholangiocytes within the 
intrahepatic compartment display differences in transcriptional profiles, proliferative 
capacity, and biological function.55,57 Despite the identification of heterogeneity within 
the liver, research has not yet been extended to characterization of the extrahepatic 
compartment. Little is known on what diversity, if any, may exist between individual 
anatomic regions of the extrahepatic biliary system. This basic understanding is critical 
as many human cholangiopathies such as biliary atresia, primary sclerosing cholangitis, 
and non-anastomotic biliary strictures preferentially target extrahepatic bile ducts 
(EHBDs) early in disease.84,85,129  
Additionally, it has recently been demonstrated that in vitro 3D-culture of human biliary 
organoids is possible from both intrahepatic and extrahepatic tissues.97,98,116,122 However, 
it remains unclear whether the extrahepatic cultures, like other epithelial organoid 
systems such as intestinal organoids, contain true stem/progenitor cell populations.93 
Huch et al (2015) isolated human intrahepatic bile ducts (IHBDs) and cultured them in 
conditions promoting canonical WNT signalling. These IHBD organoids were capable of 
long-term expansion and bi-potential differentiation capacity towards either hepatocyte 
or biliary cell fates.97 This work strongly suggested the presence of an intrahepatic 
stem/progenitor cell population. Using a similar WNT based culture system, Lugli et al 
(2016) established both mouse and human extrahepatic GBD organoids.116 However, the 
differentiation capacity was only assessed for the murine organoids and showed 
incomplete differentiation towards a hepatocyte fate with no in vivo differentiation 
potential demonstrated.116 Further, our group recently demonstrated that human biliary 
organoids from CBD and GBD, grown in the presence of a canonical WNT pathway 
inhibitor, were capable of long-term expansion, yet lacked characteristic markers of 
adSCs such as LGR5 and PROM1.122 The differentiation capacity of these organoids 
beyond a biliary fate was not assessed in our prior work.122 Taken together, these reports 
suggest that both intra- and extrahepatic human cholangiocytes are capable of forming 
3D-organoid cultures, which under certain culture conditions display adult tissue 
stem/progenitor phenotypes. However, it is still unclear whether EHBD organoids are 
capable of bi-potential differentiation like IHBD organoids. Additionally, how EHBD 
organoids from different anatomical regions of the biliary tree compare to each other, to 
their tissue of origin, and to IHBD organoids is also unknown.  
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In this chapter, we describe the derivation and characterization of human biliary organoids 
from three major regions of the human extrahepatic biliary tree: CBD, GBD, and PancD. 
We demonstrate that these EHBD organoids, when grown in media conditions promoting 
canonical WNT signalling, express markers of adSCs such as LGR5 and PROM1. We 
additionally establish IHBD organoids and show they are divergent in culture condition 
requirements from EHBD organoids.  
In chapter 4, we use these organoids and primary tissue samples in order to perform RNA-
sequencing to assess what differences exist between (1) the three extrahepatic tissue 
regions, (2) extrahepatic tissues compared to their corresponding organoid cultures, (3) 
intrahepatic organoids compared to extrahepatic organoids, and (4) intrahepatic tissues 
compared to extrahepatic tissues. 
Lastly, in chapter 5 we assess the differentiation capacity of both EHBD and IHBD 
organoids towards a hepatocyte fate.  
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3.3 Results 
3.3.1 Mechanical dissociation allows for enrichment of human extrahepatic 
biliary epithelial cells 
 
We previously reported a method for the isolation of biliary epithelial cells using 
mechanical dissociation.122 This method results in a higher viability than enzymatic 
dissociation methods and enriches for cells co-expressing the biliary markers KRT7 and 
KRT19 (Figure 3.1). Given our previous results, we employed this method again to 
isolate biliary epithelial cells from human CBD, GBD, and PancD.  
 
Figure 3.1 Mechanical dissociation of biliary epithelial cells improves viability. 
Ratio of viable to dead primary biliary epithelial cells after being subjected to different methods of 
dissociation. One-way ANOVA with Dunnett correction comparing mechanical dissociation to others, 
***= p<0.001, ****=p<0.0001. Error bars are standard deviation and each dissociation method was 
attempted three independent times (n=3). Data and figure generated by Dr. Fotios Sampaziotis. Reproduced 
with permission from Sampaziotis et al (2017)122 first published in Nature Medicine. C= collagenase. D= 
dispase. 
 
Our previous work demonstrated mechanical dissociation from CBD donors (n=3) 
yielded 94.6% ± 2.4% (mean ± SD) of cells co-expressing KRT7/KRT19.122 Since this 
method had only been assessed in extrahepatic ductal tissue samples, we re-validated this 
method of isolation on epithelial scrapings from GBD donors (n=2), which showed a 
similar percentage of cells co-expressing KRT7/KRT19 using mechanical dissociation 
(94.7% ± 4.31%, mean ± SD) (Figure 3.2 and 3.3). Established organoid cultures also 
demonstrated a high level of purity with an average of 95.04 ± 2.09 % (n=5) of cultured 
cells co-expressing KRT19/KRT7 (Figure 3.2 and 3.3). 
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Figure 3.2 Flow cytometry analysis for KRT7 and KRT19 
Representative flow cytometry analysis of primary epithelial cells mechanically dissociated from human 
gallbladder tissue (n=2) or in vitro cultured extrahepatic biliary organoids (n=5) showing percentage of 
cells co-expressing KRT7 and KRT19 (black). Tissue and organoids represent independent experiments 
and gates were set for each experiment separately. Negative control: secondary antibody only stained cells 
(grey). Single stained/fluorescence minus one and secondary only stained controls were used to set gates. 
 
 
Figure 3.3 Percentages of cells co-expressing KRT7 and KRT19 
Percentage of cells co-expressing KRT7 and KRT19 determined by flow cytometry analysis of either 
epithelial cells mechanically dissociated from primary human gallbladder tissue (n=2), epithelial cells 
mechanically dissociated from primary human common bile duct tissue (n=3), or in vitro cultured 
extrahepatic biliary organoids (n=5 cell lines). Flow cytometry data for the three common bile duct primary 
tissue samples was generated by Dr. Fotios Sampaziotis.122 All other data points were generated by the 
author of this dissertation. 
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3.3.2 Extrahepatic biliary epithelial cells can be cultured as 3D organoids 
in conditions promoting canonical WNT signalling  
 
In the course of our previous experiments, we noted that extrahepatic cholangiocytes 
cultured as organoids in the presence of RSPO-1, DKK-1 (a canonical WNT pathway 
inhibitor), and EGF were capable of long-term expansion but did not express 
characteristic adSC markers such as LGR5 and PROM1.122 In parallel, we also observed 
that growing these extrahepatic cholangiocyte organoids in the presence of CHIR 99021, 
a small molecule inhibitor of GSK3b, instead of DKK-1, resulted in lower levels of 
phosphorylated ß-Catenin and thus a higher level of WNT signalling activity.122 Given 
these observations, we decided to test a new culture media which promotes canonical 
WNT signalling. We hypothesized this media would allow for the isolation of 
extrahepatic biliary cells with a progenitor phenotype.  
We based this new culture media on protocols previously used by our group to maintain 
human intestinal organoids derived from induced pluripotent stem cells.130 This media 
consisted of R-Spondin 1, CHIR 99021, Noggin, PGE2 , and EGF. We found this media 
allowed for establishment of EHBD organoid cultures, which expressed markers of adSCs 
such as LGR5 and PROM1. However, all cultures eventually deteriorated, and 
proliferation ceased 4-12 weeks after isolation, such that cultures could only be 
maintained at a 1:1-1:2 splitting ratio.  
Around this time, a report was published by Huch et al. (2015) on human IHBD organoids 
and demonstrated that for long-term proliferation, addition of a TGF-β inhibitor (A 83-
01) and cAMP activator (Forskolin, FSK) was necessary.97 Given this finding, we 
attempted to rescue our deteriorating EHBD organoids by addition of 5 μM A 83-01 and 
10 μM FSK (Figure 3.4). Within 48 hours, addition of A 83-01 and FSK to late passage 
organoids rescued the cultures. Splitting ratios returned to 1:3 or greater. The growth 
impact of A 83-01 and FSK was also noticeable even when added at early passages before 
proliferation deteriorated (Figure 3.4). Addition of A 83-01 and FSK did not significantly 
change the expression profile of the organoids and they continued to express adSC 
markers and biliary markers equal to our original media conditions (Figure 3.5).  
Chapter 3: Establishment and characterization of human biliary organoids 
    
 
54 
 
Figure 3.4 Images of organoids cultured with or without A 83-01 and FSK. 
Scale bar = 1000 μm 
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Figure 3.5 qPCR analysis of extrahepatic bile duct organoids cultured with or 
without A 83-01 / FSK. 
Extrahepatic organoids were cultured with or without A8301 and FSK (n=3). Unpaired t-tests comparing 
+A8301/FSK vs. -A8301/FSK were not significant for any genes (p > 0.05). Gene expression is normalized 
to the housekeeping gene UBC and data is plotted as mean and SEM. H9 embryonic stem cells (n=3) were 
used as negative controls.  
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All future tissue samples were derived in these new optimized conditions and in total we 
derived 7 CBD lines, 9 GBD lines, and 3 PancD lines in these conditions from donors 
ranging in age from 20-68 years old with 100% of the tissue samples yielding organoid 
cultures. The organoids displayed similar morphology and growth dynamics regardless 
of their tissue of origin and could not be readily distinguished from one another (Figure 
3.6). 
 
Figure 3.6 Images of organoids isolated from three regions of the extrahepatic 
biliary tree 
Representative images of organoids isolated from CBD, GBD, and PancD extrahepatic tissues.  
Scale Bars: 1000 μm 
3.3.3 Extrahepatic organoids express markers of adult stem cells while 
maintaining biliary markers and histological similarity to primary tissues 
 
With our culture conditions stabilized, we sought next to characterize the organoids 
derived from each region of the extrahepatic biliary tree. qPCR analyses demonstrated 
that EHBD organoids expressed adSC markers (LGR5 and PROM1), ductal markers 
(SOX9, KRT7, HNF1B), and early hepatocyte markers (TBX3, HNF4A), but not markers 
of mature hepatocytes (ALB) (Figure 3.7) and that most of these markers remained 
consistently expressed over time in culture (Passage 0 vs. Passage 10+, Figure 3.8). 
Levels of ductal markers in EHBD organoids were comparable to or greater than primary 
tissue. With the exception of the mature biliary marker, HNF1B, which was reduced in 
the EHBD organoids. The stem/progenitor cell markers LGR5 and PROM1, and TBX3, 
were significantly enriched in EHBD organoids compared to primary tissue. Expression 
of all markers by qPCR did not differ significantly between CBD, GBD, and PancD 
primary tissues. Furthermore, CBD, GBD, and PancD organoids did not differ 
significantly for any of the markers examined.  
Common Bile Duct Gallbladder Pancreatic Duct
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Figure 3.7 qPCR characterization of extrahepatic bile duct organoids and primary 
tissues demonstrates expression of adult stem cell and biliary markers 
qPCR analyses showing the expression of biliary and adSC markers in EHBD organoids and primary tissue 
samples from common bile duct (CBD), gallbladder (GBD), and pancreatic duct (PancD). Organoids 
derived from human sigmoid colon biopsies (SC, n=4), primary hepatocytes (PH, n=4, 2 donors), and H9 
human embryonic stem cells (H9, n=3) were used as controls. Gene expression is normalized to the 
housekeeping gene UBC and data is plotted as mean and SEM. CBD Tissue (n=5), CBD organoids at P5 
(n=7), GBD tissue (n=9), GBD organoids at P5 (n=7), PancD tissue (n=3), PancD organoids at P5 (n=3). 
*=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001, ****p ≤ 0.0001. If not otherwise indicated, comparisons between 
groups were not significantly different (p>0.05). 
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Figure 3.8 qPCR characterization of extrahepatic bile duct organoids over time in 
culture demonstrates maintanence of biliary and adult stem cell markers. 
qPCR analyses showing the expression of biliary and adSC markers in EHBD organoids (n=3-11, n=2-7 
donor lines per passage) derived from common bile duct (CBD), gallbladder (GBD), and pancreatic duct 
(PancD) tissues over time in culture (P0, P5, P10 or higher). Gene expression is normalized to the 
housekeeping gene UBC and data is plotted as mean and SEM.  *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001, 
****p ≤ 0.0001. If not otherwise indicated, comparisons between groups were not significantly different 
(p>0.05). 
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Immunofluorescence (IF) analyses demonstrated a substantial fraction of cells were 
actively proliferating as indicated by KI67 positivity (Figure 3.9). Interestingly, primary 
tissues had no detectable levels of KI67, suggesting that proliferation is extremely rare in 
the biliary epithelium. Finally, the organoids bore a striking similarity to their tissues of 
origin, with both organoids and tissues uniformly expressing EPCAM, SOX9, KRT19, 
HNF4A and KRT7.  
Taken together, these results demonstrate biliary organoids can be derived from any 
region of the extrahepatic biliary tree and that the addition of WNT induces the expression 
of stem cell markers in these cell lines. These extrahepatic bile duct (EHBD) organoids 
can be distinguished from our previously described organoids cultured without canonical 
WNT, which did not express stem cell markers and instead more closely resembled fully 
differentiated cholangiocytes.  
3.3.4 Intrahepatic bile duct organoids cannot be maintained in 
extrahepatic culture conditions and display divergent characteristics from 
EHBD organoids. 
 
We next sought to establish organoids from intrahepatic bile ducts (IHBD) using the same 
culture conditions used to derive EHBD organoids. For that, liver tissue obtained from 
cadaveric donor was subjected to enzymatic dissociation and the resulting cells grown in 
the culture conditions described above for extrahepatic organoids. The resulting 
organoids (IHBD_ex) could be established and grew well for the first 2-3 weeks in 
culture. Interestingly, the IHBD_ex organoids were very different from the EHBD 
organoids (Figure 3.10) and displayed a heterogeneous morphology with some organoids 
having a cryptic phenotype with budding structures, while others maintained a cystic 
structure similar to EHBD organoids.  
After 5-7 passages, these cryptic structures began to predominate, proliferation ceased 
and cultures could not be maintained.  Given this result, we also isolated IHBD organoids 
in conditions previously published by Huch and colleagues (2015).97 The resulting 
organoids (IHBD_Huch) grown in these culture conditions maintained their proliferative 
ability for at least 10 passages without evidence of deterioration (Figure 3.11) while 
displaying a homogenous cystic morphology.   
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Figure 3.9. Extrahepatic primary tissues and corresponding organoids express 
biliary markers and show histologic similarities.  
Representative immunofluorescence images of extrahepatic bile duct organoids and primary tissues for 
selected markers. Scale bars: 50 μm. 
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Figure 3.10 Intrahepatic bile duct organoids cultured in extrahepatic media 
conditions display morphological heterogeneity. 
Images of intrahepatic bile duct organoids cultured in extrahepatic culture conditions (IHBD_ex) 
highlighting the morphological heterogeneity of the organoids with both cystic and budding/cryptic 
organoids present in the cultures. Scale bar = 1000 or 400 μm 
 
 
Figure 3.11 Intrahepatic bile duct organoids cultured in extrahepatic media 
conditions cannot be maintained long-term in culture. 
Images of intrahepatic bile duct organoids cultured in either extrahepatic culture conditions (IHBD_ex) or 
Huch et al (2015) conditions (IHBD_Huch) at Passage 0 or Passage 5. Scale bar = 1000 μm. 
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qPCR analyses between EHBD, IHBD_ex and IHBD_Huch organoids revealed only 
minor differences in the expression of biliary markers and stem cells markers (Figure 
3.12). IF confirmed that, similarly to EHBD organoids, IHBD organoids expressed 
EPCAM, SOX9, KRT19, and KRT7 (Figure 3.13). Of note, IHBD organoids expressed 
HNF4A like their EHBD counterparts, but this transcription factor was absent from 
primary IHBD tissue. KI67 expression was present in a substantial number of cells in 
IHBD_Huch organoids. While this marker for proliferative cells was variable in the 
IHBD_ex organoids and the budding/cryptic organoids demonstrated fewer KI67 positive 
cells than cystic organoids in the same culture (Figure 3.14). KI67 was absent in the 
primary tissue (Figure 3.13). The morphological variation between the budding/cryptic 
and the cystic IHBD_ex organoids was also readily apparent (Figure 3.14).  
Further investigation into these morphologic and proliferative differences revealed that 
the presence of CHIR 99021 in the culture media was most likely responsible for the 
divergence between conditions (Figure 3.15). IHBD_Huch organoids were transferred 
into various media combinations including extrahepatic organoid conditions with or 
without CHIR 99021 or alternatively into the conditions described by Huch and 
colleagues (2015) with or without CHIR 99021. Only organoids in the conditions with 
CHIR 99021 demonstrated the budding morphology. Additionally, conditions with CHIR 
99021 present showed decreased organoid size, fewer organoids, and could not be 
maintained for more than 4 passages. Whereas conditions without CHIR 99021 continued 
to proliferate. 
We also performed qPCR for adult stem cell, biliary, and hepatocyte specific genes on 
the IHBD organoids in these culture conditions with or without CHIR 99021 hoping to 
gain a better understanding of why such morphological and proliferative differences were 
observed (Figure 3.16). However, for the genes we examined, very few significant 
changes in expression were observed. Suggesting that for these genes at least, CHIR 
99021 does not significantly alter the expression profile in the organoids.   
Taken together, these data demonstrate that cells from the extra- and intrahepatic biliary 
tree diverge in their growth factor requirements with continuous WNT signalling being 
detrimental for the proliferation and maintenance of IHBD organoids but not for EHBD 
organoids. However, this difference seems to have little consequence on the expression 
of biliary markers.   
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Figure 3.12 qPCR analysis of intrahepatic and extrahepatic bile duct organoids 
demonstrates subtle differences for selected markers.  
qPCR analysis of IHBD_ex (n=3) and IHBD_Huch (n=3) organoids in comparison to extrahepatic 
organoids from common bile duct (CBD) (n=7), gallbladder (GBD) (n=7), and pancreatic duct (PancD) 
(n=3) at passage 5. Primary hepatocytes (PH, n=4), sigmoid colon organoids (SC, n=4), and H9 embryonic 
stem cells (H9, n=3) were used as controls. Gene expression is normalized to the housekeeping gene UBC 
and data is plotted as mean and SEM. IHBD_ex organoids were derived in collaboration with Dr. Wei-Yu 
Lu and Dr. Stuart Forbes. *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001, ****p ≤ 0.0001. If not otherwise 
indicated, comparisons between groups were not significantly different (p>0.05) 
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Figure 3.13 Intrahepatic bile duct primary tissues and corresponding organoids 
express biliary markers and show histologic similarities.  
Immunofluorescence analysis for select markers of IHBD_Huch, IHBD_ex, and primary liver tissue. Scale 
Bars: 50 μm  
 
 
Figure 3.14 Immunofluorescence analysis of IHBD_ex organoids highlights the 
morphological heterogeneity of the organoids. 
Immunofluorescence analysis for KI67 and ß -Catenin on IHBD_ex organoids. White arrows indicate cystic 
organoids. Scale bar=50-100 μm 
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Figure 3.15 IHBD_Huch organoids treated with CHIR 99021 
Intrahepatic bile duct organoids isolated and cultured originally in conditions published by Huch et al 
(2015) were transferred into different medias with or without 3 uM CHIR 99021 added. The five media 
combinations included: EHBD organoid media with CHIR 99021, EHBD organoid media without CHIR 
99021, IHBD_Huch organoid media with CHIR 99021, IHBD_Huch media without CHIR 99021, or media 
with only CHIR 99021. Within 72 hr, morphological changes could be observed, and budding/cryptic 
structures developed in organoids treated with CHIR 99021 similar to what had previously been observed 
in IHBD organoids isolated and cultured in extrahepatic organoid conditions which contained CHIR 99021.  
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Figure 3.16 qPCR analysis of IHBD_Huch organoids cultured in Huch et al (2015) 
conditions or EHBD organoid conditions with or without CHIR 99021.  
qPCR analysis of IHBD_Huch organoids (n=3 donor lines) transferred into various media conditions to 
assess the effect of CHIR 99021 on the expression profile of organoids. Conditions included EHBD 
organoid media with CHIR 99021 (n=6), EHBD organoid media without CHIR 99021 (n=6), Huch et al 
conditions with CHIR 99021 (n=7), Huch et al conditions without CHIR (n=6) and Basal Media with only 
CHIR 99021 (n=3). # = p ≤ 0.05, ## = p ≤ 0.01, ### = p ≤ 0.001, #### = p ≤ 0.0001 for the particular media 
condition compared to Huch et al Conditions NO CHIR. If not otherwise indicated, comparisons between 
groups were not significantly different (p>0.05) 
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3.4 Discussion 
 
In this chapter, the derivation and characterization of biliary organoids from four regions 
of the human biliary tree including: GBD, CBD, PancD, and IHBDs was described. To 
do this, culture conditions that promote canonical WNT signalling were developed 
allowing for the isolation and propagation of cells with a stem/progenitor cell phenotype. 
In the first portion of this chapter, the enrichment of extrahepatic biliary epithelial cells 
from extrahepatic tissues through the use of mechanical dissociation was described. Using 
these mechanically dissociated cells, it was shown that EHBD organoids from CBD, 
GBD, and PancD can be derived with a 100% efficiency rate and from a large number of 
donors and donors of various ages. These extrahepatic organoids show significantly 
higher expression of adult stem cell markers LGR5 and PROM1 when compared to their 
primary tissue of origin. The EHBD organoids also display long-term proliferation 
capacity suggesting these organoid cultures may represent a stem/progenitor population. 
Lastly, in the second half of the chapter, the derivation of organoids from intrahepatic bile 
duct tissue was described. It was discovered that IHBD organoids cannot be maintained 
long-term in the same conditions used for EHBD organoids. Further, when cultured in 
extrahepatic conditions, IHBD derived organoids are morphologically very different from 
EHBD organoids and this may be due to CHIR 99021. Together, these results suggest 
key differences exist between IHBD and EHBD organoids.  
We feel the work presented in this chapter represents a significant progression for the 
field. To our knowledge, it is the first attempt to directly compare biliary organoids 
derived from these different anatomical regions of the biliary tree. However, there are 
limitations to the work, which must be acknowledged. 
The first limitation is that we were unable to culture both IHBD and EHBD derived 
organoids long-term in the same media conditions. When we first began this work, the 
report by Huch et al (2015) on the derivation of IHBD organoids had not been published.97 
Therefore, when beginning our attempts to derive EHBD organoids in WNT-based 
conditions for the first time, we used protocols already established in our lab. These 
conditions allowed us to establish EHBD organoids and our early characterizations 
suggested enrichment for a stem/progenitor phenotype. We did not anticipate that our 
EHBD organoids would cease proliferating, as many of the cell lines we derived grew 
well for more than 1-2 months in culture. However, as we continued to derive additional 
EHBD organoids we noticed the organoids could not be maintained and began to consider 
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that our culture conditions were sub-optimal. Around this time, the report by Huch et al 
(2015) was published and reported the need for A 83-01 and FSK. As we had already put 
a considerable amount of work in to the early characterization of our EHBD organoids, 
we decided to assess whether adding A 83-01 and FSK into our existing conditions would 
rescue the cultures and it was able to do so. Adding A 83-01 and FSK to the EHBD 
organoids did not change their expression profile significantly and the organoids 
continued to be enriched for stem/progenitor markers. It is interesting that for long-term 
proliferation, the organoids required inhibition of TGF-ß signalling. TGF-ß has been 
implicated in cholangiocyte quiescence/senescence and has been shown to act as a key 
negative regulator of cholangiocyte proliferation.131,132  
Given these results, we moved forward with this culture system and performed the 
characterization experiments described in this chapter. After this, we then attempted to 
derive IHBD organoids. We quickly realized that IHBD organoids in extrahepatic 
conditions (IHBD_ex) are unable to proliferate long-term. To circumvent this limitation, 
we also isolated IHBD cells in the culture conditions reported by Huch et al (2015) 
(IHBD_Huch) and characterized these alongside of the IHBD_ex to account for 
differences in proliferation. EHBD organoids were not derived in Huch et al (2015) 
conditions as doing so would have required a large number of new donor tissue samples, 
which were unavailable to us at the time. Although it would have been ideal to have IHBD 
and EHBD organoids cultured in the same media conditions this was not possible. It is 
important to note, that despite this being a limitation, it did allow us to discover that IHBD 
and EHBD organoids are intrinsically different and their requirement for different media 
conditions suggests these organoid systems are not equivalent to one another. Further, we 
found preliminary results suggesting that response to CHIR 99021/WNT signalling may 
be responsible for the divergence between IHBD and EHBD organoid culture conditions. 
IHBD_Huch organoids adopted morphological heterogeneity when CHIR 99021 was 
present in the media. Interestingly, this result is similar to what has been previously 
observed with human gastric organoids and may suggest a similar mechanism acts in 
IHBD organoids.20 However, these results are preliminary and should be explored further 
in future studies. 
An additional limitation is that our mechanical dissociation method for EHBD tissue does 
not isolate biliary epithelial cells with 100% purity. An alternative to these isolation 
methods would have been to use cell sorting and to isolate cells from each tissue which 
express markers such as KRT19, KRT7, or EPCAM for instance. However, in order to 
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use such methods, cells must be dissociated to single cells and enzymatic dissociation 
greatly reduced the viability of extrahepatic biliary epithelial cells making this 
challenging. Additionally, the number of cells obtained from common bile duct, and 
especially pancreatic duct tissues, was often low. It was already challenging to obtain 
enough cells from these tissues for primary tissue RNA, let alone enough viable cells for 
sorting. We also found that the contamination by non-biliary cell types is likely low with 
only 5-10% of the cells isolated by mechanical dissociation not expressing KRT19/KRT7. 
Overall, we felt that mechanical dissociation, although having these obvious limitations, 
was the best approach to enrich for EHBD epithelial cells. Further, it has been well-
established in the literature that organoid culture systems such as these are selective for 
epithelial cells, making it unlikely that our cultures contain non-epithelial cells and this 
was supported with our flow cytometry and IF analyses. This has also been previously 
demonstrated for enzymatically dissociated, manually picked IHBD ducts and IHBD 
organoid cultures are only derived from ductal cells and not from other liver cell types.97  
Lastly, despite our characterizations, it is still unclear whether our EHBD organoids 
represent a stem/progenitor population. Although informative, qPCR and IF 
characterizations are limited in the number of markers which can be reasonably assessed. 
To address some of these limitations, the following two chapters attempt to further 
characterize the nature of the organoids described in this chapter. In chapter 4 we expand 
our characterization to include the entire transcriptome through the use of RNA-
Sequencing (RNA-Seq) profiling. Finally, in chapter 5 we explore the differentiation 
capacity of EHBD and IHBD organoids in order to further assess the stem/progenitor 
characteristics possessed by these biliary organoids. 
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4 TRANSCRIPTOMIC PROFILING 
OF HUMAN BILIARY TISSUES 
AND IN VITRO ORGANOIDS 
4.1 Statement of Source 
 
The results presented here are largely based on experiments presented in the following 
first author manuscript written by the author of this dissertation. Therefore, some parts 
have been taken verbatim or with only minor changes from this source.  
Rimland CA, Tilson S, Morell C, Tomaz R, Lu WY, Adams S, Georgakopoulos N, 
Otaizo-Carrasquero F, Myers T, Sun HW, Gieseck RL, Sampaziotis F, Tysoe O, 
Wesley B, Oniscu GC, Hannan NRF, Forbes S, Saeb-Parsy K, Wynn TA, Vallier 
L. (2018) Regional differences in human biliary tissues and corresponding in 
vitro derived organoids. Manuscript in preparation. 
The RNA-Sequencing experiments presented in this chapter were performed in 
collaboration with a number of individuals.  
The RNA samples for IHBD_ex organoids and IHBD tissues were generated in 
collaboration with Drs. Wei-Yu Lu and Stuart Forbes. The NIAID Genomics 
Technologies Branch at the NIH, particularly Dr. Timothy Meyers and Mr. Francisco 
Otaizo-Carrasquero, performed the library preparations and sequencing. The mapping 
and transcriptome-based alignment using Salmon was performed by Dr. Rute Tomaz.  
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Differential gene expression analyses in R using DeSeq2, and all other analyses, including 
figure preparation, were performed by the author of this dissertation. Dr. Rute Tomaz and 
Dr. John Ferdinand provided support, example code, and guidance while performing the 
differential gene expression analyses.  
4.2 Introduction 
 
RNA-Sequencing has gained in popularity over the last 10 years as a method for profiling 
the entire RNA transcriptome of a biological sample.133,134 The transcriptome represents 
all of the RNA transcripts present in a given biological sample at a point in time and 
includes messenger RNA (mRNA), non-coding RNAs, and small RNAs. Profiling of the 
entire transcriptome allows for the comparison of individual transcript expression levels 
across biological groups and can provide insight into differential expression patterns. 
Originally, transcriptome analyses were only accomplished using low-throughput 
methods such as PCR or northern blots. These techniques only allowed for the profiling 
of a small number of transcripts at a time. With the advent of microarray technology, the 
transcriptome could be assayed for the first time. Microarray technology has limitations 
such as a need to know the transcript sequence beforehand and difficulties assessing the 
expression of transcripts with highly similar sequences. RNA-Sequencing eliminates 
these limitations.  
The general principle behind RNA-Sequencing is similar to methods employed for high-
throughput DNA sequencing but cDNA libraries are prepared from reverse transcribed 
RNA samples (Figure 4.1). First, ribosomal RNA is depleted using either poly-adenosine 
selection or ribosomal depletion. The RNA is then reverse transcribed into cDNA, 
fragmented, and chemical adapters ligated to each sample for identification. Samples are 
placed into lanes on a flow cell and a high throughput sequencer is used for sequencing. 
Most high throughput sequencers use sequencing by synthesis chemistry, which works 
by incorporating fluorescently labelled nucleotides complementary to the cDNA 
fragment. These fluorescent nucleotides are recorded by the sequencer and output as a 
FASTQ file. From the sequencing FASTQ file, millions of reads corresponding to the 
sequences present in the fragmented cDNA samples are obtained.  
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Figure 4.1 Diagram depicting the workflow for performing RNA-Seq. 
Reproduced from http://web.bioinformatics.cicbiogune.es/  
 
These reads are then aligned to either the genome or transcriptome and the mapped reads 
are counted to estimate expression levels. This count data is then normalized to account 
for differences in sequencing depth between samples and used to perform differential 
gene expression analyses using statistical models such as DeSeq2 or EdgeR that takes 
advantage of the negative binomial distribution of RNA-Seq data.127,135 Ultimately, a list 
of differentially expressed genes between biological groups can be obtained. These gene 
lists can be used for further analyses, for example, biological process/pathway enrichment 
analyses such as gene ontology, gene set enrichment analysis, or pathway 
analysis.128,136,137 These analyses provide insight into potential biologically meaningful 
differences between groups and can be used for biomarker discovery.  
In this chapter, we take advantage of RNA-Sequencing technology to perform differential 
gene expression analysis on EHBD primary tissues, EHBD organoids, IHBD organoids, 
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and IHBD tissue samples. To our knowledge, only human gallbladder tissue has been 
previously sequenced. As part of the Human Protein Atlas effort, human gallbladder 
donor tissue samples were sequenced and the transcriptome compared to 27 other 
tissues.138,139 Only five genes were found to be enriched in gallbladder tissue, when 
defined as having five-fold higher expression in gallbladder tissue than all other tissues. 
This included the genes FGF19, CHST4, MOGAT1, UGT2B28, and AC083862.1. A 
further 135 genes were identified which were either “group-enriched” (five-fold higher 
in gallbladder tissue and at least one other tissue type versus the others) or “enhanced” 
(genes that were five-fold higher in gallbladder tissue in comparison to the average 
expression level across all other 27 tissues). This work represents an important effort in 
characterizing the transcriptome of one region of the human extrahepatic biliary tree. 
However, these experiments were performed on whole GBD tissue, not epithelial 
enriched tissue samples. Further, other regions of the extrahepatic biliary tree have not 
been sequenced and it remains unclear how the transcriptome of these tissues compare to 
each other.  
4.3 Results 
4.3.1 RNA isolation from human biliary tissue and in vitro organoids 
 
In order to perform our RNA-Sequencing experiments, we first isolated RNA from 
mechanically dissociated, epithelial enriched, human CBD, GBD, and PancD tissue 
samples. We also isolated RNA from enzymatically dissociated and manually picked 
IHBD ducts. RNA was also isolated from CBD, GBD, PancD, IHBD_ex, and 
IHBD_Huch organoids. RNA quantity and quality were assessed on an agilent 
bioanalyzer (Table 4.1). It was found that EHBD tissue samples had some level of 
degradation with RNA integrity numbers (RIN) ranging from 4.1-8.9. RIN is a measure 
of the degradation present in RNA samples and has values from 1 (completely degraded) 
to 10 (intact). In examining the literature, it seems this may be an intrinsic challenge with 
these tissues, especially when using mechanical dissociation.140 As we wanted to match 
the primary tissue and cell line donors whenever the amount of starting material would 
allow, it was decided not to re-attempt RNA isolation for the EHBD tissue samples. 
Additionally, obtaining a large number of donor samples for a second time was not 
feasible. Therefore, we continued with the sample set and performed sequencing 
experiments in collaboration with the NIH NIAID Genomics Technologies Branch.  
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4.3.2 Batch effect and outlier assessment of RNA-sequencing data 
 
Due to sample availability, we were required to sequence our samples in two separate 
batches (Table 4.1). Additionally, thirteen samples in the first batch did not have enough 
read depth after the first round of sequencing. Those thirteen samples required deeper 
sequencing and were re-sequenced with our second batch of samples. This created three 
potential batches within the data. Batch 1A consisted of samples which had library 
preparation performed in 2016 (libbatch = 1) and were sequenced in 2016 (seqyear = A). 
Batch 1B consisted of samples which had library preparation in 2016 (libbatch = 1) but 
then required deeper sequencing in 2017 (seqyear = B). Batch 2B consisted of samples 
which became available after the initial sequencing, with both library preparation and 
sequencing performed in 2017 (libbatch = 2, seqyear = B). Additionally, when our second 
batch of samples was being prepared, new libraries were prepared of four samples from 
the initial libbatch = 1 set to serve as internal batch controls. These four replicates were 
then re-sequenced alongside batch 2B samples. Before moving forward with down-
stream analyses of our RNA-Seq data, the presence of batch effects in the data needed to 
be assessed. As seen in Figures 4.2 and 4.3, there were no observable batch effects. For 
the analyses described below, data was combined from technical replicates across 
sequencing runs and data from 7 CBD tissue, 5 GBD tissue, 3 PancD tissue, 6 CBD 
organoid, 3 GBD organoid, 3 PancD organoid, 4 IHBD_ex organoid, 3 IHBD_Huch 
organoid, and 3 IHBD tissue samples was ultimately analysed.  
In the early, exploratory analyses of the data, it was noted that one of the IHBD_ex 
organoid samples appeared to be an outlier from the other three samples (Figure 4.4). 
This particular sample was from an IHBD_ex organoid line at passage 3 and not passage 
5 like the others. We included it in the analyses to increase our number of samples. 
However, when the sample was collected, the cells were still moderately proliferative, 
unlike the other lines at passage 5 whose growth had slowed. Given this known variability 
in the samples we excluded this IHBD_ex sample from further analyses.  
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Table 4.1 Details on RNA integrity number, donor, and batch for samples 
sequenced. 
RIN = RNA Integrity number. Batch 1A = samples library prepped and sequenced in 2016. Batch 1B= 
samples library prepped in 2016 that required deeper sequencing in 2017. Batch 2B = samples library 
prepped and sequenced in 2017.  
Sample Internal ID RIN Donor Batch 
CBD Tissue 1 CBD4 5.7 1 1A 
CBD Tissue 2 CBD5/PD4 5.6 2 1A / 1B 
CBD Tissue 3 CBD8 4.7 4 1A / 1B 
CBD Tissue 4 PD1 6.5 19 1A 
CBD Tissue 5 PD2 5.6 20 1A 
CBD Tissue 6 PD3 5.7 21 1A 
CBD Tissue 7 PD5 5.5 22 1A/1B/2B 
     
GBD Tissue 1 GBD4 4.2 7 1A 
GBD Tissue 2 GBD6 4.1 8 1A 
GBD Tissue 3 GBD8 4.4 1 1A/1B/2B 
GBD Tissue 4 GBD10 4.2 5 1A/1B 
GBD Tissue 5 GBD11 4.7 3 1A/1B 
     
PancD Tissue 1 PancD1 8.9 15 2B 
PancD Tissue 2 PancD2 8.6 16 2B 
PancD Tissue 3 PancD5 6.7 18 2B 
     
IHBD Tissue 1 H01 6.3 10 1A/1B 
IHBD Tissue 2 H02 7.3 11 1A/1B 
IHBD Tissue 3 H03 7.1 12 1A/1B 
     
CBD Organoids 1 CBD4 8.4 1 1A 
CBD Organoids 2 CBD5/PD4 9.6 2 1A 
CBD Organoids 3 CBD6 9.5 3 1A / 1B 
CBD Organoids 4 PD2 9.8 20 1A 
CBD Organoids 5 PD3 9.7 21 1A 
CBD Organoids 6 PD5 9.5 22 1A/1B/2B 
     
GBD Organoids 1 GBD8 9.8 1 1A 
GBD Organoids 2 GBD10 8.7 5 1A 
GBD Organoids 3 GBD11 9.5 3 1A/1B/2B 
     
PancD Organoids 1 PancD1 8.2 15 2B 
PancD Organoids 2 PancD2 10 16 2B 
PancD Organoids 3 PancD4 9.3 17 2B 
     
IHBD_ex Organoids 1 IHBD1_c 10 10 2B 
IHBD_ex Organoids 2 IHBD2_c 9.3 11 2B 
IHBD_ex Organoids 3 IHBD3_c 10 12 2B 
IHBD_ex Organoids 4 IHBD5_c 9.7 14 2B 
     
IHBD_Huch Organoids 1 IHBD1_m 9.8 10 2B 
IHBD_Huch Organoids 2 IHBD4_m 9.6 13 2B 
IHBD_Huch Organoids 3 IHBD5_m 10 14 2B 
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Figure 4.2 Principal component analysis of all samples to assess for batch effects. 
Principal component analysis of the DeSeq2 variance stabilized counts for all genes with greater than zero 
counts across all samples (19,376) with samples labelled by either type or by batch. 
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Figure 4.3 Principal component analysis of samples sequenced in all three batches. 
Principal component analysis of the DeSeq2 variance stabilized counts for all genes (19,376) in samples 
which were sequenced in all three batches labelled by type or by batch. 
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Figure 4.4 Principal component analysis of IHBD organoids to assess for outliers. 
Principal component analysis of the DeSeq2 variance stabilized counts for all genes (19,376) in IHBD_ex 
and IHBD_Huch organoids demonstrates one of the IHBD_ex samples is an outlier (red circle).  
 
We also noted that IHBD tissue samples clustered very far from the EHBD tissue samples 
by Principal Component Analysis (PCA) (Figure 4.2). The IHBD tissue was obtained 
from previously frozen liver tissue that had been thawed, enzymatically dissociated, and 
the bile ducts manually picked, making contamination with other cell types likely. We 
included these samples as a preliminary exploratory attempt to compare IHBD and EHBD 
tissues. Given the known limitations of the IHBD tissue samples, we excluded these 
samples from our initial main analyses. However, these samples will be discussed in 
section 4.3.8 in the context of preliminary and exploratory analyses.  
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4.3.3 Transcriptomic profiling of extrahepatic biliary tissues reveals 
distinct signatures between anatomic regions 
 
To assess what differences may exist between the organoids and their regions of origin, 
we decided to establish a transcriptional profile for the CBD, GBD, and PancD tissues. 
Of note, the epithelial enriched tissue samples used for these analyses were collected as 
described for organoid derivation without any purification step in order to avoid cellular 
stress associated with dissociation and sorting. Thus, we cannot exclude a limited 
contamination by non-biliary cell types in the samples. Accordingly, hormonal markers 
were detected in PancD tissue (i.e. PPY, SST), thereby a low level of contaminating 
pancreas tissue could explain this gene signature. Interestingly, it has been shown in both 
human and rodent studies that there may be populations of hormone producing cells 
which reside in the pancreatic ductal epithelial system and this gene signature could 
alternatively represent a true population of cells in the pancreatic duct.70,72,141 
Nonetheless, expression of biliary markers such as KRT7, KRT19, SOX9 and EPCAM 
could be detected at a similar level in the three tissues confirming enrichment for ductal 
epithelial cells (Figure 4.5).  
 
Figure 4.5 Normalized counts of biliary epithelial specific markers for the three 
extrahepatic tissue regions. 
DeSeq2 normalized counts for four bile duct epithelial specific markers. # = false discovery rate (adj p-
value) < 0.05 and fold change > 1. 
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Based on this reassuring observation, we performed PCA, which revealed clustering of 
samples by tissue type as did correlation analysis (Figure 4.6 and 4.7).  
Further, differential gene expression (DGE) analyses demonstrated a number of genes 
were differentially expressed between the tissue regions at a cut-off of false discovery 
rate (adj p-value) < 0.05 and absolute log2FoldChange > 1 (Figure 4.8, Annex File 1).  
3,102 genes were differentially expressed between GBD and PancD tissues with 1,665 
genes upregulated in GBD tissue and 1,437 genes upregulated in PancD tissue. 3,715 
genes were differentially expressed between CBD and PancD tissues with 1,884 genes 
upregulated in CBD tissue and 1,831 genes upregulated in PancD Tissues. 1,481 genes 
were differentially expressed between CBD and GBD tissues with 716 genes upregulated 
in CBD tissue and 765 genes upregulated in GBD tissue.  
 
 
Figure 4.6 Principal component analysis of extrahepatic bile duct tissues  
Principal component analysis of the DeSeq2 variance stabilized counts for the top 5,000 most variable genes 
between Common Bile Duct (CBD, n=7), Gallbladder (GBD n=5), and Pancreatic Duct (PancD, n=3) 
tissues. 
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Figure 4.7 Pearson correlation matrix of extrahepatic bile duct tissues 
Pearson correlation matrix and clustering for pancreatic duct, gallbladder, and common bile duct tissue 
samples. Matrix was generated using the R pheatmap package.  
 
Using these gene lists, we identified genes likely to be tissue-specific as those which are 
upregulated in a given tissue type compared to both of the other two tissues. 419 genes 
were determined to be GBD tissue-specific, 967 PancD tissue-specific, and 256 CBD 
specific (Figure 4.8, Annex File 2).  Using this set of genes, we performed hierarchical 
clustering analysis and showed that both the samples and genes cluster by tissue region 
(Figure 4.9).  
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Figure 4.8 Number of genes differentially expressed between the three extrahepatic 
bile duct tissue regions. 
Venn diagrams showing the number, as well as overlap, of genes upregulated in either GBD, CBD, or 
PancD tissues in comparison to each of the other two tissues. Significance cut-off: abs(log2Fold Change) 
>1 and adj p-value < 0.05. 
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Figure 4.9 Heatmap and hierarchical clustering analysis of genes specifically 
upregulated in extrahepatic tissue region. 
Heatmap of the tissue-specific genes upregulated in CBD compared to both GBD and PancD tissues (n=256 
genes), GBD compared to both PancD and CBD tissues (n=419 genes), and PancD compared to both CBD 
and GBD tissues (n=967 genes). Hierarchical clustering performed on the variance stabilized transformed 
counts using one minus Pearson correlation distance with average linkage. 
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Gene ontology (GO) analyses on the tissue-specific gene lists and the genes differentially 
expressed between pairs of tissues yielded interesting insight into functional differences, 
which may exist between the regions. The 419 GBD specific genes included ones such as 
UGT1A6, MOGAT1, CA4, SOX17, VDR and were enriched for GO terms (adj p-value 
< 0.05) involved in xenobiotic, lipid, carbohydrate, and steroid metabolic processes, 
among others (Figure 4.10, Annex File 3). Similar enrichment was observed when 
comparing genes upregulated in GBD tissue to either CBD or PancD tissues separately 
(Figure 4.11 and 4.12, Annex File 3), suggesting that of these EHBD regions, GBD 
tissue plays the largest role in active metabolic processes. 
 
 
Figure 4.10 Top ten enriched gene ontology terms for 419 genes upregulated in GBD 
tissue compared to both CBD and PancD tissues.  
Top ten most significant gene ontologies (biological processes) for 419 genes upregulated in GBD tissue 
compared to both CBD and PancD. 
 
 
Figure 4.11 Top ten enriched gene ontology terms for genes upregulated in GBD 
tissue compared to PancD tissue. 
Top ten most significant gene ontologies (biological processes) for 1,665 genes upregulated in GBD 
compared to PancD tissue. 
0 2 4 6
unsaturated fatty acid metabolic process
cellular lipid metabolic process
xenobiotic metabolic process
carboxylic acid metabolic process
long-chain fatty acid metabolic process
organic acid metabolic process
small molecule metabolic process
lipid metabolic process
oxoacid metabolic process
monocarboxylic acid metabolic process
-log10(adj p-value)
GO: Overlap of genes upregulated in GBD Tissue
0 4 8 12 16
regulation of biological quality
xenobiotic glucuronidation
cellular glucuronidation
cellular lipid metabolic process
lipid metabolic process
carboxylic acid metabolic process
oxoacid metabolic process
organic acid metabolic process
monocarboxylic acid metabolic process
small molecule metabolic process
-log10(adj p-value)
GO: Genes upregulated in GBD vs PancD tissue
Chapter 4: Transcriptomic profiling of human biliary tissues and in vitro organoids 
    
 
85 
 
Figure 4.12 Top ten enriched gene ontology terms for genes upregulated in GBD 
tissue compared to CBD tissue. 
Top ten most significant gene ontologies (biological processes) for 765 genes upregulated in GBD 
compared to CBD tissue. 
 
The 967 PancD specific genes included ones such as SCTR and CDX2 and were enriched 
for GO terms involved in protein targeting and localization to the membrane or 
endoplasmic reticulum, among others (Figure 4.13, Annex File 3). Similar GO terms 
were observed when comparing genes upregulated in PancD tissue compared with GBD 
or CBD tissue alone (Figure 4.14 and Figure 4.15, Annex File 3). 
 
 
Figure 4.13 Top ten enriched gene ontology terms for 967 genes upregulated in 
PancD tissue compared to both GBD and CBD tissues.  
Top ten most significant gene ontologies (biological processes) for 967 genes upregulated in PancD 
compared to GBD and CBD tissues. 
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Figure 4.14 Top ten enriched gene ontology terms for genes upregulated in PancD 
compared to CBD tissue.  
Top ten most significant gene ontologies (biological processes) for 1831 genes upregulated in PancD 
compared to CBD tissue. 
 
 
Figure 4.15 Top ten enriched gene ontology terms for genes upregulated in PancD 
compared to GBD tissue.  
Top ten most significant gene ontologies (biological processes) for 1437 genes upregulated in PancD 
compared to GBD tissue. 
 
The 256 CBD specific genes included ones such as HOXB2, HOXB3, and ABCA1 but 
were only enriched significantly for five GO terms with tissue morphogenesis and signal 
transduction among them (Figure 4.16, Annex File 3). Genes upregulated in CBD 
compared to GBD tissue were enriched for GO terms such as developmental processes, 
tube development, and tube morphogenesis (Figure 4.17, Annex File 3). Genes 
upregulated in CBD tissue compared to PancD tissue were enriched for GO terms such 
as xenobiotic glucuronidation and lipid transport (Figure 4.18, Annex File 3). 
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Figure 4.16 Five significantly enriched gene ontology terms for 256 genes 
upregulated in CBD compared to both GBD and PancD tissues.  
Five gene ontology terms (biological processes) were significantly enriched for the 256 genes upregulated 
in CBD compared to both GBD and PancD tissues. 
 
 
 
Figure 4.17 Top ten significantly enriched gene ontology terms for genes 
upregulated in CBD compared to GBD tissue.  
Top ten most significant gene ontology terms (biological processes) for 716 genes upregulated in CBD 
compared to GBD tissue. 
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Figure 4.18 Top ten significantly enriched gene ontology terms for genes 
upregulated in CBD compared to PancD tissue.  
Top ten most significant gene ontology terms (biological processes) for 1884 genes upregulated in CBD 
compared to PancD tissue. 
 
We also looked at the genes that were upregulated in both GBD and CBD tissue in 
comparison to PancD tissue, and found 856 overlapping genes (Figure 4.19, Annex File 
4). This list included genes known to be involved in lipid, cholesterol, bile acid, and 
xenobiotic/bilirubin related metabolic processes (i.e. FGF19, NR1I2, VDR, UGT1A4, 
UGT1A6, UGT1A10, ABCA1, APOA1, PPARG), which are known constituents of bile 
secretions that are only in contact with GBD/CBD epithelium and not the PancD (Figure 
4.20). GO analyses further confirmed this observation (Figure 4.21, Annex File 5).  
 
 
Figure 4.19 Overlap of genes differentially expressed between GBD and CBD tissues 
compared to PancD tissue. 
Venn diagram showing the number, as well as overlap, of genes upregulated in either GBD compared to 
PancD tissue or CBD compared to PancD tissue. Significance cut-off: abs (log2Fold Change) >1 and adj p-
value < 0.05. 
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Figure 4.20 Heatmap of 
selected genes involved 
in lipid, cholesterol, bile 
acid, and bilirubin 
related metabolic 
processes upregulated 
in GBD and CBD 
tissues compared to 
PancD tissues. 
Heatmap of the variance 
stabilized counts of selected 
genes that are upregulated in 
both GBD and CBD compared 
to PancD tissues involved in 
lipid, cholesterol, xenobiotic 
related metabolic processes.  
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Figure 4.21 Top ten significantly enriched gene ontology terms for genes 
upregulated in both GBD and CBD tissues compared to PancD tissue.  
Top ten most significant gene ontology terms (biological processes) for 856 genes upregulated in both GBD 
and CBD tissues compared to PancD tissue. 
 
It is also interesting to note that of the 856 genes upregulated in both GBD and CBD, 
compared to PancD tissue, 108 of these were additionally upregulated in GBD compared 
to CBD tissue. These 108 genes were enriched for GO terms similar to those for the 856 
genes (Figure 4.22, Annex File 5). Taken together, this supports the conclusion that 
anatomical niche shapes the expression profile of cholangiocytes within the biliary tree, 
with the GBD appearing to play the largest role in xenobiotic, lipid, and cholesterol 
metabolism.  
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Figure 4.22 Top ten most significantly enriched gene ontology terms for 108 genes 
upregulated in GBD tissue compared to CBD tissue that were also upregulated in 
CBD tissue in comparison to PancD tissue.  
Top ten most significant gene ontology (biological processes) terms. Out of 856 genes that were upregulated 
in both GBD and CBD in comparison to PancD tissues, 108 genes were also found to be upregulated in 
GBD compared to CBD tissue.  
 
4.3.4 Comparing extrahepatic bile duct tissue RNA-Sequencing results to 
previously published works 
 
As part of the Human Protein Atlas, Kampf et al (2014) performed RNA-sequencing on 
GBD tissue from three donors and compared GBD tissue to 27 other human tissues in 
order to determine GBD enriched genes.138 To further validate and benchmark our own 
data, we compared our data to this published work. Kampf et al (2014) previously 
identified 140 genes with increased expression in human GBD tissue in comparison to 27 
other tissue types, but this did not include comparisons to CBD or PancD tissues. Of these 
genes, we found 131 represented in our dataset. The nine genes not included in our dataset 
represented either genes no longer annotated in the current ENSEMBL database or non-
protein coding genes, which were not included in our analyses.  
Five genes were identified as being GBD specific with expression levels five-fold higher 
in GBD tissue than in any other tissue. We first looked to see whether these five genes 
were represented in our dataset and whether they remained GBD tissue-specific even 
when compared to more closely related tissues such as CBD and PancD. Four of the 
genes: FGF19, CHST4, MOGAT1, and UGT2B28 were expressed in our dataset. The 
fifth gene, AC083862.1 has been re-classified as a pseudogene in the current ENSEMBL 
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annotation and was therefore not included in our dataset of protein-coding genes. 
MOGAT1 and UGT2B28 were found to be upregulated in GBD tissue in comparison to 
both PancD and CBD tissues (Figure 4.23). Further, FGF19 and CHST4 were 
upregulated in GBD and CBD, compared to PancD tissues, but were not differentially 
expressed between GBD and CBD tissues. 
 
 
Figure 4.23 Normalized counts for four genes previously identified as being 
Gallbladder-tissue specific by Kampf et al (2014) 
DeSeq2 normalized counts for the three extrahepatic bile duct tissue regions for four genes previously 
identified as being gallbladder-tissue specific when comparing to 27 other human tissue types. # = false 
discovery rate (adj p-value) < 0.05 between the groups and fold change > 1. n.s. = not significant 
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We further compared our data with the list of 131 gallbladder-enriched genes by first 
comparing them to our list of 419 genes which were differentially expressed in GBD 
tissue compared to both CBD and PancD tissues. We found fifteen genes overlapped 
(Figure 4.24). A further ten genes were found to overlap the list of 856 genes which had 
been found to be upregulated in both GBD and CBD tissue compared to PancD tissue. 
Interestingly, twelve genes, which were GBD enriched in the work by Kampf et al (2014), 
were found to be upregulated in either PancD tissue or CBD tissue when compared to 
GBD tissue in our dataset. This suggests that some genes, although having enrichment in 
GBD tissue, may actually be enriched in the other two extrahepatic tissue types to a 
greater degree. Lastly, 78 genes from the Kampf et al (2014) list were not differentially 
expressed between any of the three tissues in our dataset. These genes included ones such 
as CFTR and ONECUT2, which are ubiquitously expressed in biliary epithelial cells. 
Therefore, these 78 genes likely represent basal cholangiocyte specific genes, which are 
not differentially expressed between the three extrahepatic tissue regions, but are simply 
enriched in biliary tissues compared to other non-related tissue types (Figure 4.25).  
By comparing our data with that of Kampf et al (2014) we were able to validate our own 
dataset by confirming that certain genes, such as MOGAT1 and UGT2B28, are 
gallbladder-tissue enriched even when compared to CBD and PancD tissues. 
Furthermore, it was found that the gallbladder enriched genes CHST4 and FGF19 are not 
specific to GBD tissue but are also expressed in CBD tissues, but are not highly expressed 
in PancD tissue. Ultimately, this continues to support our results by suggesting 
differences in the transcriptional profile exist for these three tissue regions. 
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Figure 4.24 Heatmap of gallbladder tissue enriched genes previously identified by 
Kampf et al (2014) that were identified in our dataset. 
Heatmap of the variance stabilized counts for the three extrahepatic bile duct tissue regions. Genes shown 
were ones identified as being in common with our dataset and that of Kampf et al (2014). The first cluster 
shows 15 genes upregulated in GBD compared to both CBD and PancD tissues which were also in the list 
of gallbladder-enriched genes identified by Kampf et al (2014). The second cluster contains 10 genes 
upregulated in GBD and CBD compared to PancD tissues that were also in the gallbladder-enriched list. 
The third cluster contains 12 genes upregulated in either CBD or PancD compared to GBD tissue despite 
being in the gallbladder-enriched gene list.  
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Figure 4.25 Heatmap of genes identified by 
Kampf et al (2014) as enriched in gallbladder 
tissue that are not differentially expressed 
between GBD, CBD, or PancD tissues 
Heatmap of the variance stabilized transformed counts for 
genes not differentially expressed between GBD, PancD, 
or CBD tissues that were previously identified by Kampf 
et al (2014) as being enriched in GBD tissues. 
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4.3.5 Transcriptomic profiling of extrahepatic biliary organoids reveals 
downregulation of mature biliary markers and upregulation of cell cycle 
and WNT signalling genes 
 
In other epithelial derived organoid systems, such as the intestine, organoids maintain a 
remarkable similarity to their tissue of origin and express markers of both adult stem cells 
and differentiated cell lineages.124 As biliary tissue is made up of predominantly one 
mature cell type, the cholangiocyte, we wanted to also investigate how extrahepatic 
biliary organoids compare to their tissue of origin and whether any regional tissue-
specific markers are maintained. To do so, RNA-sequencing was performed on organoids 
derived from CBD, GBD, and PancD tissues. PCA revealed that the largest source of 
variation in the samples (56%) was between tissues and organoids and that tissue-specific 
differences only accounted for 10% of the variation between samples (Figure 4.26). The 
three different organoid types clustered closely. However, clustering by tissue of origin 
was still discernible. 
 
Figure 4.26 Principal component analysis of extrahepatic bile duct tissues and 
organoids 
Principal component analysis of variance stabilized counts for the top 5,000 most variable genes between 
Common Bile Duct (CBD) tissue (n=7), CBD organoids (n=6), Gallbladder (GBD) tissue (n=5), GBD 
organoids (n=3), Pancreatic Duct (PancD) tissue (n=3), and PancD organoids (n=3).   
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In line with the large separation between tissue and organoid samples by PCA, DGE 
analyses showed a large number of genes were differentially expressed between each 
organoid type and their corresponding tissue of origin (5,586 genes, CBD tissue vs 
organoids; 4,537 genes, GBD tissue vs organoids; and 5,594 genes, PancD tissue vs 
organoids) (Figure 4.27, Annex File 6). To explore these differences, we examined the 
expression levels of selected genes known to be involved in mature biliary epithelial 
function, adult stem cells, WNT signalling, and cell cycle regulation which were 
differentially expressed between organoids and tissues (Figure 4.28).  
 
 
Figure 4.27 Number of genes differentially expressed between the extrahepatic bile 
duct tissues and corresponding organoids. 
Venn diagram showing the number, and overlap, of genes differentially expressed between CBD tissue and 
organoids, PancD tissue and organoids, or GBD tissue and organoids. Significance cut-off: log2Fold 
Change >1 and adj p-value < 0.05. 
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Figure 4.28 Heatmap and hierarchical clustering analysis of selected biliary and 
adult stem cell genes comparing EHBD organoids and primary tissues. 
Heatmap of selected biliary and adult stem cell/WNT signalling genes. Hierarchical clustering performed 
on the variance stabilized transformed counts using one minus Pearson correlation distance with average 
linkage. 
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Hierarchical clustering of these genes highlighted the differences between organoids and 
primary tissues, with organoids having significantly lower expression of functional 
biliary markers (i.e. GGT1/6, CFTR, MUC1, VIPR1) and significantly higher expression 
of adult stem cell markers and genes known to be involved in WNT and cell cycle 
pathways (i.e. LGR5/6, PROM1, AXIN2, CDK6). Ductal markers such as KRT7, 
KRT19, EPCAM, and SOX9 were not differentially expressed between tissues and 
organoids suggesting that these genes are intrinsic biliary markers, which are not affected 
by WNT or in vitro culture conditions. Further, GO analyses of the top 200 differentially 
expressed genes (genes with the smallest adj p-value) between each of the organoids and 
their corresponding primary tissues were enriched for GO terms involved in cell cycle 
processes and cell division. Genes upregulated in tissues compared to organoids were 
enriched for GO terms involved in secretion, transport, and metabolic processes (Figure 
4.29, Annex File 7).  
 
 
Figure 4.29 Top ten significantly enriched gene ontology terms for the top 200 
differentially expressed genes in EHBD organoids compared to primary tissues. 
Top ten most significant gene ontologies (biological processes) for the top 200 differentially expressed 
genes upregulated in extrahepatic tissues compared to organoids or upregulated in extrahepatic organoids 
compared to tissues.   
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We also assessed whether any regional tissue-specific signatures were maintained in the 
EHBD organoids. It was found that, on average, only 45% of significantly differentially 
expressed genes between CBD, GBD, and PancD derived organoids overlapped with 
differentially expressed genes previously identified in their corresponding primary tissues 
(Figure 4.30, Annex File 8 and 9). 91.6% of these genes showed the same directionality 
of expression when comparing organoid and tissue expression patterns. This suggests that 
EHBD organoids, despite differing from their tissue of origin, do maintain some regional 
specific markers in culture.  
 
 
Figure 4.30 Number of genes differentially expressed between the extrahepatic bile 
duct tissues, between the organoids, and the number of genes overlapping. 
Venn diagrams displaying number, as well as overlap, of genes differentially expressed comparing GBD 
versus PancD tissues and in vitro organoids, CBD versus PancD tissues and in vitro organoids, and CBD 
versus GBD tissues and in vitro organoids. Significance cut-off: abs (log2Fold Change) >1 and adj p-value 
< 0.05 
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We validated the expression of three of these genes, SOX17, CDX2, HOXB2, by qPCR 
(Figure 4.31) and also of SOX17 and CDX2 at the protein-level by IF (Figure 4.32). 
Unfortunately, we were unable to find an antibody against HOXB2 that worked on frozen 
tissue sections. However, our RNA-Seq data and also qPCR validation of HOXB2 
suggests that it is a CBD specific marker.  
 
 
Figure 4.31 RNA-Seq normalized read counts and qPCR validation of three tissue 
specific markers which are maintained in the organoids. 
RNA-Seq read counts and qPCR validation of three genes found to retain tissue-specific expression patterns 
in organoid cultures.  For qPCR validation: CBD Tissue (n=6), CBD Organoids (n=7), GBD Tissue (n=10), 
GBD Organoids (n=7), PancD Tissue (n=3), and PancD organoids (n=3) and gene expression is normalized 
to the housekeeping gene UBC and data is plotted as mean and SEM. *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 
0.001, ****p ≤ 0.0001, n.s. = not significant. Sigmoid colon (SC) organoids (n=4) were used as controls. 
 
SOX17 was only expressed in GBD tissue and showed the highest expression level in 
GBD organoids. CBD organoids, despite having lower expression of SOX17 at the RNA 
level, did show expression by IF. PancD organoids were negative for SOX17. CDX2 was 
exclusively expressed in PancD tissue and organoids. These expression patterns did not 
change significantly over time in culture (Figure 4.33).  
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Taken together, these data show that biliary epithelial cells lose, in part, their regional 
identity when grown as organoids in the presence of WNT signalling. Nonetheless, this 
seems to only be partial as the expression of a few, but very specific, regional markers 
are maintained in EHBD organoids. 
 
 
Figure 4.32 Immunofluorescence analysis of EHBD organoids and primary tissues 
for two genes found to be differentially expressed between tissue regions. 
Scale bar=50 μm 
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Figure 4.33 Expression of SOX17, CDX2, and HOXB2 over time in culture in 
extrahepatic bile duct organoids. 
qPCR analyses showing the expression of SOX17, CDX2, and HOXB2 in extrahepatic bile duct organoids 
(n=3-7, n=2-7 donor lines per passage) from common bile duct (CBD), gallbladder (GBD), and pancreatic 
duct (PancD) over time in culture (P0, P5, P10 or higher). Gene expression is normalized to the 
housekeeping gene UBC and data is plotted as mean and SEM.   
 
4.3.6 Comparison of extrahepatic bile duct organoids to intestinal LGR5+ 
stem cell signature from previously published works. 
 
In comparing our EHBD organoids to their tissues of origin, it was found that many 
functional biliary markers were down-regulated and genes such as LGR5/6 and PROM1, 
which are commonly associated with adSCs, were upregulated. To explore this potential 
stem cell signature further, we compared our EHBD organoids to a previously published 
gene signature for LGR5+ intestinal stem cells described in work performed by Munoz 
et al (2012).142 The work by Munoz et al (2012) was performed in mouse and utilized the 
transgenic LGR5-EGFP-ires-CreERT2 knock-in mouse which labels LGR5 positive cells 
with GFP, allowing them to be selectively sorted from intestinal tissue and only the LGR5 
positive cells to be analysed. Munoz et al (2012) performed both microarray profiling and 
also proteomic analyses using mass spectrometry to identify genes that were enriched in 
LGR5+ intestinal stem cells compared to non-LGR5+ intestinal cells from freshly sorted 
cells. In doing so, they found 510 genes that were enriched in LGR5+ cells and deemed 
these genes to make up an intestinal stem cell signature. Unfortunately, as there are 
currently no reliable LGR5 antibodies that stain human tissue, a human intestinal stem 
cell signature has not yet been described. 
However, many of the genes found by Munoz et al (2012) have been shown to be markers 
of human intestinal stem cells grown in organoid cultures suggesting this intestinal stem 
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cell signature discovered in the mouse may be informative also for human adult stem 
cells.88 
Given this, we first took the list of 510 intestinal stem cell signature genes and determined 
whether human orthologs exist for the genes and if the genes were represented in our own 
RNA-Sequencing data set. Of the 510 genes, we found 493 genes which met these criteria 
(Annex File 10). Next, genes which were upregulated in EHBD organoids compared to 
their tissue of origin were compared to this list of 493 genes. It was found that a number 
of genes overlapped between the lists (Figure 4.34, Annex File 10). This suggested that 
EHBD organoids, when compared to their primary tissues, appear to upregulate some of 
these intestinal stem cell signature genes. Further, a large number of these genes were in 
common across the three different organoid types, with 135 of the intestinal stem cell 
signature genes being upregulated in at least two out of the three EHBD organoid types 
in comparison to their primary tissues. A heatmap of those 135 genes is shown in Figure 
4.35.  
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Figure 4.34 Genes upregulated in EHBD organoids compared to their tissues of 
origin which overlap with an intestinal stem cell signature of 493 genes described by 
Munoz et al (2012). 
The top three diagrams show the number of genes that were upregulated in extrahepatic bile duct organoids 
in comparison to their tissues of origin (1,845 common bile duct, 1,624 gallbladder, and 2,332 pancreatic 
duct organoids) and the number of these genes that overlap a 493 gene signature reported by Munoz et al 
(2012) for intestinal LGR5+ adult stem cells (134 common bile duct, 126 gallbladder, 153 pancreatic duct). 
The bottom diagram shows the overlap of these overlapping genes between the three different organoid 
types. 
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Figure 4.35 Intestinal stem cell signature genes 
described by Munoz et al (2012) that are 
upregulated in extrahepatic bile duct organoids 
compared to their tissues of origin. 
Heatmap of the variance stabilized counts depicting 
the 135 intestinal stem cell signature genes which 
were upregulated in at least two out of the three 
EHBD organoid types in comparison to their primary 
tissues.  
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We also performed GO enrichment analyses on these 135 genes and found they were 
largely involved in cell cycle processes and WNT signalling (Figure 4.36, Annex File 
10). This comparison further supports our earlier conclusions that EHBD organoids differ 
greatly from their tissue of origin and upregulate genes involved in cell cycle progression 
and WNT signalling. It is interesting to find that many of these genes are also over-
represented in a population of cells known to be well-established as adult stem cells in 
the intestine.  
 
 
Figure 4.36 Gene ontology analysis of the 135 intestinal stem cell signature genes 
described by Munoz et al (2012) which were upregulated in extrahepatic bile duct 
organoids in comparison to their tissues of origin.  
Top twenty gene ontology terms (biological processes) which were enriched in the 135 intestinal stem cell 
signature genes described by Munoz et al (2012) which were upregulated in at least two out of the three 
extrahepatic bile duct organoid types compared to their tissues of origin.  
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4.3.7 Intrahepatic biliary organoids and extrahepatic biliary organoids 
display different transcriptional profiles 
 
In addition to performing the basic characterizations of our EHBD and IHBD organoids 
described in Chapter 3, we also performed sequencing on CBD, GBD, PancD, IHBD_ex, 
and IHBD_Huch organoids. PCA analysis demonstrated that the largest source of 
variation was between EHBD organoids and IHBD organoids. EHBD organoids clustered 
closely together regardless of their tissue of origin, while both IHBD_ex and IHBD_Huch 
clustered separately from EHBD organoids and each other (Figure 4.37). Correlation 
analysis further confirmed this observation (Figure 4.38). As all three of the EHBD 
organoid types clustered closely and the number of genes differentially expressed 
between the three organoid types was minimal in our earlier analyses, we combined them 
into a single “EHBD” group for further analyses.   
 
 
Figure 4.37 Principal component analysis of EHBD and IHBD organoids. 
Principal component analysis of variance stabilized counts for the top 5,000 most variable genes between 
common bile duct (CBD) (n=6), gallbladder (GBD) (n=3), and pancreatic duct (PancD) (n=3) extrahepatic 
bile duct organoids (EHBD) as well as intrahepatic bile duct (IHBD) organoids cultured in extrahepatic 
conditions (IHBD_ex, n=3) or in conditions described by Huch et al (2015) (IHBD_Huch (n=3)). 
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Figure 4.38 Pearson correlation matrix of IHBD and EHBD organoids. 
Sample distance matrix of one minus Pearson correlation between EHBD and IHBD organoids. Matrix was 
generated using the R pheatmap package. 
 
We then sought to understand the transcriptional divergence of IHBD_ex organoids from 
IHBD_Huch and EHBD organoids. 2,122 genes were differentially expressed between 
IHBD_ex and IHBD_Huch organoids (1,120 upregulated in IHBD_ex and 1,002 
upregulated in IHBD_Huch). While 2,990 genes were differentially expressed between 
IHBD_ex and EHBD organoids (1,411 upregulated in IHBD_ex and 1,579 upregulated 
in EHBD). Many of these genes overlapped between these comparisons and 612 genes 
were upregulated in IHBD_ex organoids compared to both IHBD_Huch and EHBD 
organoids and 544 genes upregulated in IHBD_Huch and EHBD organoids compared to 
IHBD_ex organoids (Figure 4.39, Annex File 11).  
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Figure 4.39 Number and overlap of genes differentially expressed between IHBD_ex 
and EHBD or IHBD_Huch organoids. 
Venn diagram showing the number, and overlap, of genes differentially expressed in IHBD_ex organoids 
compared to IHBD_Huch and EHBD organoids. 
 
As expected, given the proliferation differences observed between the organoids, the 544 
genes upregulated in IHBD_Huch and EHBD organoids were enriched significantly for 
just two GO terms including mitotic cell cycle process (adj p-value = 4.01E10-2) and cell 
cycle process (adj p-value = 4.06E10-2). Interestingly, the 612 genes upregulated in 
IHBD_ex organoids included genes involved in mature hepatocyte function (i.e. ALB, 
TTR, NR1H4, CYP7B1, complement/clotting factors) (Figure 4.40, Annex File 11). 
However, the progenitor cell markers (i.e. PROM1, SPP1) were also upregulated, as were 
markers known to be involved in cell death/senescence and epithelial mesenchymal 
transition (i.e. CASP1, VIM). Thus, this analysis suggests complex differences between 
IHBD organoids without uncovering a major source of divergence. Nonetheless, these 
results clearly demonstrate that EHBD and IHBD organoids are transcriptionally distinct, 
even when cultured in the same conditions. Further, the extrahepatic culture conditions, 
and WNT, may promote the senescence and/or differentiation of IHBD cells.  
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Figure 4.40 Heatmap of selected genes upregulated in IHBD_ex organoids. 
Heatmap of selected genes involved in mature hepatocyte function (cluster 1), liver progenitor cells (cluster 
2) and cell death/epithelial mesenchymal transition (cluster 3) that were upregulated in IHBD_ex compared 
to both IHBD_Huch and EHBD organoids. 
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Next, we sought to more broadly understand the differences that may exist between the 
IHBD and EHBD organoids. Given the transcriptional signature of the IHBD_ex 
organoids, and their known proliferative difference, we focused these comparisons on 
EHBD organoids and IHBD_Huch organoids. 1,393 genes were differentially expressed 
between EHBD and IHBD_Huch organoids (792 genes upregulated in EHBD and 601 
genes upregulated in IHBD_Huch) (Annex File 11). Of note, some of these genes also 
overlapped with genes differentially expressed between EHBD and IHBD_ex organoids 
(Figure 4.41), suggesting EHBD and IHBD organoids are intrinsically different 
independently of the culture conditions. 
 
 
 
Figure 4.41 Number and overlap of genes differentially expressed between EHBD 
and IHBD_ex or IHBD_Huch organoids. 
Venn diagram showing the number and overlap of genes differentially expressed between EHBD organoids 
compared to the two IHBD organoid types. 
 
We then examined these genes further and found the 601 genes upregulated in 
IHBD_Huch organoids were enriched for GO terms involved with developmental 
processes and cell differentiation (Figure 4.42, Annex File 12). Interestingly, these genes 
included the hedgehog signalling pathway ligands IHH and SHH, which have been shown 
to promote the maintanence of intrahepatic progenitor cells.143   
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The 792 genes upregulated in EHBD organoids were enriched for GO terms involved in 
cell cycle processes and DNA replication, including genes such as Cyclin B2/A2/E2 and 
PCNA. This finding could suggest that proliferation is controlled by different 
mechanisms between intra- and extrahepatic cholangiocytes and/or that a larger 
proportion of cells in the EHBD organoids cycle more quickly than IHBD_Huch 
organoids. Such differences could have broad implications since cholangiopathies are 
associated with cholangiocyte senescence and thus proliferative capacity could play an 
essential role in disease development.131 In sum, these results demonstrate that IHBD and 
EHBD organoids differ in their proliferative capacity, growth factor requirements and 
gene expression profile.  
 
Figure 4.42 Heatmap of the 1,393 genes differentially expressed between EHBD and 
IHBD_Huch organoids  
Heatmap of the 792 genes upregulated in EHBD organoids and the 601 genes upregulated in IHBD_Huch 
organoids, as well as representative gene ontology terms (biological processes) and examples of genes 
upregulated in each organoid type. 
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4.3.8 Exploratory analyses of the transcriptional profile of intrahepatic 
biliary tissues suggest differences from extrahepatic biliary tissues 
 
As mentioned above, three IHBD primary tissue samples were also sequenced. These 
samples were obtained during isolation of IHBD organoids. Liver tissue from three 
donors was frozen in Cell Banker 2 freezing media. The liver tissue was thawed and 
enzymatically dissociated until only ductal structures remained visible in the digestion 
media. These ductal structures were manually picked using a p200 pipette, under a 
microscope, pelleted, and lysed for RNA. Dissociation methods similar to this have been 
previously employed and shown to enrich for IHBD units with efficiencies as high as 
90%.66 However, in our RNA-Sequencing data, it was noted that the IHBD tissue samples 
clustered very far from EHBD tissue samples by PCA analysis (Figure 4.43).  
 
 
Figure 4.43 Principal component analysis of EHBD and IHBD tissues. 
Principal component analysis of variance stabilized counts for the top 5,000 most variable genes between 
CBD tissue (n=7), GBD tissue (n=5), PancD tissue (n=3) and IHBD tissue (n=3). 
Therefore, we further examined the sequencing data for biliary specific markers KRT7, 
KRT19, SOX9, EPCAM, and HNF1B in the IHBD tissue samples compared to our 
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EHBD tissue samples. We found that all three of the EHBD tissues (CBD, GBD, and 
PancD) had significantly higher expression of several of these markers by DGE analysis 
(KRT19, HNF1B, EPCAM) (Figure 4.44). KRT7 and SOX9 were not differentially 
expressed. We also examined the hepatocyte specific marker ALB and found it was 
significantly up-regulated in IHBD tissues compared to EHBD tissues. These 
observations were further confirmed by qPCR analysis and we compared the expression 
profile of IHBD tissue samples to that of whole liver tissue and to EHBD tissues (Figure 
4.45).  
 
Figure 4.44 RNA-Seq normalized counts for biliary specific markers and liver 
markers in EHBD and IHBD tissue samples. 
DeSeq2 normalized counts for bile duct epithelial specific markers and Albumin. # = false discovery rate 
(adj p-value) < 0.05 and fold change > 1. n.s.= not significant (adj p-value > 0.05). 
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Figure 4.45 Quantitative PCR analysis for biliary and liver markers in EHBD, 
IHBD, and whole liver tissue samples. 
qPCR analysis for biliary markers and hepatocyte markers. Gene expression is normalized to the 
housekeeping gene UBC and data is plotted as mean and SEM. For KRT7, SOX9, HNF1B, and ALB: CBD 
tissue (n=5), GBD tissue (n=9), and PancD tissue (n=3). For KRT19 and CYP3A4: PancD tissue (not 
available), CBD tissue (n=3) and GBD tissue (n=6). All genes: IHBD tissue (n=3) and liver tissue (n=3). 
*=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001, ****p ≤ 0.0001. If not indicated, comparisons between groups 
were not significantly different (p>0.05) 
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Taken together, the sequencing and qPCR results suggest enrichment for intrahepatic 
biliary epithelial cells to some degree, given the higher expression of KRT19 and KRT7, 
as well as the lower expression of Albumin, in IHBD tissues compared to liver tissue. 
However, this enrichment was not as high as that achieved for EHBD tissues and IHBD 
tissues showed lower expression of biliary markers than the EHBD tissue samples. With 
these limitations in mind, we continued to explore the data to see if anything further could 
be observed.  
As expected, when IHBD and EHBD tissues were compared, a large number of genes 
were differentially expressed. Between IHBD tissues and GBD tissue, 7,266 genes were 
differentially expressed (3,930 upregulated in IHBD tissue, 3,336 upregulated in GBD 
tissue). Between IHBD and CBD tissues 7,000 genes were differentially expressed (3,870 
upregulated in IHBD tissue, 3,130 upregulated in CBD tissue). Lastly, between IHBD 
and PancD tissues 7,915 genes were differentially expressed (4,391 upregulated in IHBD 
tissue, 3,524 upregulated in PancD tissue). Many of these genes overlapped (Figure 4.46, 
Annex File 13).  
GO analysis on overlapping genes upregulated in IHBD tissues compared to the three 
EHBD tissues showed enrichment for GO terms involved with regulation of 
developmental process, among others (Figure 4.47, Annex File 13). Interestingly, similar 
GO terms were upregulated in IHBD organoids compared to EHBD organoids in the 
analyses above. It was also noted that many genes in the NOTCH signalling pathway, a 
pathway known to be important in biliary fate specification, were upregulated in the 
IHBD tissues (Figure 4.48). It is difficult to conclude whether this expression profile 
originates from the intrahepatic biliary epithelial cells or from other possible 
contaminating cell sources. For instance, the NOTCH signalling profile may be 
originating from periportal mesenchymal cells, as both these and biliary epithelial cells 
have been shown to express NOTCH pathway genes.144 
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Figure 4.46 Number and overlap of genes differentially expressed between IHBD 
and EHBD tissues. 
Venn diagram showing the number and overlap of genes differentially expressed between IHBD tissue 
compared EHBD tissues. 
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Figure 4.47 Gene Ontology enrichment for genes upregulated in IHBD vs EHBD 
tissues. 
Top ten gene ontology terms (biological processes) which were enriched in the 2,595 genes upregulated in 
IHBD tissue samples compared to all three of the EHBD tissue regions.  
 
 
 
Notch signalling genes: ADAM17, SNW1, DLL1, DLL3, DLL4, DTX1, HES1, HES5, 
JAG1, JAG2, MAML2, NOTCH3, NOTCH4, HEY1, HEY2 
Figure 4.48 NOTCH signalling genes upregulated in IHBD tissues compared to 
EHBD tissues.  
Notch signalling genes upregulated in IHBD tissues compared to all three of the EHBD tissue regions are 
indicated by red stars on the pathway diagram and listed below the diagram. Pathway diagram generated 
using DAVID (Database for Annotation, Visualization and Integrated Discovery).137 
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Finally, we examined the expression of the three genes we previously discovered to be 
tissue specific amongst the three EHBD regions (HOXB2, CDX2, and SOX17) to reveal 
if any of these genes are also expressed in IHBD tissues or organoids (Figures 4.49 and 
4.50).  
CDX2 remained PancD specific and was significantly higher in both PancD tissue and 
organoids (Figure 4.49).  Both IHBD tissue and IHBD_Huch organoids were negative 
for CDX2 by IF staining (Figure 4.50). HOXB2 was not significantly differentially 
expressed between CBD and IHBD tissue samples in the sequencing data, however, by 
qPCR it was significantly lower in IHBD tissues. SOX17 was not differentially expressed 
between GBD and IHBD tissues by both sequencing and qPCR analyses. However, 
SOX17 was not detectable by IF in IHBD tissue or IHBD_Huch organoids (Figure 4.50) 
suggesting that it is not a marker of IHBDs.  
In summary, due to the limitations of the IHBD tissue samples, it is difficult to draw 
definitive conclusions from the data. However, we were able to show that our previously 
identified EHBD regional specific genes (CDX2, HOXB2, and SOX17) are likely not 
markers of IHBD tissues. Further, we demonstrated that manual enrichment of IHBDs is 
not sufficient to isolate an enriched population of biliary epithelial cells. Lastly, we 
identified the NOTCH signalling pathway as a potential pathway upregulated in IHBDs, 
however, further validation of this finding, on a pure population of IHBD biliary epithelial 
cells, is necessary. 
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Figure 4.49 RNA-Seq normalized read counts and qPCR validation on IHBD tissues 
and organoids for three genes previously identified as regional specific markers of 
EHBD tissues.  
RNA-Seq normalized read counts and qPCR validation on IHBD tissue and organoids of three genes 
previously found to be regional specific in EHBD tissues. For qPCR validation: CBD Tissue (n=6), CBD 
Organoids (n=7), GBD Tissue (n=10), GBD Organoids (n=7), PancD Tissue (n=3), and PancD organoids 
(n=3), IHBD tissue (n=3), IHBD_Huch organoids (n=3), and IHBD_ex organoids (n=3). Gene expression 
is normalized to the housekeeping gene UBC and data is plotted as mean and SEM. Sigmoid colon (SC) 
organoids (n=4) were used as controls. *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001, ****p ≤ 0.0001. If not 
otherwise indicated, comparisons between groups were not significantly different (p>0.05) 
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Figure 4.50 Immunofluorescence staining on human liver tissue and IHBD_Huch 
organoids for CDX2 and SOX17. 
Scale bar=50 μm 
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4.4 Discussion 
 
This chapter presented the results from a comprehensive transcriptional profiling of 
human biliary tissues and in vitro cultured organoids derived from these tissues. Using 
RNA-sequencing, a transcriptional profile of epithelial enriched samples from three 
EHBD tissue regions including the CBD, GBD, and PancD was established. These 
profiles allowed assessment of differences in expression between the three tissues and 
allowed regional specific markers for these tissues, including HOXB2, CDX2, and 
SOX17, to be uncovered. Further, the consistency of these results with previously 
published work was demonstrated. Many of the genes identified as being GBD tissue 
specific compared to both CBD and PancD tissues in our own dataset, were also 
previously reported to be GBD tissue enriched, even when compared to 27 other unrelated 
human tissues. Our findings on SOX17 and CDX2 have precedence in the literature. In 
the case of SOX17, some reports in the mouse suggest it to be a marker of only GBD 
tissue, however, others suggest it is also expressed in bile duct tissue.53,94 To our 
knowledge, this finding has not been confirmed before in human tissues and we show that 
SOX17 is only expressed in GBD tissue and not expressed in CBD, PancD, or IHBD 
tissue at the protein level. Two reports of CDX2 expression in PancD tissues exist, 
however, it was not known until now that it is a marker of only PancD tissue and not other 
regions of the EHBD biliary tree.145,146 It was also observed that even genes considered 
to be biliary specific genes, such as ABCC2, SLC10A2 (ASBT), and SCTR, were 
differentially expressed between the three EHBD regions, with GBD tissue having 
upregulated expression of ABCC2 and SLC10A2, while SCTR was upregulated in PancD 
tissue.  
Additionally, we were able to gain insight into functional differences these tissues may 
have. Most notably, we discovered that GBD tissue has higher expression of genes 
associated with active metabolic processes involved in bile modification, including 
xenobiotic metabolism, lipid metabolism, and cholesterol metabolism, when compared to 
both CBD and PancD tissues. Ultimately, it appears from the data, that each of these three 
tissue regions display a transcriptional profile in line with their function in bile transport, 
while at the same time maintaining a key underlying expression of essential 
cholangiocyte-specific genes (i.e. CFTR, HNF1B, KRT7, KRT19). The GBD acts as the 
primary site of bile storage, and as such, displays a transcriptional profile consistent with 
having the predominant role in bile modification. While the CBD acts as a conduit for 
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bile and is in contact with bile for a shorter period of time and after it leaves the GBD. 
This may explain why the CBD tissue had lower expression levels of key bile 
modification pathways when compared to GBD tissue, as when the bile reaches the CBD 
it has already been modified extensively in the GBD. Additionally, the PancD, which is 
never in contact with bile, has downregulated and/or no expression of these bile 
modification pathway genes compared to both the CBD and GBD tissues. Instead, the 
PancD tissue appears to be enriched for genes involved in protein synthesis and RNA 
processing. This enrichment however, could be explained by contaminating acinar cells, 
as they produce a large amount of secreted proteins and require a high level of 
translational machinery. It is intriguing to consider whether the epithelial cells themselves 
impart this functional difference between tissue regions or if the anatomical environment 
itself, such as the higher bile concentration in the GBD, imposes these functional 
differences onto the epithelial cells.  
Also, interesting to consider, are the effects of GBD removal, or cholecystectomy. 
Cholecystectomy is one of the most common surgeries performed worldwide and the 
GBD is considered as a non-essential organ as patients usually tolerate cholecystectomy 
with limited to no long-term side effects.51 Following cholecystectomy, however, it has 
been shown that many biological alterations do occur. These include things such as a 
decrease in circulating levels of FGF19, increased enterohepatic recycling of bile acids, 
alterations to the composition of the bile acid pool, and even possible changes in the gut 
microbiota. There have even been reports on the association of cholecystectomy with an 
increased risk of developing metabolic syndrome (type 2 diabetes, high 
cholesterol/triglycerides) and non-alcoholic fatty liver disease. This risk was found to be 
independent of gallstone disease.51 These associations are very interesting, as our own 
data suggests that GBD epithelial cells likely play an active role in the metabolic 
processes that are perturbed in these disease states. Therefore, cholecystectomy may in 
fact be removing a reservoir of cells that participate in crucial metabolic functions. 
Interestingly, our data also suggested that, when compared to the PancD, CBD tissue may 
serve as a site for some of these metabolic functions, although to a lesser degree than 
GBD tissue. It would be interesting to assess in future studies how CBD epithelial cells 
adapt to cholecystectomy and whether the CBD or other regions of the biliary tree are 
capable of taking on some of the functional roles that the GBD epithelium appears to be 
important in maintaining.  
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One key limitation to this RNA sequencing data, which must be mentioned, is that the 
EHBD tissue samples were derived from epithelial enriched samples obtained by 
mechanical dissociation and were not purified beyond this. This method, as we 
demonstrated in Chapter 1, does enrich for biliary epithelial cells with only 5-10% of the 
cells not expressing KRT7/KRT19. However, in the RNA-sequencing data, we could 
observe expression of genes not typically associated with biliary epithelial cells. For 
example, we observed expression of blood cell markers such as CD4 and Haemoglobin 
in the three EHBD tissue samples. This limitation was most apparent in the PancD tissue 
samples and we found the PancD tissue samples had significantly higher expression of 
several acinar and endocrine-specific genes. This suggests that the PancD tissue samples 
may have contained a low-level of contaminating pancreatic parenchymal tissue. This 
does lead to limitations in the interpretations that can be drawn from the genes 
upregulated in PancD tissue samples and this data should be considered cautiously as they 
may not originate from the pancreatic ductal cells. However, even given this limitation, 
we were still able to uncover PancD specific gene signatures, including CDX2, and gain 
insight into genes that are upregulated in GBD/CBD tissue in comparison to PancD 
tissues. 
In this chapter, we also characterized the transcriptomic profile of organoids derived from 
EHBD and IHBD tissue sources. It was found that EHBD organoids are different from 
their tissue of origin but that a small number of regional tissue specific markers are 
maintained in the organoids. We also discovered that the organoids upregulate expression 
of cell cycle genes, WNT signalling genes, and genes that have previously been associated 
with intestinal adSCs. The organoids also down-regulate many functional markers of 
mature biliary cells. These results continue to support the idea that the EHBD organoids 
likely contain a population of cells with a stem/progenitor-like phenotype, consistent with 
our earlier characterizations of the organoids in Chapter 3. Further, we demonstrated that 
IHBD_Huch and IHBD_ex organoids have unique transcriptional profiles from that of 
the EHBD organoids and also from each other. However, the biological significance of 
these differences was difficult to interpret given the proliferative differences observed in 
the IHBD_ex organoids and the different media components needed to culture 
IHBD_Huch organoids. This limitation causes difficulties in interpreting weather 
differences in the organoid transcriptional profiles are due to IHBD versus EHBD 
differences, or if they are due simply to differences in proliferation rate and/or media 
composition. Despite this limitation, we were able to discover that our extrahepatic 
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organoid culture conditions may be inducing IHBD_ex organoids to differentiate towards 
a hepatocyte-fate or undergo EMT. Interestingly it has been shown that WNT signals 
from macrophages in the liver act to push intrahepatic liver progenitor cells towards a 
hepatocyte fate during tissue injury.147 It is possible this may explain the differences we 
observed in IHBD organoids cultured in media containing CHIR 99021.   
Lastly, we considered sequencing data from IHBD tissue samples. However, it was found 
that these samples were likely contaminated by other cell types including hepatocytes and 
possibly mesenchymal cells from the liver, making it difficult to draw definitive 
conclusions from the data. However, despite these limitations in the samples, we were 
still able to examine the expression of CDX2, SOX17, and HOXB2 in IHBD tissues and 
organoids. We found these genes are likely not expressed to a significant degree in the 
IHBD compartment and that they are truly unique tissue-specific markers for different 
regions of the extrahepatic biliary tree.  
In summary, we feel these results are significant and have provided the first evidence that 
the transcriptional profile of biliary tissues differs throughout the human extrahepatic 
biliary tree. Furthermore, we found that unlike other organoid systems, EHBD organoids 
are unique from their tissue of origin. Lastly, we show that IHBD and EHBD organoids 
are not equivalent and that differences exist in their transcriptional profiles. 
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5 ASSESSING THE 
DIFFERENTIATION CAPACITY 
OF HUMAN BILIARY 
ORGANOIDS 
5.1 Statement of Source 
 
The results presented here are largely based on experiments presented in the following 
first author manuscript written by the author of this dissertation. Therefore, some parts 
have been taken verbatim or with only minor changes from this source.  
Rimland CA, Tilson S, Morell C, Tomaz R, Lu WY, Adams S, Georgakopoulos N, 
Otaizo-Carrasquero F, Myers T, Sun HW, Gieseck RL, Sampaziotis F, Tysoe O, 
Wesley B, Oniscu GC, Hannan NRF, Forbes S, Saeb-Parsy K, Wynn TA, Vallier 
L. (2018) Regional differences in human biliary tissues and corresponding in 
vitro derived organoids. Manuscript in preparation. 
The experiments presented in this chapter were performed in collaboration with several 
individuals and this is noted in the figure legends. 
In particular, Ms. Samantha Tilson assisted in performing the differentiation experiments 
on IHBD_Huch and IHBD_ex organoids. While Ms. Simone Adams assisted in the 
screening experiments on EHBD organoids while under the supervision of the author of 
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this dissertation. Ms. Olivia Tysoe and Mr. Kourosh Saeb-Parsy performed the liver 
capsule injections. All data analysis, figure preparation and interpretation of these 
experiments was performed by the author of this dissertation.  
5.2 Introduction 
 
As introduced in Chapter 1.4, there are mixed reports in the literature on the 
differentiation capacity of biliary organoids. It has been shown that intrahepatic biliary 
cells in vivo and intrahepatic bile duct derived organoids likely contain a bipotent 
progenitor population with the capacity to express hepatocyte-specific markers under 
certain conditions. However, the ability of extrahepatic biliary cells and organoids to 
differentiate is still unclear. Several reports suggest it may be possible, while others have 
shown extrahepatic cells are limited in their differentiation capacity.111,113,116,122 
Therefore, in this chapter we sought to assess the differentiation capacity of our EHBD 
organoid cell lines. As we presented in the previous two chapters, these EHBD organoids 
share many characteristics of adSCs with IHBD organoids such as the expression of key 
markers LGR5 and PROM1. However, as our analyses in Chapter 3 and 4 demonstrated, 
the EHBD organoids are distinct from IHBD organoids in vitro suggesting that their 
differentiation capacity may also be divergent.  
5.3 Results 
5.3.1 Extrahepatic biliary organoids do not demonstrate differentiation 
capacity towards a hepatocyte fate when using a previously published 
differentiation protocol 
 
In the course of our experiments detailed in the previous two chapters, we were able to 
assess EHBD organoids for several characteristics of stem/progenitor cells. EHBD 
organoids demonstrated long-term proliferative ability and expressed markers 
traditionally associated with adult stem/progenitor cells. However, stem/progenitor cells 
should have the ability to differentiate. To assess this, we first took advantage of the 
differentiation protocol previously published by Huch et al (2015) to assess the capacity 
of EHBD organoids to express hepatocyte-specific markers, potentially indicating a 
capacity to differentiate (Figure 5.1). IHBD_Huch organoids from three donors and 
IHBD_ex organoids from one donor were used as positive controls. 
Chapter 5: Assessing the differentiation capacity of human biliary organoids 
    
 
129 
 
Figure 5.1 Diagram depicting the differentiation protocol described by Huch et al 
(2015) used to assess the differentiation capacity of EHBD and IHBD organoids.  
 
As previously reported, IHBD_Huch organoids, under differentiation conditions, showed 
significantly reduced expression of the stem cell markers LGR5 and PROM1 by qPCR 
(Figure 5.2). KRT19 continued to be expressed while SOX9 expression decreased. 
Induction of a low-level expression of hepatocyte-specific markers such as TTR, 
CYP3A4, and ALB was also observed in IHBD_Huch organoids by qPCR. However, as 
previously reported, their expression was significantly lower than expression levels in 
primary human hepatocytes. IHBD_ex organoids demonstrated identical trends (Figure 
5.3) in expression indicating the conditions in which IHBD organoids were isolated and 
maintained did not impact their ability to express these hepatocyte-specific markers.  
Next, the effect of this differentiation protocol on EHBD organoids from all three tissue 
regions was assessed. When subjected to the differentiation protocol, EHBD organoids, 
similarly to IHBD organoids, had significantly decreased expression of LGR5, PROM1, 
and SOX9, with stable expression of KRT19 (Figure 5.2). However, EHBD organoids 
showed no induction of the hepatocyte-specific markers TTR, ALB, or CYP3A4. These 
results were confirmed at the protein level showing ALB expression exclusively in IHBD 
organoids (Figure 5.4 and Figure 5.5).  
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Figure 5.2 Extrahepatic bile duct organoids do not display differentiation capacity 
towards a hepatocyte fate when compared to intrahepatic bile duct organoids. 
qPCR analyses showing expression of biliary and hepatocyte markers in IHBD_Huch, CBD, GBD, or 
PancD organoids grown in expansion media (EM) or differentiation media (DM) (n=3-11 independent 
experiments, n=1-3 donors per tissue region). IHBD samples were generated in collaboration with Ms. 
Samantha Tilson. Primary hepatocytes (PH, n=3) were used as controls. Gene expression is normalized to 
the housekeeping gene UBC and data are plotted as mean and SEM. *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 
0.001, ****p ≤ 0.0001. 
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Figure 5.3 IHBD organoids grown in extrahepatic culture conditions up-regulate 
hepatocyte specific markers under differentiation conditions. 
qPCR analysis for stem cell, biliary, and liver genes in IHBD_ex organoids (n=2 independent experiments, 
n=1 donor line) in either expansion media (EM) or differentiation media (DM). IHBD samples were 
generated in collaboration with Ms. Samantha Tilson. Primary human hepatocytes (n=3) were used as 
positive controls. Gene expression is normalized to the housekeeping gene UBC and data is plotted as mean 
and SEM.  
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Figure 5.4 Representative immunofluorescence images for Albumin and KRT7 on 
IHBD_Huch and EHBD organoids cultured in differentiation conditions.  
IF images for Albumin and KRT7 of either IHBD_Huch or EHBD organoids cultured for 15 days in the 
differentiation conditions described by Huch et al (2015). 
 
 
Figure 5.5 Immunofluorescence for Albumin on IHBD_ex organoids cultured in 
differentiation conditions or expansion conditions. 
IF images of IHBD_ex organoids cultured for 15 days in the differentiation conditions described by Huch 
et al (2015) or alternatively in EHBD organoid expansion media. Experiment performed by Ms. Samantha 
Tilson. 
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5.3.2 Screening various culture conditions on extrahepatic bile duct 
organoids to assess differentiation capacity. 
 
Given the negative results for EHBD organoids, we decided to screen different culture 
conditions capable of inducing expression of hepatocyte-specific markers. A wide variety 
of growth factors and small molecule inhibitors aimed at perturbing signalling pathways 
important in hepatocyte development and liver regeneration were tested (Figure 5.6, 
Figure 5.7, and Table 5.1). None of these compounds appeared to significantly increase 
the expression levels of hepatocyte-specific markers in EHBD organoids. qPCR results 
for stem cell, biliary, and hepatocyte specific genes for single factors screened on at least 
two independent donor cell lines are shown in Figure 5.7.  
 
 
Figure 5.6 Diagram depicting the methods employed for screening experiments 
performed on EHBD organoids. 
EHBD organoids were split and cultured in EHBD expansion media for 2-3 days. The EHBD organoids 
were then switched into basal media only (ADF+) plus one or a combination of screening factors. The cells 
were treated for 4-6 days and then harvested for RNA.  
 
Additionally, even when combinations of these factors were tested together, a consistent 
increase in the hepatocyte markers ALB, CYP3A4, or TTR was not observed (Figure 
5.8). Interestingly, some of the combinations (i.e. CHIR/DAPT, CHIR/DAPT/SB, 
CHIR/DAPT/SB/BMP4, and CHIR/DBZ/SB/BMP4) did increase the level of Albumin 
and CYP3A4 significantly in the EHBD cells compared to the expansion media. Despite 
being statistically significant, this was overall a low-level induction and in the case of 
Albumin, induction was magnitudes lower than what was previously observed for IHBD 
organoids cultured in the differentiation conditions described by Huch et al (2015).  
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Table 5.1 List of screening compounds tested to assess differentiation capacity of 
EHBD organoids. 
 
In the case of CYP3A4, this induction was not seen alongside any significant increases 
in Albumin or TTR expression. It is possible that this up-regulation of CYP3A4 could be 
explained by cellular stress as the EHBD organoids did not survive well in these 
conditions and CYP3A4 expression has been reported to increase in cells undergoing 
oxidative stress.148  
Ultimately these results, and those described in the previous section, suggest that only 
biliary cells located within the liver have the capacity to express hepatocyte markers. This 
suggests a fundamental divergence in terms of the capacity of differentiation between 
different regions of the biliary tree.  
 
Compound Pathway Proliferation Impact Hepatocyte Markers 
Activin (50ng/mL) TGFβ Activation - n.s. 
SB 431542 (10μM ) TGFβ inhibition - n.s. 
A 83-01 (5μM) TGFβ inhibition + n.s. 
BMP4 (25ng/mL) BMP activation - n.s. 
BMP7 (25ng/mL) BMP activation - n.s. 
Noggin (200ng/mL) BMP inhibition + n.s. 
Forskolin (10μM) cAMP activation + n.s. 
CHIR (3μM) Wnt activation -  (alone)  
+ (with RSPO) 
n.s. 
Wnt3a Cond. Media (30%) Wnt activation +/o n.s. 
DKK (100ug/ml) Wnt inhibition - n.s. 
DAPT (10μM) Notch Inhibition - n.s. 
DBZ (10μM) Notch Inhibition - n.s. 
HGF (50-100ng/mL) HGF signaling + (caused 2D growth in 
matrigel) 
n.s. 
Oncostatin-M  (100ng/mL) OSM signaling + n.s. 
FGF10 (100ng/mL) FGF signaling + n.s. 
FGF7 (100ng/mL) FGF signaling + n.s. 
FGF2 (24ng/mL) FGF signaling - n.s. 
FGF19 (100ng/mL) FGF signaling o n.s. 
Dexamethasone (30 μM) Glucocorticoid 
signaling 
- n.s. 
Hepatozyme Media n/a - n.s. 
 
+ = increased, o = neither increased or decreased, - = decreased, n.s. = not significant 
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Figure 5.7 Images of organoids treated with a single screening factor for 4-6 days. 
Scale bar= 1000 um 
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Figure 5.8 Screening of single factors on EHBD organoids to assess for 
differentiation capacity 
qPCR analyses of extrahepatic bile duct organoids (n = 3-7 donor cell lines per condition, except for TTR 
where A8301 and FSK conditions only have n=2) treated with a single screening factor for 4-6 days. H9 
embryonic stem cells (H9, n=3) and primary hepatocytes (Heps, n=3) were used as controls. Gene 
expression is normalized to the housekeeping gene, UBC, and data is plotted as mean and SEM. EM = 
extrahepatic bile duct expansion media. BM = basal media alone. # = p ≤ 0.05, ## = p ≤ 0.01 for the 
screening condition compared to EM. 
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Figure 5.9 Screening combinations of factors on EHBD organoids to assess for 
differentiation capacity 
qPCR analysis of extrahepatic bile duct organoids (n = 3-7 donor cell lines per condition, except for the 
D/SB/B4 condition which only has n=2) treated with a combinations of screening factors for 4-6 days. H9 
embryonic stem cells (H9, n=3) and primary hepatocytes (Heps, n=3) were used as controls. Gene 
expression is normalized to the housekeeping gene, UBC, and data is plotted as mean and SEM. W= 
WNT3A conditioned media, D=DAPT, SB = SB 431542, B4= BMP4, C=CHIR 99021, DZ= DBZ, EM = 
extrahepatic bile duct expansion media. # = p ≤ 0.05, ## = p ≤ 0.01, ### = p ≤ 0.001 for the screening 
condition compared to EM. Experiments performed in collaboration with Ms. Simone Adams. 
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5.3.3 Transplantation of extrahepatic bile duct organoids into 
immunodeficient mice 
 
Given our lack of success with inducing differentiation of our EHBD organoids in vitro, 
we attempted to assess if EHBD organoids have the capacity for engraftment in the mouse 
liver and if in vivo conditions may prompt a differentiation capacity that we were unable 
to discern in vitro. For this, we collaborated with Mr. Kourosh Saeb-Parsy in the 
Department of Surgery at Cambridge University, who transplanted EHBD organoids 
derived from a single common bile duct tissue donor, under the liver capsule of 
immunodeficient, 6-8 week old NOD-SCID IL2-gamma (NSG) mice. All animal studies 
were performed in accordance with UK Home Office regulations. In brief, dense cultures 
of EHBD organoids were collected by incubating with cell recovery solution at 4°C for 
30 minutes. The organoids were then mechanically dissociated into medium sized clumps 
and washed twice with media. Organoid clumps were then re-suspended in 200-300uL of 
ice-cold Matrigel. Organoids and matrigel suspensions were then loaded into a pre-chilled 
syringe and kept on ice to prevent Matrigel polymerization.  
Mice were anaesthetized with isoflurane, the abdominal cavity opened by a transverse 
laparotomy, and the liver exposed. The upper liver lobe was lifted using a sterile cotton 
swab and 30uL of matrigel was injected into the subcapsular space of the lower lobe. 
Approximately 2x106 cells were injected per animal. These injections were performed on 
eight mice. Four mice were sacrificed at 2 weeks and the remaining four mice were 
sacrificed at three months. The livers were frozen in OCT and serially cryosectioned. 
Unfortunately, we were unable to find any human cells engrafted in the livers using a 
human specific nuclear antibody, Ku80 (Figure 5.9). We did observe in one of the livers, 
an area that appeared to be the site of injection, but no human cells remained (Figure 
5.10).  
These results suggest that EHBD organoids may not survive in vivo and do not have the 
capability to engraft in the mouse liver. However, it is also possible that we were unable 
to locate the cells, especially if only a small population remained engrafted. These 
experiments should be repeated before drawing definite conclusions.  
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Figure 5.9 Immunofluorescence staining for a human-specific nuclear antibody, 
KU80, in human and mouse liver. 
IF staining of human and mouse liver demonstrates that KU80 is specific for human cells and does not label 
mouse cells. Scale bar =100 um. 
 
 
Figure 5.10 Haematoxylin and Eosin histology and Ku80 immunofluorescence 
staining of mouse liver injected with EHBD organoids under the liver capsule.  
Images from one mouse liver that was injected with EHBD organoids, under the liver capsule, showing an 
area where it is likely the human cells were injected but did not remain engrafted. Top images show 
Haematoxylin and Eosin (H&E) staining of an acellular area and the bottom image shows IF analysis for 
KU80 indicating the absence of human cells engrafted under the mouse liver capsule.  
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5.4 Discussion 
 
In this chapter, the differentiation capacity of EHBD and IHBD organoids was assessed. 
We took advantage of a previously published protocol that has been shown to increase 
the expression of hepatocyte specific markers in IHBD organoids. Using this protocol, it 
was discovered that only IHBD organoids up-regulate the expression of hepatocyte 
specific markers such as ALB, TTR, and CYP3A4, while EHBD organoids do not. 
Further, a wide-variety of compounds were tested on EHBD organoids to further evaluate 
their capacity for differentiation, but none of these results suggested a differentiation 
capacity towards a hepatocyte fate for EHBD organoids. Lastly, we attempted to 
transplant our EHBD organoids under the liver capsule of immunodeficient mice, but 
unfortunately, we were unable to locate any engrafted cells following transplantation. 
We feel these results are significant in several ways. The first is that it continues to support 
our previous observations that IHBD and EHBD organoids are unique. Not only do these 
cells require different culture conditions and differ on the transcriptional level, but they 
also appear to have key differences in their capacity for differentiation. However, these 
results do raise several questions about the nature of the extrahepatic organoids.  
If the EHBD organoids are not capable of differentiation towards a hepatocyte fate, can 
they be a stem/progenitor population? In all of our experiments, we only observed the 
EHBD organoids as having a phenotype consistent with that of biliary cells. However, 
our RNA-sequencing results demonstrated that despite expressing key biliary lineage 
markers such as KRT19/KRT7, these organoids down-regulate functional markers of 
biliary epithelial cells such as GGT1, HNF1B, MUC1.  
Ultimately, we see two possible explanations for the origin of our EHBD organoids. First, 
it could be that, within the extrahepatic biliary tree, there is a rare population of cells 
which express adult stem cell markers and are selected for and expanded in our in vitro 
culture conditions. Alternatively, and more likely given the lack of adult stem cell marker 
expression in EHBD tissues, it could be that our in vitro culture conditions cause 
mature/differentiated extrahepatic biliary cells to undergo a type of “de-differentiation”. 
These cells down-regulate the expression of mature biliary markers and upregulate the 
expression of adSC markers, possibly in response to in vitro provided factors such as 
RSPO and WNT. In the intrahepatic compartment, it has been shown that WNT signalling 
is induced in response to tissue injury, which then activates intrahepatic biliary cells to 
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express LGR5 and proliferate.98 It is possible that this mechanism in the intrahepatic 
biliary system, may also be at play in the extrahepatic system. Perhaps our in vitro culture 
system is mimicking a state of tissue injury. Within the intrahepatic compartment, which 
has a closer relationship both developmentally and spatially to the liver, biliary cells are 
capable of bipotential differentiation. This perhaps represents an embryologic memory, 
as intrahepatic cholangiocytes and hepatocytes share a common developmental 
progenitor, unlike the extrahepatic cholangiocytes. However, in the extrahepatic 
compartment, there is only one mature cell type. Despite sharing many characteristics 
with IHBD cells, EHBD cells, when exposed to WNT signalling, may also adopt an adSC 
and proliferative phenotype but cannot differentiate beyond a cholangiocyte fate. Perhaps 
then, these extrahepatic organoids may represent a biliary progenitor population which is 
only capable of biliary differentiation. 
Lastly, it must be addressed that these results are contrary to several reports in the 
literature stating that EHBD derived cell-lines are capable of differentiation. In particular, 
work by Lola Reid and colleagues has suggested that EHBD derived cell lines from both 
CBD and GBD, are capable of differentiation towards a hepatocyte fate.111,113 One 
explanation for the differences in our results is that we may have isolated and/or expanded 
different populations of cells from the biliary tree.  
Interestingly, the bile duct cell lines isolated by Reid and colleagues are claimed to 
originate from the peribiliary glands (PBGs) and not the main epithelium. Their cells were 
isolated from bile ducts and gallbladders using enzymatic dissociation and EPCAM as a 
sorting marker. However, EPCAM is not a PBG specific marker and would isolate most, 
if not all, of the epithelial cells from the biliary epithelium and PBGs. Additionally, the 
GBD lacks PBGs.  
It is possible, given our use of a mechanical dissociation technique, that we did not access 
this same population of cells, particularly in our CBD cell lines. However, given the larger 
overall percentage of epithelial cells compared to PBG cells, the ease at which epithelial 
cells were dissociated by scraping the mucosal surface with a scalpel, and the fact that the 
PBG cells are deeply embedded in underlying stromal tissue, it is likely that the cells 
isolated by Reid and colleagues also contains a large population of epithelial cells. 
Further, this would not explain the differences in results we observed in our GBD cell 
lines, as there are no PBGs in the GBD.  
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Perhaps then, the differentiation capability observed in their work may represent a 
response similar to what we observed in our organoids, where a very low-level of 
ALB/CYP3A4 expression was detected in stressed/dying cells. In fact, the fold change in 
ALB in their bile duct cell lines under differentiation conditions was only 2-fold higher 
than cells in their expansion conditions and was unfortunately not compared to primary 
hepatocytes or even IHBD cells. In contrast, we observed a 60-fold increase in Albumin 
expression in IHBD organoids. Although we did not directly test the differentiation media 
used by Reid and colleagues on our own EHBD organoids, we did screen all of the main 
individual factors present in their differentiation medium (i.e. Oncostatin-M, EGF, HGF, 
and Dexamethasone) and did not find any of these factors capable of inducing expression 
of hepatocyte markers in our cells. These two culture systems, and the cells they isolate, 
should be compared further in future studies in order to reconcile these discrepancies in 
results. However, what we are able to conclude, is that our results strongly suggest that, 
when compared to IHBD cells cultured as organoids, EHBD cells cultured as organoids 
do not have a capacity for differentiation towards a hepatocyte fate.  
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6 FUTURE DIRECTIONS AND 
CONCLUSION 
6.1 Future directions 
 
The discussions in Chapters 3, 4, and 5 outlined several future areas of research to further 
validate and expand upon the findings presented in the individual chapters of this 
dissertation. The limitations to the work were also discussed. In this chapter, we focus 
more broadly on the collective work of this dissertation and the future directions planned.  
6.1.1 Extrahepatic biliary organoids 
 
6.1.1.1 Further exploring the differentiation capacity of EHBD organoids 
 
In this dissertation, we were able to comprehensively characterize our EHBD organoids 
and found that, when cultured in media conditions promoting canonical WNT signalling, 
biliary epithelial cells from the CBD, GBD, and PancD adopt a stem/progenitor-like 
phenotype with expression of adSC markers and long-term proliferative ability. However, 
it was also discovered that EHBD organoids do not appear to have a capacity for 
differentiation towards a hepatocyte-fate, whereas IHBD organoids are capable of 
upregulating expression of hepatocyte specific markers. These results are surprising, in 
some regards, given the in vitro characterizations and RNA-Seq data demonstrating the 
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EHBD organoids have some characteristics of a stem/progenitor phenotype. Therefore, it 
still remains unclear whether or not these EHBD organoids are truly a stem/progenitor 
population and if they have any capacity for differentiation. Here, we only focused on 
hepatocyte differentiation capacity and future work is still needed to assess for a 
differentiation capacity towards other cell lineages, especially towards either a mature 
cholangiocyte and/or pancreatic endocrine fate. To do this, we plan to take advantage of 
several recently published reports that have been described for differentiating 
intrapancreatic and intrahepatic biliary organoids towards a pancreatic endocrine and/or 
mature cholangiocyte fate.95,149 We plan to screen these protocols on the EHBD organoids 
to assess for any differentiation capacity towards these cell fates using qPCR for lineage 
specific markers and functional profiling of the cells if we see any induction of these 
markers.  
We also would like to explore the differences observed between the two culture systems 
developed in our lab to derive extrahepatic biliary organoids. As previously mentioned, 
biliary organoids were first derived in culture conditions containing DKK, a canonical 
WNT pathway inhibitor. It was found that the organoids cultured with DKK, maintained 
expression of functional biliary markers. However, in the system described in this 
dissertation, in which CHIR 99021 was used to promote canonical WNT signalling, the 
organoids instead expressed adSC markers and down-regulated functional biliary 
markers. We plan to further characterize the mechanistic role that WNT signalling may 
play in maintaining these two phenotypes and how these two culture systems differ 
through gene expression analyses. 
Lastly, we plan to repeat the transplantation experiments already attempted in order to 
confirm the engraftment capacity of EHBD organoids and to confirm that our in vitro 
observations on the differentiation capacity remains true in vivo. To do so, we first plan 
to repeat the liver capsule injections of the EHBD organoids. However, to overcome the 
limitation previously encountered of finding engrafted cells, organoids will be 
fluorescently labelled before transplantation. Further, it would also be interesting to 
transplant organoids derived from both the IHBD and EHBDs into a mouse model of 
hepatocyte and/or cholangiocyte senescence.  
Our collaborators recently reported that murine intrahepatic bile duct derived cells are 
capable of repopulating the liver and differentiating into hepatocytes in this model.38 They 
are currently working to humanize this mouse model and it will serve as an invaluable in 
vivo tool.  
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6.1.2 Regional diversity in the biliary tree 
 
6.1.2.1 Single cell RNA sequencing of intrahepatic and extrahepatic biliary tissues 
 
Our RNA-sequencing experiments yielded a number of impactful results by 
characterizing the transcriptional profile of biliary tissues and in vitro derived organoids.  
However, one of the key limitations to our RNA-sequencing experiments was the 
contamination by non-biliary cell types in our primary tissue samples. This was 
particularly evident in PancD and IHBD tissue samples. Our lab has recently gained the 
ability to perform single cell RNA-sequencing and has been developing improved 
protocols for enzymatic dissociation of human tissues, including bile duct and liver tissue, 
that improves cell viability. This new expertise will allow us to circumvent some of the 
limitations encountered in our bulk RNA-sequencing data. We plan to perform single cell 
RNA-sequencing on EHBD and IHBD tissue samples in order to continue our efforts to 
profile and understand the regional diversity that exists in these tissues. In particular, by 
using single cell RNA-sequencing, we will not only be able to profile the epithelial biliary 
cells but can also profile other cell types in these tissues including the immune cells. This 
may ultimately help provide insight into the regionalization of autoimmune 
cholangiopathies within the biliary tree.  
6.1.2 Regeneration in the extrahepatic biliary tree 
 
Lastly, the results presented in this dissertation suggest that within the human extrahepatic 
biliary tree, cells are capable of adopting a stem/progenitor phenotype when cultured as 
in vitro organoids. This capability may be driven by canonical WNT signalling. However, 
these findings also raise questions on what functions these cells may play in vivo and 
whether or not these cells actually represent a regenerative population that plays a role in 
extrahepatic biliary tissue repair or homeostasis. Overall, it still is unknown what 
mechanisms drive regeneration in the extrahepatic biliary tree and this represents a large 
gap in knowledge. Whether or not a resident stem/progenitor cell population exists in 
these tissues in vivo, where the cells are located, or if there are cells that adopt a progenitor 
role during states of tissue injury is unknown. Therefore, we feel that this is an essential 
area in which future research is required and we propose several key experiments that 
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could be considered in the future to address this, some of which our lab has already begun 
working on.  
 
6.1.2.1 Brief background on what is currently known on extrahepatic biliary 
regeneration 
 
Many groups have suggested the existence of a stem/progenitor cell within the 
extrahepatic biliary tree and the data presented in this dissertation further supports the 
idea that human extrahepatic cholangiocytes are capable of adopting phenotypes of 
stem/progenitor cells in vitro.53,54,110–117 In the large extrahepatic bile ducts and pancreatic 
ducts, it has been suggested that progenitor cells may reside in PBGs. PBGs are small 
epithelial/glandular structures that underlie the biliary epithelium. It was recently 
demonstrated that PBGs are directly connected to the biliary epithelium through small 
channels and that these cells express markers such as BrdU and KI67 and proliferate 
during bile duct injury.53,54 However, Porte et al. (2012) also showed that, in human 
biliary disease, there is heterogeneity in which cellular compartment expresses 
proliferation markers during disease.54 For example, in ischemic-type injury patients, 
where large portions of the epithelium are destroyed, the PBGs became the predominant 
source of proliferative cells.54 Whereas in cholangitis patients, the epithelium appeared to 
be the strongest source of KI67 positive proliferating cells.54 Further, in two mouse 
models of biliary injury: Bile Duct Ligation and RRV-virus infection, both the epithelium 
and peribiliary glands demonstrated BrdU uptake after injury.53 These findings suggest 
that the regenerative compartment of the extrahepatic biliary system may not just be 
located in the PBGs. No study has definitively shown that PBG cells are capable of 
regenerating the epithelium of extrahepatic bile ducts or that progeny of PBG cells 
contribute to the bile duct epithelium. Furthermore, very little is known about the 
distribution of adSC markers like LGR5 and PROM1 in the PBG cells compared to the 
epithelium. 
Also important to note, is that the GBD, another key organ in the extrahepatic biliary 
system, does not contain PBGs and instead consists of a highly folded mucosa. Potential 
stem/progenitor cells have been identified and cultured from the GBD epithelium by two 
different groups and also in this dissertation.113,115–117 However, where these cells are 
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located in vivo and whether or not they actively participate in repair of the GBD 
epithelium is still not well known, as is true of the extrahepatic bile ducts. 
Understanding what cellular compartment regenerates the extrahepatic biliary system is 
important as key human extrahepatic diseases such as PSC and Biliary Atresia may 
involve failure of regenerative mechanisms. Further, it has been shown that in human 
liver transplants, over 80-90% of all donor grafts show significant biliary epithelial cell 
loss before ever being transplanted and upwards of 40% of all patients receiving a liver 
transplant will go on to develop biliary complications.129 These complications include 
non-anastomotic biliary strictures (NAS) in the large extrahepatic ducts, which are 
thought to result from a failure to regenerate the extrahepatic biliary epithelium after 
ischemic damage.129,150 Interestingly, it was shown that NAS correlate strongly with the 
degree of histological damage to PBGs in biopsies taken of bile duct grafts prior to 
transplantation.150 
With these ideas in mind, it is critical that future research works to identify the cellular 
compartment and also the cell population(s) responsible for regenerating the extrahepatic 
bile duct and gallbladder in states of tissue injury. Furthermore, we feel the results 
described in this dissertation provide a crucial foundation for addressing these questions.  
 
6.1.2.2 Developing a reversible, acute injury model of the extrahepatic bile duct and 
gallbladder 
 
One aspect that currently hinders further research into extrahepatic biliary regeneration is 
the lack of a reversible, acute extrahepatic injury model in mice. The most commonly 
used biliary injury model is bile duct ligation, but this procedure is irreversible and cannot 
be used to study the repair process following injury. Therefore, our lab has begun working 
to characterize a chemical bile duct injury model using 4,4’-methylene dianiline (DAPM) 
in mice. DAPM is a bile duct toxicant most well studied in Rats and the intrahepatic bile 
ducts, where it selectively injures biliary epithelial cells.151 We have already begun work 
to validate its ability to cause injury in the extrahepatic biliary tree and hope this can serve 
as a model system to study biliary regeneration in the future.  
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6.1.2.3 Lineage tracing to identify stem/progenitor cells in the extrahepatic bile duct 
and gallbladder 
 
Lineage tracing is a technique used to identify and track all of the progeny of a single 
cell.152 It has been used to identify adSCs in various adult organs including intestine, 
stomach, and liver. Using the knowledge we gained from our human EHBD organoids, 
in particular, that the expression of PROM1 and LGR5 is upregulated in these organoids, 
we plan to attempt lineage tracing experiments in the extrahepatic biliary tree using these 
markers. Our lab currently has access to both LGR5 and PROM1 inducible reporter 
mouse lines and we plan to use these models to assess if these markers are expressed in 
the uninjured EHBDs of mice and also in DAPM injured EHBDs of mice. Ultimately, we 
feel that these experiments will allow us to build upon the findings presented in this 
dissertation and continue to further address these important open questions in the field. 
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6.2 Conclusions 
 
According to the Cambridge guidelines for the award of PhD Degree, the candidate must 
demonstrate that his or her dissertation “represents a significant contribution to learning, 
for example through the discovery of new knowledge, the connection of previously 
unrelated facts, the development of new theory, or the revision of older views.” To this 
end, this dissertation has accomplished these criteria through the following: 
• Developing and extensively characterizing an in vitro organoid culture system 
capable of supporting cells from the human CBD, GBD, PancD, and IHBDs that 
express markers of adSCs. 
• Demonstrating that organoids derived from human EHBD and IHBDs are unique 
and require different conditions for long-term proliferation.  
• Describing for the first time the transcriptional profile of three human extrahepatic 
biliary tissue regions and uncovering that these tissues have key differences in 
expression and potential differences in biologic functions. 
• Uncovering novel regional specific markers of human biliary tissues including 
SOX17, CDX2, and HOXB2. 
• Revealing that EHBD organoids are transcriptionally unique from their tissue of 
origin, losing expression of mature biliary markers and upregulating expression 
of adSC markers in vitro. 
• Presenting preliminary attempts to compare the transcriptional profile of IHBD 
and EHBD primary tissues. 
• Discovering key differences in the differentiation capacity of EHBD and IHBD 
derived organoids towards a hepatocyte-fate. 
 
Overall, this data has significantly furthered both the knowledge and tools available in 
the field. It has provided important insight to the understanding of both basic biliary 
physiology and regional diversity and also the field of biliary stem/progenitor cell 
organoids. These results may help to identify new targets for therapeutic development for 
cholangiopathies and regenerative medicine and has laid the groundwork for many future 
projects in the years to come. 
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8 APPENDICES 
Appendix I: List of Annex Files 
 
Annex File 1 EHBD Tissue DGE.xlsx 
List of genes differentially expressed between the three EHBD tissue regions. 
 
Annex File 2 EHBD Tissue Specific Genes.xlsx 
List of genes upregulated in one EHBD tissue region compared to both of the other two 
tissues. 256 genes were CBD specific, 419 genes were GBD specific, 967 genes were 
PancD specific. 
 
Annex File 3 EHBD Tissue Gene Ontology Analyses.xlsx 
Gene ontology analyses on the EHBD tissue specific gene lists and also genes 
differentially expressed between pairs of EHBD tissues. 
 
Annex File 4 Genes Upregulated in GBD and CBD vs PancD Tissue.xlsx 
List of 856 genes that were upregulated in both GBD and CBD tissues compared to PancD 
tissues. 
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Annex File 5 Genes Upregulated in GBD and CBD vs PancD Tissue Gene Ontology 
Analyses.xlsx 
Gene ontology analyses on the 856 genes that were upregulated in both GBD and CBD 
tissues compared to PancD tissues.  
Gene ontology analyses on 108 of these 856 genes that additionally were upregulated in 
GBD tissue compared to CBD tissue. 
 
Annex File 6 EHBD Tissue vs Organoids DGE.xlsx 
List of genes differentially expressed between EHBD tissues and organoids. 
 
Annex File 7 EHBD Tissue vs Organoids Gene Ontology 
Gene ontology analyses on the top 200 differentially expressed genes between each of 
the three EHBD tissues compared to their corresponding in vitro organoids. 
 
Annex File 8 EHBD Organoids vs Organoids DGE.xlsx 
List of genes differentially expressed between the three EHBD organoid types. 
 
Annex File 9 Genes Upregulated in both EHBD Organoids and Tissues.xlsx 
List of genes that were upregulated in CBD, GBD, or PancD tissues which were also 
upregulated in the corresponding in vitro Organoids when compared to the other two 
regions. 
 
Annex File 10 Comparing EHBD Organoids to ISC Signature.xlsx 
List of 493 genes making up the ISC signature.  
List of genes that were upregulated in CBD, GBD, or PancD organoids compared to their 
tissue of origin which were represented in the list of 493 ISC signature genes.  
Gene ontology analyses of 135 ISC signature genes which were upregulated in at least 
two out of the three EHBD organoid types compared to their tissue of origin.  
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Annex File 11 EHBD vs IHBD Organoids DGE.xlsx 
List of genes differentially expressed between IHBD_ex, IHBD_Huch, and EHBD 
organoids.  
List of genes upregulated in IHBD_ex organoids compared to both IHBD_Huch and 
EHBD organoids.  
List of genes upregulated in both IHBD_Huch and EHBD compared to IHBD_ex 
organoids (a.k.a genes downregulated in IHBD_ex organoids).  
 
Annex File 12 IHBD_Huch vs EHBD Organoids Gene Ontology Analyses.xlsx 
Gene ontology analyses of genes differentially expressed between IHBD_Huch organoids 
and EHBD organoids 
 
Annex File 13 IHBD vs EHBD Tissues DGE.xlsx 
List of genes differentially expressed between IHBD tissue and CBD, GBD, or PancD 
tissues. 
List of 2,595 genes that were upregulated in IHBD tissue when compared to CBD, GBD, 
and PancD tissues. 
Gene ontology analyses on the 2,595 genes that were upregulated in IHBD tissue 
compared to CBD, GBD, and PancD tissues. 
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Inthisscript, IperformRNA-seqDGEanalysisonprimarytissueand in vitro culturedorganoidcell lines
from human common bile duct (CBD), gallbladder (GBD), pancreatic duct (PBODD), and intrahepatic bile
ducts(IHBD).Allbiologicalgroupshaveat least3biologicalreplicatesperconditions.
LoadingLibraries
First,I loadtherequiredRpackagesandsetthedesiredworkingdirectory.
library("DESeq2")
library("tximport")
library("readr")
library("tximportData")
library("org.Hs.eg.db")
library("AnnotationDbi")
library("pheatmap")
library("RColorBrewer")
library("biomaRt")
library("pheatmap")
library("ggplot2")
dir <- "/users/rimlandca/Desktop/R files"
1
setwd(dir)
library(knitr)
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I. Preliminary data exploration
A. Loading Data (all samples)
Next I load files containing sample group information (samples) and previously generated SALMON transcipt
abundance files for each sample (files).
samples_ALL <- read.table(file.path(dir, "samples_v3_noliver.txt"), header = TRUE)
files_ALL <- file.path(dir, "salmon", paste("salmon_", samples_ALL$run, ".txt",
sep = ""))
names(files_ALL) <- samples_ALL$run
rownames(samples_ALL) <- samples_ALL$run
samples_ALL$group <- samples_ALL$group
samples_ALL$dge <- samples_ALL$dge
samples_ALL$type <- samples_ALL$type
samples_ALL$techrep <- samples_ALL$techrep
samples_ALL$libbatch <- samples_ALL$libbatch
samples_ALL$seqyear <- samples_ALL$seqyear
samples_ALL$name <- samples_ALL$name
samples_ALL$sampletype <- samples_ALL$sampletype
B. Creating a DeSeq Data Set (all samples)
Next, I create a DeSeq data set using the tximport function.
load("/Users/rimlandca/Desktop/R files/tx2gene_GRCh38.80.RData")
txi_ALL <- tximport(files_ALL, type = "salmon", tx2gene = tx2gene)
ddsTxi_ALL <- DESeqDataSetFromTximport(txi_ALL, colData = samples_ALL, design = ~type)
C. Assessing for batch e ects
Before continuing with further analyses, we must assess for any batch e ects present in the data. Due to
sample availability timing, we had to prepare libraries and sequence the samples in two batchs (Library
Preparation 1 vs 2). Additionally some of the samples originally sequenced in the first batch had to be
re-sequenced due to low read depth therefore we also have the potential for a batch e ect by year of sequencing
(Sequencing Year A vs B). To help account for variability between batches and serve as an internal control, 4
samples from the first library batch were re-prepped and sequenced with the second batch.
# Filter out genes with 0 counts across all samples
ddsTxi_batch <- ddsTxi_ALL[rowSums(counts(ddsTxi_ALL)) > 0, ]
nrow(ddsTxi_batch)
## [1] 54622
# Subset for just protein coding genes
collinfocoding <- read_csv("collinfocoding_nodups.csv", col_names = TRUE)
ddsTxi_batch_proteincoding <- subset(ddsTxi_batch, rownames(ddsTxi_batch) %in%
collinfocoding$ID)
nrow(ddsTxi_batch_proteincoding)

## [1] 19376
# normalize counts with varaince stabilizing transformation
vsd_ddstxi_batch <- vst(ddsTxi_batch_proteincoding)
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Plot PCA plots
All Samples by Type and Batch
pcadata_batch_All_type <- plotPCA(vsd_ddstxi_batch, intgroup = c("type"), ntop = 19376,
returnData = TRUE)
percentVar_batch_All_type <- round(100 * attr(pcadata_batch_All_type, "percentVar"))
ggplot(pcadata_batch_All_type, aes(PC1, PC2, color = type)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_batch_All_type[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_batch_All_type[2], "% variance"))

−50
0
50
100
150
−50 500
PC1: 33% variance
PC
2:
 2
8%
 va
ria
nc
e
type
CBD Organoids
CBD Tissue
GBD Organoids
GBD Tissue
IHBD_ex Organoids
IHBD_Huch Organoids
IHBD Tissue
PancD Organoids
PancD Tissue
Figure1: PCAofAllSamplesbyType
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Figure2: PCAofAllSamplesbyBatch
Batch E ect Control Samples by Type and Batch
vsd_ddstxi_batchctrls <- vsd_ddstxi_batch[, vsd_ddstxi_batch$name == "GBD11_c" |
vsd_ddstxi_batch$name == "GBD8_t" | vsd_ddstxi_batch$name == "PD5_c" | vsd_ddstxi_batch$name ==
"PD5_t"]
pcadata_batchctrls_type <- plotPCA(vsd_ddstxi_batchctrls, intgroup = c("type"),
ntop = 19376, returnData = TRUE)
percentVar_batchctrls_type <- round(100 * attr(pcadata_batchctrls_type, "percentVar"))
ggplot(pcadata_batchctrls_type, aes(PC1, PC2, color = type)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_batchctrls_type[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_batchctrls_type[2], "% variance"))
pcadata_batchctrls_batch <- plotPCA(vsd_ddstxi_batchctrls, intgroup = c("libbatch",
"seqyear"), ntop = 19376, returnData = TRUE)
percentVar_batchctrls_batch <- round(100 * attr(pcadata_batchctrls_batch, "percentVar"))
ggplot(pcadata_batchctrls_batch, aes(PC1, PC2, color = group)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_batchctrls_batch[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_batchctrls_batch[2], "% variance"))

pcadata_batch_All_batch <- plotPCA(vsd_ddstxi_batch, intgroup = c("libbatch",
"seqyear"), ntop = 19376, returnData = TRUE)
percentVar_batch_All_batch <- round(100 * attr(pcadata_batch_All_batch, "percentVar"))
ggplot(pcadata_batch_All_batch, aes(PC1, PC2, color = group)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_batch_All_batch[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_batch_All_batch[2], "% variance"))
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Figure 3: PCA of Batch Controls by Type
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Figure 4: PCA of Batch Controls by Batch
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# Collapse replicates
ddsColl_ALL <- collapseReplicates(ddsTxi_ALL, samples_ALL$name)
## Pre-Filter
nrow(ddsColl_ALL)
## [1] 61692
ddsColl_ALL <- ddsColl_ALL[rowSums(counts(ddsColl_ALL)) > 0, ]
nrow(ddsColl_ALL)
## [1] 54622
# Subset for protein coding genes (protein coding gene data from biomart
# website)
ddsCollcoding_ALL <- subset(ddsColl_ALL, rownames(ddsColl_ALL) %in% collinfocoding$ID)
nrow(ddsCollcoding_ALL)
## [1] 19376
E. Principalcomponentanalyses
Withtechnicalreplicatescollapsedandpre-filteringperformed,wenowperformpreliminaryPCAanalyseson
thedataset inordertoassesssamplerelationshipsaswellas identifyanyoutliers.
WedofindthatoneIHBD_Fxsampleappearstobeanoutlier.Thissamplewassequencedatpassage3andwas
stillproliferativewhiletheotherswereatpassage5,giventhisknowndi erenceweexcludethissamplefrom
furtheranalysis.
WealsonotethatIHBDTissueclustersvery far fromEHBDTissues.AstheIHBDtissuesampleswere from
frozen,enzymaticallydissociatedlivertissue,andpossiblycontainscontaminatingcelltypesotherthanbiliary
cells,wewillexcludethesesamples fromanalyses fornowand focusonEHBDtissuesandtheEHBD/IHBD
organoidsonly insectionII.ExploratoryanalyseswillbeperformedontheIHBDtissue insectionIII.
PCAofAllSampleswithReplicatesCollapsed
vsd_coll_ALL <- vst(ddsCollcoding_ALL)
plotPCA(vsd_coll_ALL, "type", ntop = 19376)
PCA of IHBD Organoids
vsd_IHBDorganoids <- vsd_coll_ALL[, vsd_coll_ALL$group == "cells" & vsd_coll_ALL$EHBD_IHBD ==
"IHBD"]
pcadata_IHBDorganoids <- plotPCA(vsd_IHBDorganoids, intgroup = c("type"), ntop = 19376,
returnData = TRUE)
percentVar_IHBD <- round(100 * attr(pcadata_IHBDorganoids, "percentVar"))
ggplot(pcadata_IHBDorganoids, aes(PC1, PC2, color = type)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_IHBD[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_IHBD[2], "% variance"))

D. CollapsingTechnicalReplicates,pre-filter,andsubset for justproteincoding
genes
Aswecouldnotobserveanysignificantbatche ects inthedatabysequencingyearor libarypreparation
date,we collapse these technical replicates into single samples. We alsofilter for only geneswhichhave
greaterthan0counts forallsamplesandfilter for justproteincodinggenes.
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II. Di erential expression analyses
A. Load data for only the subset of samples
(excluding IHBD tissue samples and the outlier IHBD_ex sample)
# Loading Data without IHBD tissue samples or IHBD_ex outlier
samples <- read.table(file.path(dir, "samples_paper.txt"), header = TRUE)
files <- file.path(dir, "salmonpaper", paste("salmon_", samples$run, ".txt",
sep = ""))
names(files) <- samples$run
rownames(samples) <- samples$run
samples$group <- samples$group
samples$dge <- samples$dge
samples$type <- samples$type
samples$techrep <- samples$techrep
samples$libbatch <- samples$libbatch
samples$seqyear <- samples$seqyear
samples$name <- samples$name
samples$sampletype <- samples$sampletype
# Create a DeSeq Matrix
txi <- tximport(files, type = "salmon", tx2gene = tx2gene)
ddsTxi <- DESeqDataSetFromTximport(txi, colData = samples, design = ~type)
# Collapsing Technical Replicates
ddsColl <- collapseReplicates(ddsTxi, samples$name)
# Pre-Filter
nrow(ddsColl)
## [1] 61692
ddsColl <- ddsColl[rowSums(counts(ddsColl)) > 0, ]
nrow(ddsColl)
## [1] 53803
# Subset protein coding genes
ddsCollcoding <- subset(ddsColl, rownames(ddsColl) %in% collinfocoding$ID)
nrow(ddsCollcoding)
## [1] 19327

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vsd_coll <- vst(ddsCollcoding)
# Just EHBD Tissues
vsd_coll_Tissue <- vsd_coll[, vsd_coll$group != "cells"]
pcadata_tissues <- plotPCA(vsd_coll_Tissue, intgroup = c("type"), ntop = 5000,
returnData = TRUE)
percentVar_tissues <- round(100 * attr(pcadata_tissues, "percentVar"))
ggplot(pcadata_tissues, aes(PC1, PC2, color = type)) + geom_point(size = 6,
shape = 17) + xlab(paste0("PC1: ", percentVar_tissues[1], "% variance")) +
ylab(paste0("PC2: ", percentVar_tissues[2], "% variance"))
B. MakePCAPlots
PCAPlotofEHBDTissueSamples
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GBD
PancD

PCA Plot of EHBD Tissue and Organoids
vsd_coll_EHBD <- vsd_coll[, vsd_coll$EHBD_IHBD != "IHBD"]
pcadata <- plotPCA(vsd_coll_EHBD, intgroup = c("group", "origin"), ntop = 5000,
returnData = TRUE)
percentVar <- round(100 * attr(pcadata, "percentVar"))
ggplot(pcadata, aes(PC1, PC2, color = origin, shape = group.1)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar[1], "% variance")) + ylab(paste0("PC2: ",
percentVar[2], "% variance"))
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C. Export VST counts for making heatmaps
mat_vsdColl <- assay(vsd_coll)
mat_vsdColl.df <- as.data.frame(mat_vsdColl)
mat_vsdColl.df$ID <- rownames(mat_vsdColl.df)
mat_vsdColl.df <- merge(collinfocoding, mat_vsdColl.df, by = c("ID"), all.y = TRUE)
write_delim(mat_vsdColl.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/vsd_normalized_allsamples.csv")

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PCA Plot of EHBD and IHBD Organoids
$group != "tissue"]vsd_coll_cells <- vsd_coll[, vsd_coll
pcadata_cells <- plotPCA(vsd_coll_cells, intgroup = c("type"), ntop = 5000,
attr(pcadata_cells, "percentVar"))
returnData = TRUE)
percentVar_cells <- round(100 *
ggplot(pcadata_cells, aes(PC1, PC2, color = type)) + geom_point(size = 6) +
1], "% variance")) + ylab(paste0("PC2: ",xlab(paste0("PC1: ", percentVar_cells[
percentVar_cells[2], "% variance"))
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Figure 11: Correlation Matrix EHBD Tissues
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D. Pearson Correlation Matrices for Organoid Types and Tissue Types
Pearson Correlation Matrix EHBD Tissues
corrs_EHBDtissues <- cor(assay(vsd_coll_Tissue), method = "pearson")
corr.dists_EHBDtissues <- as.dist(1 - corrs_EHBDtissues)
library("pheatmap")
colors <- colorRampPalette(c("red", "white", "blue"))(99)
pheatmap(corrs_EHBDtissues, breaks = seq(from = -1, to = 1, length = 100), clustering_distance_rows =
corr.dists_EHBDtissues, clustering_distance_cols = corr.dists_EHBDtissues, col = colors)
library(RColorBrewer)
diag(corrs_EHBDtissues) <- NA
colors <- colorRampPalette(brewer.pal(9, "Blues"))(99)
pheatmap(corrs_EHBDtissues, clustering_distance_rows = corr.dists_EHBDtissues,
clustering_distance_cols = corr.dists_EHBDtissues, col = colors)
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Figure 13: Correlation Matrix EHBD vs IHBD Organoids
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E. Perform di erential gene expression analyses
# Run DeSeq2
dds_DGE <- DESeq(ddsCollcoding, betaPrior = TRUE)
# Get base mean expression levels for each individual group
baseMeanPerLvl <- sapply(levels(dds_DGE$type), function(lvl) rowMeans(counts(dds_DGE,
normalized = TRUE)[, dds_DGE$type == lvl]))
baseMeanPerLvl.df <- as.data.frame(baseMeanPerLvl)
baseMeanPerLvl.df$ID <- row.names(baseMeanPerLvl.df)
Pearson correlation matrix EHBD and IHBD Organoids
corrs_Organoids <- cor(assay(vsd_coll_cells), method = "pearson")
corr.dists_Organoids <- as.dist(1 - corrs_Organoids)
library("pheatmap")
colors <- colorRampPalette(c("red", "white", "blue"))(99)
pheatmap(corrs_Organoids, breaks = seq(from = -1, to = 1, length = 100), clustering_distance_rows =
corr. dists_Organoids, clustering_distance_cols = corr.dists_Organoids, col = colors)
library(RColorBrewer)
diag(corrs_Organoids) <- NA
colors <- colorRampPalette(brewer.pal(9, "Blues"))(99)
pheatmap(corrs_Organoids, clustering_distance_rows = corr.dists_Organoids, clustering_distance_cols =
corr. dists_Organoids, col = colors)
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F. Export normalized counts for making count plots
# Export normalized counts
normalizedcounts_noIHBDt <- counts(dds_DGE, normalized = TRUE)
normalizedcounts_noIHBDt <- as.data.frame(normalizedcounts_noIHBDt)
normalizedcounts_noIHBDt$ID <- row.names(normalizedcounts_noIHBDt)
normalizedcounts_noIHBDt <- merge(collinfocoding, normalizedcounts_noIHBDt,
by = c("ID"), all.y = TRUE)
write_delim(normalizedcounts_noIHBDt, path = "/Users/rimlandca/desktop/DeSeq2 Combined/normalizedcounts_
noIHBDt.csv" )
G. Results forDGEanalysesbetween the threeEHBD tissue regions
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# Results for GBD vs CBD tissue
resultsGtCt <- results(dds_DGE, contrast = c("type", "GBD_t", "CBD_t"), alpha = 0.05)
summary(resultsGtCt)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 1603, 8.3%
## LFC < 0 (down) : 1526, 7.9%
## outliers [1] : 19, 0.098%
## low counts [2] : 2617, 14%
## (mean count < 3)
resultsGtCt$ID <- row.names(resultsGtCt)
GtCt.df <- as.data.frame(resultsGtCt)
GtCt.df <- merge(collinfocoding, GtCt.df, by = c("ID"), all.y = TRUE)
GtCt.df <- merge(GtCt.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(GtCt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/GtCt_Results.csv")
# GBD vs PancD tissue
resultsGtPt <- results(dds_DGE, contrast = c("type", "GBD_t", "PancD_t"), alpha = 0.05)
summary(resultsGtPt)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 2416, 13%
## LFC < 0 (down) : 2445, 13%
## outliers [1] : 19, 0.098%
## low counts [2] : 1873, 9.7%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsGtPt$ID <- row.names(resultsGtPt)
GtPt.df <- as.data.frame(resultsGtPt)
GtPt.df <- merge(collinfocoding, GtPt.df, by = c("ID"), all.y = TRUE)
GtPt.df <- merge(GtPt.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(GtPt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/GtPt_Results.csv")
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# CBD vs PancD tissue
resultsCtPt <- results(dds_DGE, contrast = c("type", "CBD_t", "PancD_t"), alpha = 0.05)
summary(resultsCtPt)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 3056, 16%
## LFC < 0 (down) : 3103, 16%
## outliers [1] : 19, 0.098%
## low counts [2] : 1499, 7.8%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsCtPt$ID <- row.names(resultsCtPt)
CtPt.df <- as.data.frame(resultsCtPt)
CtPt.df <- merge(collinfocoding, CtPt.df, by = c("ID"), all.y = TRUE)
CtPt.df <- merge(CtPt.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(CtPt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/CtPt_Results.csv")
H. Results forDGEanalysesbetween the threeEHBDorganoids types
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# GBD vs CBD organoids
resultsGcCc <- results(dds_DGE, contrast = c("type", "GBD_c", "CBD_c"), alpha = 0.05)
summary(resultsGcCc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 84, 0.43%
## LFC < 0 (down) : 84, 0.43%
## outliers [1] : 19, 0.098%
## low counts [2] : 1873, 9.7%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsGcCc.df <- as.data.frame(resultsGcCc)
resultsGcCc.df$ID <- row.names(resultsGcCc.df)
GcCc.df <- merge(collinfocoding, resultsGcCc.df, by = c("ID"), all.y = TRUE)
GcCc.df <- merge(GcCc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(GcCc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/GcCc_Results.csv")
# GBD cells vs PancD organoids
resultsGcPc <- results(dds_DGE, contrast = c("type", "GBD_c", "PancD_c"), alpha = 0.05)
summary(resultsGcPc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
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## LFC > 0 (up) : 216, 1.1%
## LFC < 0 (down) : 202, 1%
## outliers [1] : 19, 0.098%
## low counts [2] : 2244, 12%
## (mean count < 2)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsGcPc.df <- as.data.frame(resultsGcPc)
resultsGcPc.df$ID <- row.names(resultsGcPc.df)
GcPc.df <- merge(collinfocoding, resultsGcPc.df, by = c("ID"), all.y = TRUE)
GcPc.df <- merge(GcPc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(GcPc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/GcPc_Results.csv")
# CBD cells vs PancD organoids
resultsCcPc <- results(dds_DGE, contrast = c("type", "CBD_c", "PancD_c"), alpha = 0.05)
summary(resultsCcPc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 110, 0.57%
## LFC < 0 (down) : 129, 0.67%
## outliers [1] : 19, 0.098%
## low counts [2] : 1873, 9.7%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsCcPc.df <- as.data.frame(resultsCcPc)
resultsCcPc.df$ID <- row.names(resultsCcPc.df)
CcPc.df <- merge(collinfocoding, resultsCcPc.df, by = c("ID"), all.y = TRUE)
CcPc.df <- merge(CcPc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(CcPc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/CcPc_Results.csv")
I. ResultsforDGEanalysesbetweenthethreeEHBDtissuesandcorresponding
organoid types
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# CBD tissue vs CBD organoids
resultsCtCc <- results(dds_DGE, contrast = c("type", "CBD_t", "CBD_c"), alpha = 0.05)
summary(resultsCtCc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 5167, 27%
## LFC < 0 (down) : 3627, 19%
## outliers [1] : 19, 0.098%
## low counts [2] : 0, 0%
## (mean count < 0)
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## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsCtCc.df <- as.data.frame(resultsCtCc)
resultsCtCc.df$ID <- row.names(resultsCtCc.df)
CtCc.df <- merge(collinfocoding, resultsCtCc.df, by = c("ID"), all.y = TRUE)
CtCc.df <- merge(CtCc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(CtCc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/CtCc_Results.csv")
# GBD tissue vs GBD organoids
resultsGtGc <- results(dds_DGE, contrast = c("type", "GBD_t", "GBD_c"), alpha = 0.05)
summary(resultsGtGc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 3740, 19%
## LFC < 0 (down) : 2636, 14%
## outliers [1] : 19, 0.098%
## low counts [2] : 1499, 7.8%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsGtGc.df <- as.data.frame(resultsGtGc)
resultsGtGc.df$ID <- row.names(resultsGtGc.df)
GtGc.df <- merge(collinfocoding, resultsGtGc.df, by = c("ID"), all.y = TRUE)
GtGc.df <- merge(GtGc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(GtGc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/GtGc_Results.csv")
# PancD tissue vs PancD organoids
resultsPtPc <- results(dds_DGE, contrast = c("type", "PancD_t", "PancD_c"),
alpha = 0.05)
summary(resultsPtPc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 4229, 22%
## LFC < 0 (down) : 3225, 17%
## outliers [1] : 19, 0.098%
## low counts [2] : 1499, 7.8%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsPtPc.df <- as.data.frame(resultsPtPc)
resultsPtPc.df$ID <- row.names(resultsPtPc.df)
PtPc.df <- merge(collinfocoding, resultsPtPc.df, by = c("ID"), all.y = TRUE)
PtPc.df <- merge(PtPc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
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write_delim(PtPc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/PtPc_Results.csv")
J. Resultsof IHBDorganoidscompared toEHBDorganoids
Asall threeof theextrahepaticbileductorganoidsclusteredcloselybyPCAanalysisand thenumberof
genesdi erentiallyexpressedbetweeneachofthethreetypeswasminimal,wecombinethem intoasingle
“EHBDorganoid”groupandcompare theaverageacrossall threeEHBDorganoid types to IHBDorganoids
usinganumericcontrast inDeSeq2.
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# IHBD_Huch vs all EHBD organoids
resultsImEHBDc <- results(dds_DGE, contrast = list("typeIHBD_Huch", c("typeGBD_c",
"typeCBD_c", "typePancD_c")), listValues = c(1, -1/3), alpha = 0.05)
summary(resultsImEHBDc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 1072, 5.5%
## LFC < 0 (down) : 1158, 6%
## outliers [1] : 19, 0.098%
## low counts [2] : 2244, 12%
## (mean count < 2)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsImEHBDc.df <- as.data.frame(resultsImEHBDc)
resultsImEHBDc.df$ID <- row.names(resultsImEHBDc.df)
resultsImEHBDc.df <- merge(collinfocoding, resultsImEHBDc.df, by = c("ID"),
all.y = TRUE)
ImEHBDc.df <- merge(resultsImEHBDc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(ImEHBDc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ImEHBDc_Results.csv")
# IHBD_ex vs all EHBD organoids
resultsIcEHBDc <- results(dds_DGE, contrast = list("typeIHBD_ex", c("typeGBD_c",
"typeCBD_c", "typePancD_c")), listValues = c(1, -1/3), alpha = 0.05)
summary(resultsIcEHBDc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 2768, 14%
## LFC < 0 (down) : 2757, 14%
## outliers [1] : 19, 0.098%
## low counts [2] : 1873, 9.7%
## (mean count < 1)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsIcEHBDc.df <- as.data.frame(resultsIcEHBDc)
resultsIcEHBDc.df$ID <- row.names(resultsIcEHBDc.df)
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resultsIcEHBDc.df <- merge(collinfocoding, resultsIcEHBDc.df, by = c("ID"),
all.y = TRUE)
IcEHBDc.df <- merge(resultsIcEHBDc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(IcEHBDc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/IcEHBDc_Results.csv")
# IHBD_ex vs IHBD_Huch organoids
resultsIcIm <- results(dds_DGE, contrast = c("type", "IHBD_ex", "IHBD_Huch"),
alpha = 0.05)
summary(resultsIcIm)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 1569, 8.1%
## LFC < 0 (down) : 1423, 7.4%
## outliers [1] : 19, 0.098%
## low counts [2] : 2244, 12%
## (mean count < 2)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsIcIm.df <- as.data.frame(resultsIcIm)
resultsIcIm.df$ID <- row.names(resultsIcIm.df)
resultsIcIm.df <- merge(collinfocoding, resultsIcIm.df, by = c("ID"), all.y = TRUE)
IcIm.df <- merge(resultsIcIm.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(IcIm.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/IcIm_Results.csv")
# IHBD_huch vs CBD organoids
resultsImCc <- results(dds_DGE, contrast = c("type", "IHBD_Huch", "CBD_c"),
alpha = 0.05)
summary(resultsImCc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 1058, 5.5%
## LFC < 0 (down) : 1070, 5.5%
## outliers [1] : 19, 0.098%
## low counts [2] : 2244, 12%
## (mean count < 2)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsImCc.df <- as.data.frame(resultsImCc)
resultsImCc.df$ID <- row.names(resultsImCc.df)
resultsImCc.df <- merge(collinfocoding, resultsImCc.df, by = c("ID"), all.y = TRUE)
ImCc.df <- merge(resultsImCc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(ImCc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ImCc_Results.csv")
# IHBD_huch vs GBD Organoids
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resultsImGc <- results(dds_DGE, contrast = c("type", "IHBD_Huch", "GBD_c"),
alpha = 0.05)
summary(resultsImGc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 720, 3.7%
## LFC < 0 (down) : 759, 3.9%
## outliers [1] : 19, 0.098%
## low counts [2] : 2617, 14%
## (mean count < 3)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsImGc.df <- as.data.frame(resultsImGc)
resultsImGc.df$ID <- row.names(resultsImGc.df)
resultsImGc.df <- merge(collinfocoding, resultsImGc.df, by = c("ID"), all.y = TRUE)
ImGc.df <- merge(resultsImGc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(ImGc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ImGc_Results.csv")
# IHBD_huch vs PancD Organoids
resultsImPc <- results(dds_DGE, contrast = c("type", "IHBD_Huch", "PancD_c"),
alpha = 0.05)
summary(resultsImPc)
##
## out of 19327 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 514, 2.7%
## LFC < 0 (down) : 584, 3%
## outliers [1] : 19, 0.098%
## low counts [2] : 2617, 14%
## (mean count < 3)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsImPc.df <- as.data.frame(resultsImPc)
resultsImPc.df$ID <- row.names(resultsImPc.df)
resultsImPc.df <- merge(collinfocoding, resultsImPc.df, by = c("ID"), all.y = TRUE)
ImPc.df <- merge(resultsImPc.df, baseMeanPerLvl.df, by = c("ID"), all.y = TRUE)
write_delim(ImPc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ImPc_Results.csv")

Chapter 8: Appendices 
III. Exploratory analysis of IHBD tissue samples
A. PCA Plots
PCA Plot of IHBD and EHBD Tissues
vsd_tissue_ALL <- vsd_coll_ALL[, vsd_coll_ALL$group != "cells"]
pcadata_tissue_ALL <- plotPCA(vsd_tissue_ALL, intgroup = c("type"), ntop = 5000,
returnData = TRUE)
percentVar_tissue <- round(100 * attr(pcadata_tissue_ALL, "percentVar"))
ggplot(pcadata_tissue_ALL, aes(PC1, PC2, color = type)) + geom_point(size = 6,
shape = 17) + xlab(paste0("PC1: ", percentVar_tissue[1], "% variance")) +
ylab(paste0("PC2: ", percentVar_tissue[2], "% variance"))
PCA Plot of IHBD Tissue and IHBD Organoids
vsd_coll_ALL_IHBDonly <- vsd_coll_ALL[, vsd_coll_ALL$EHBD_IHBD != "EHBD" & vsd_coll_ALL$name !=
"IHBD5_Ex"]
pcadata_IHBDonly <- plotPCA(vsd_coll_ALL_IHBDonly, intgroup = c("type", "group"),
ntop = 5000, returnData = TRUE)
percentVar_IHBDonly <- round(100 * attr(pcadata_IHBDonly, "percentVar"))
ggplot(pcadata_IHBDonly, aes(PC1, PC2, color = type, shape = group.1)) + geom_point(size = 6) +
xlab(paste0("PC1: ", percentVar_IHBDonly[1], "% variance")) + ylab(paste0("PC2: ",
percentVar_IHBDonly[2], "% variance"))
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Figure 14: PCA Plot of IHBD and EHBD Tissues
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Figure 15: PCA Plot of IHBD Tissues and Organoids
B. Di erentialGeneExpressionAnalyses
4VNNBSZGVODUJPOEJTQMBZT-'$PG'PSGJOBMSFTVMUTQPTUIPDGJMUFSJOHXBTQFSGPSNFEJOFYDFMGPSB-'$DVUPGGPG
# DGE analyses, but now IHBD tissue in the model
ddsCollcoding_ALL <- ddsCollcoding_ALL[, ddsCollcoding_ALL$name != "IHBD5_Ex"]
ddsCollcoding_ALL$type <- droplevels(ddsCollcoding_ALL$type)
dds_DGE_ALL <- DESeq(ddsCollcoding_ALL, betaPrior = TRUE)
# Get base mean expression levels for each individual group
baseMeanPerLvl_ALL <- sapply(levels(dds_DGE_ALL$type), function(lvl) rowMeans(counts(dds_DGE_ALL,
normalized = TRUE)[, dds_DGE_ALL$type == lvl]))
baseMeanPerLvl.df_ALL <- as.data.frame(baseMeanPerLvl_ALL)
baseMeanPerLvl.df_ALL$ID <- row.names(baseMeanPerLvl.df_ALL)
# Export normalized counts
normalizedcounts_withIHBDt <- counts(dds_DGE_ALL, normalized = TRUE)
normalizedcounts_withIHBDt <- as.data.frame(normalizedcounts_withIHBDt)
normalizedcounts_withIHBDt$ID <- row.names(normalizedcounts_withIHBDt)
normalizedcounts_withIHBDt <- merge(collinfocoding, normalizedcounts_withIHBDt,
by = c("ID"), all.y = TRUE)
write_delim(normalizedcounts_withIHBDt, path = "/Users/rimlandca/desktop/DeSeq2 Combined/
normalizedcounts_ withIHBDt.csv" )
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alpha = 0.05)
summary(resultsItGt)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 4946, 26%
## LFC < 0 (down) : 4458, 23%
## outliers [1] : 21, 0.11%
## low counts [2] : 0, 0%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsItGt.df <- as.data.frame(resultsItGt)
resultsItGt.df$ID <- row.names(resultsItGt.df)
ItGt.df <- merge(collinfocoding, resultsItGt.df, by = c("ID"), all.y = TRUE)
ItGt.df <- merge(ItGt.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItGt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItGt_Results.csv")
# IHBD_tissue vs CBD Tissue
resultsItCt <- results(dds_DGE_ALL, contrast = c("type", "IHBD_t", "CBD_t"),
alpha = 0.05)
summary(resultsItCt)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 4989, 26%
## LFC < 0 (down) : 4389, 23%
## outliers [1] : 21, 0.11%
## low counts [2] : 376, 1.9%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsItCt.df <- as.data.frame(resultsItCt)
resultsItCt.df$ID <- row.names(resultsItCt.df)
ItCt.df <- merge(collinfocoding, resultsItCt.df, by = c("ID"), all.y = TRUE)
ItCt.df <- merge(ItCt.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItCt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItCt_Results.csv")
# IHBD_tissue vs PancD Tissue
resultsItPt <- results(dds_DGE_ALL, contrast = c("type", "IHBD_t", "PancD_t"),
alpha = 0.05)
summary(resultsItPt)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 5088, 26%
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# IHBD_tissue vs GBD Tissue
resultsItGt <- results(dds_DGE_ALL, contrast = c("type", "IHBD_t", "GBD_t"),
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## LFC < 0 (down) : 4440, 23%
## outliers [1] : 21, 0.11%
## low counts [2] : 0, 0%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsItPt.df <- as.data.frame(resultsItPt)
resultsItPt.df$ID <- row.names(resultsItPt.df)
ItPt.df <- merge(collinfocoding, resultsItPt.df, by = c("ID"), all.y = TRUE)
ItPt.df <- merge(ItPt.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItPt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItPt_Results.csv")
# IHBD_tissue vs EHBD tissues
resultsItEt <- results(dds_DGE_ALL, contrast = list("typeIHBD_t", c("typeGBD_t",
"typeCBD_t", "typePancD_t")), listValues = c(1, -1/3), alpha = 0.05)
summary(resultsItEt)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 5363, 28%
## LFC < 0 (down) : 4759, 25%
## outliers [1] : 21, 0.11%
## low counts [2] : 376, 1.9%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsItEt.df <- as.data.frame(resultsItEt)
resultsItEt.df$ID <- row.names(resultsItEt.df)
ItEt.df <- merge(collinfocoding, resultsItEt.df, by = c("ID"), all.y = TRUE)
ItEt.df <- merge(ItEt.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItEt.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItEt_Results.csv")
# IHBD_tissue vs IHBD_Huch Organoids
resultsItIm <- results(dds_DGE_ALL, contrast = c("type", "IHBD_t", "IHBD_Huch"),
alpha = 0.05)
summary(resultsItIm)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 5563, 29%
## LFC < 0 (down) : 3836, 20%
## outliers [1] : 21, 0.11%
## low counts [2] : 376, 1.9%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
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resultsItIm.df <- as.data.frame(resultsItIm)
resultsItIm.df$ID <- row.names(resultsItIm.df)
ItIm.df <- merge(collinfocoding, resultsItIm.df, by = c("ID"), all.y = TRUE)
ItIm.df <- merge(ItIm.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItIm.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItIm_Results.csv")
# IHBD_tissue vs IHBD_ex Organoids
resultsItIc <- results(dds_DGE_ALL, contrast = c("type", "IHBD_t", "IHBD_ex"),
alpha = 0.05)
summary(resultsItIc)
##
## out of 19373 with nonzero total read count
## adjusted p-value < 0.05
## LFC > 0 (up) : 5933, 31%
## LFC < 0 (down) : 3975, 21%
## outliers [1] : 21, 0.11%
## low counts [2] : 376, 1.9%
## (mean count < 0)
## [1] see  cooksCutoff  argument of ?results
## [2] see  independentFiltering  argument of ?results
resultsItIc.df <- as.data.frame(resultsItIc)
resultsItIc.df$ID <- row.names(resultsItIc.df)
ItIc.df <- merge(collinfocoding, resultsItIc.df, by = c("ID"), all.y = TRUE)
ItIc.df <- merge(ItIc.df, baseMeanPerLvl.df_ALL, by = c("ID"), all.y = TRUE)
write_delim(ItIc.df, path = "/Users/rimlandca/desktop/DeSeq2 Combined/ItIc_Results.csv")
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